Substituted aminoquinolones as DGK alpha inhibitors for immune activation

Abstract

To provide compounds useful for the treatment of diacylglycerol kinase α regulated disorders.SOLUTION: The present invention provides aminoquinolone compounds of general formula (I), methods of preparing the compounds, intermediate compounds useful for preparing the compounds, pharmaceutical compositions and combinations comprising the compounds and the use of the compounds for preparing pharmaceutical compositions for the treatment and / or prophylaxis of diseases, in particular of diacylglycerol kinase α regulated disorders, as a sole agent or in combination with other active ingredients.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to substituted aminoquinolone compounds of general formula (I) as described and defined herein. a method for producing the compound, an intermediate compound useful for producing the compound, and a pharmaceutical composition containing the compound. Pharmaceutical compositions and combinations, and diseases, particularly diacylglycerol kinase alpha (DGK The pharmaceutical composition for the treatment or prevention of DGKα (DGKα) regulation disorders may be used alone or in combination with other effective The present invention also includes the use of said compound for manufacturing a pharmaceutical composition in combination with an ingredient.

[0002] The compounds of general formula (I) inhibit DGKα and enhance T cell-mediated immune responses. , to overcome the immune invasive strategies utilized by many neoplastic disorders, respectively cancers. This is a novel strategy that utilizes the patient's own immune system, thereby enhancing anti-tumor immunity. In particular, the compounds are useful in treating immune disorders associated with viral infections or abnormal DGKα signaling. These compounds are used to treat disorders such as conditions with abnormal immune responses and other disorders.

[0003] The present invention further relates to the use of compounds of general formula (I), respectively for enhancing T cell mediated immune responses The present invention relates to the use of a compound of general formula (I) for preparing a pharmaceutical composition for

[0004] The present invention further relates to the use of compounds of general formula (I), respectively, as pharmaceuticals for the treatment of cancer. The present invention relates to the use of a compound of general formula (I) for preparing a composition.

[0005] The present invention further relates to the use of compounds of general formula (I) in the treatment of fibrotic disorders, viral infections, General formula for preparing a pharmaceutical composition for the treatment or prevention of cardiovascular diseases and lymphoproliferative disorders (I) relates to the use of the compound [Background technology]

[0006] Diacylglycerol kinase (DGK) is a kinase that converts the membrane lipid sn-1,2 diacylglycerol A family of enzymes that catalyzes the phosphorylation of diaminodibenzofuran (DAG) to form phosphatidic acid (PA) (Eichmann and Lass, Cell Mol Life Sci . 2015; 72: 3931). In T cells, phospholipase C (PLCγ1) γ The 1 isoform is activated and produces phosphatidylinositol 4,5-bisphosphate (PIP 2) is synthesized from DAG and an additional second messenger, inositol 1,4,5-triphosphate ( IP3), DAG is formed downstream of the T cell receptor (TCR) (Kris hna and Zhong, Front. Immunol 2013, 4, 1 78) IP3 is important for promoting calcium release from the endoplasmic reticulum, whereas D AG is a phosphodiesterase inhibitor of protein kinase Cθ (Quann et al., Nat Immunol 2011(7), 647) and Ras activating protein RasGRP1 (Krish na and Zhong, Front. Immunol 2013, 4:178 ), which interact with other proteins important in TCR signaling. DGK isoforms of the species [DGKα (DGK alpha), DGKδ (DGK delta), DGKζ (DGK zeta)] is known to exist, but DAG downstream of TCR Two types of DGKα and DGKζ are thought to play an important role in promoting metabolism. (Joshi and Koretzky, Int. J. Mol. Sci. 2013, 14, 6649).

[0007] DGKα activity in T cells by either germline deletion or chemical inhibitors Targeting this protein results in the upregulation of downstream molecules such as extracellular signal-related kinase 1 / 2 (ERK1 / 2). Enhanced and sustained downstream signaling in T cells as assessed by prolonged phosphorylation (Zhong et al., Nat Immunol 2003, 4, 882 ;Olenchock et al., Nat Immunol 2006, 7, 1174;Riese et al., J. Biol. Chem 2011, 2 86, 5254). Furthermore, overexpression of DGKα induces functional activity similar to an anergic state. induces a state of hypoxia (Zha et al., Nat Immunol 2006, 7, 1166). In contrast, deletion of DGKα in T cells results in a decrease in IL2 and IFNγ expression. and enhanced the production of effector cytokines such as β-glucan and β-glucan, and promoted proliferation (Zhong et al. al., Nat Immunol 2003, 4, 882; et al., Nat Immunol 2006, 7, 1174).

[0008] These findings suggest that DGKα serves as a useful target for enhancing the antitumor activity of T cells. The role of DGKα in anti-tumor responses has recently been investigated in renal cell It has been studied in human tumor-infiltrating CD8+ T cells (CD8-TIL) from patients with recurrent cancer (RCC). (Prinz et al., J. Immunol 2012, 188, 59 90) CD8-TILs from RCC inhibit lytic granulocyte exocytosis and target cell proliferation. The proximal signaling events in response to TCR engagement were defective in killing. Although intact, CD8- TILs upregulated ERK expression compared with non-tumor-infiltrating CD8+ T cells. Treatment of CD8-TILs with an inhibitor of DGKα activity reduced the phosphorylation of target cells. The killing ability of IL-1 was restored, the basal level of ERK phosphorylation was increased, and PMA / ionomycin Stimulation increased ERK phosphorylation.

[0009] Furthermore, Arranz-Nicolas et al. reported that DGK inhibitors inhibit Ras / ERK signaling. It not only promotes signal transduction but also AP-1 (activator protein-1) transcription, promoting the membrane localization of DGKα. This promotes activation of DGKζ, reducing the need for costimulation and enhancing activation after DGKζ silencing / deletion. In contrast to the enhanced activation induced by pharmacological inhibition, Kα silencing / gene deletion inhibits Lck (lymphocyte-specific protein tyrosine kinase) ze) and limited costimulation responses (Arranz-Nicolas et al. t al., Canc Immun, Immunother 2018, 67(6 ), 965).

[0010] Furthermore, DGKα - / - Mouse and DGKζ - / - Abtigen-specific CD from mice 8 + T cells expand and produce more cytokines after infection with lymphocytic choriomeningitis virus This indicates an increase in the number of HIV-1-associated proteins (Shin et al., J. Immunol, 2012).

[0011] Furthermore, adoptive transfer of DGKα-deficient CAR (chimeric antigen receptor)-T cells mouse mesothelioma (Riese et al., Cancer Res 2013, 73(12), 3566) and glioblastoma xenograft mouse model (Jung et al. l., Cancer Res. 2018, 78(16), 4692) showed higher efficacy compared to wild-type CAR T cells.

[0012] Apart from T cell regulation, DGKα also plays a role in cancer and in survival (Bacchio cchi et al., Blood, 2005, 106(6), 2175; Yanagisawa et al., Biochim Biophys Acta 2007, 1771, 462), cancer cell migration and invasion (Baldanzi et al., Oncogene 2008, 27, 942; et al., Anticancer Res 2007, 27, 1489; Rainero et al., J Cell Biol 2012, 196(2) It mediates many aspects of cancer cell progression, particularly in hepatocellular carcinoma (Take ishi et al., J Hepatol 2012, 57, 77) and Mela Norma cells (Yanagisawa et al., Biochim Biophys Acta 2007, 1771, 462) reported that DGKα was overexpressed. While other reports have shown that DGKα-siRNA16 can inhibit colon cancer and breast cancer, The proliferation of cancer cell lines was significantly inhibited, and the expression of DGKα / atypical PKC / b1 integrin was signaling pathway is essential for the invasion of mammary carcinoma cells into the matrix (Raineror et al. l., PLoS One 2014, 9(6):e97144) has been suggested. Furthermore, expression is higher in lymph node metastases than in primary breast tumors (Hao et al., Cancer 2004, 100, 1110).

[0013] Furthermore, a study investigating the importance of DGKα in glioblastoma multiforme (GBM) cells showed that Co-administration of the relatively nonspecific DGKα inhibitor R59022 significantly improved the survival of intracranially injected GBM tumors. It was found that tumor growth was reduced (Dominguez et al., Cancer r Discov 2013, 3(7):782).

[0014] DGKα also promotes the progression of esophageal squamous cell carcinoma (ESCC), which is thought to be due to the This supports the idea that thrombin is a potential target for SCC therapy (Chen et al., On cogene, 2019, 38 (14) 2533).

[0015] Furthermore, pharmacological inhibition of DGK reduced both airway inflammation and airway hyperresponsiveness in mice. Also, T helper 2 (T H 2) by blocking differentiation of human airways in vitro reduced bronchoconstriction in the samples (Singh et al, Sci Signal . 2019, 12, eaax3332).

[0016] Furthermore, inhibition of DGKα suppresses the proliferation of inflammatory cytokines that occur in patients with X-linked lymphoproliferative disorder 1 (XLP-1). It has the ability to reverse life-threatening Epstein-Barr virus (EBV)-associated immunopathology (Ruffo et al., Sci Transl Med. 2016, 13, 8, 321; Velnati et al., Eur J Med Chem. 2019, 164,378).

[0017] DGKα also exacerbates myocardial injury after ischemia / reperfusion heart disease (Sasaki et al., Heart Vessels, 2014, 29, 110).

[0018] Taken together, the findings from these studies support the role of DGK in T cells and tumor cells. Suppressing α activity may contribute to a more vigorous immune response against pathogens and tumors. and amoiroting Th2-driven (autoimmune) diseases This indicates that it may prove useful in balancing the immune system. Furthermore, inhibition of DGKα activity not only directly targets tumors but also has the potential to prevent fibrotic disorders, viruses, and other diseases. It has therapeutic potential in combating infection-related pathologies, cardiac diseases and lymphoproliferative disorders.

[0019] prior art DGKα inhibitors have been reported in the literature. However, it was confirmed that it acts on DGK in red blood cells (de Chaffoy de Cou rcelles et. al., J. Biol. Chem. Vol 260, No.29, (1985), p15762-70). Structurally related R5994 9(B) inhibits the conversion of 1,2-diacylglycerol to the respective phosphatidic acids. It was confirmed that the inhibitor acts on DGKα in T lymphocytes by inhibiting the et. al., J. Biol. Chem. Vol 274, No. 24, (1999), p16846-52). Originally identified as a serotonin receptor antagonist Ritanserin (C) has the same activity against DGKα as the two R compounds (A) and (B). (Boroda et al., BioChem. Pharm. 1 23, (2017), 29-39). [ka]

[0020] A further structure, CU-3(D), has submicromolar inhibitory activity against DGKα. It was the first compound identified (Sakane et al., J. Lipid Res. Vol 57, (2016), p368-79). [ka]

[0021] AMB639752(E) is a further DGKα-selective inhibitor with micromolar activity It has been reported that (S. Velnati et al., Eur J. Me d. Chem 2019, 164, p378-390.). [ka]

[0022] WO2020 / 151636 discloses PDE9 inhibitor compounds for the treatment of PDE9-mediated diseases This concerns azaquinolinone as a substance.

[0023] WO2020 / 143626 discloses a PDE9 inhibitor compound for the treatment of PDE9-mediated diseases. This relates to quinolinones as compounds.

[0024] WO2020 / 182076 discloses a method for the manufacture of a medicament for treating heart failure in a mammal. The present invention relates to the use of phosphodiesterase inhibitor compounds.

[0025] WO2020 / 006016 and W2020 / 006018 disclose methods for treating viral infections and and / or DGKζ for the treatment of proliferative disorders such as cancer. Naphthhydrinone compounds are described as cell activators. are.

[0026] WO2017 / 019723 A1 is related to phosphodiesterase 9 (PDE9) Azacyanoquinolinone compounds that may be useful as therapeutic agents for the treatment of central nervous system disorders It also relates to the use of compounds to treat neurological and psychiatric disorders. It is about use.

[0027] WO2004 / 074218 describes MIF-inhibitors and their uses, particularly in the treatment of cancer. It describes the use for

[0028] WO2007 / 109251 describes a TNFα inhibitor for the treatment of diseases, particularly cancer. It describes the use of

[0029] WO2012 / 142498 and WO2012 / 009649 disclose MIF-inhibitors and These patent applications describe several uses thereof, particularly in cancer therapy. However, many of these theoretical compounds are The specifics are not disclosed. [Prior art documents] [Patent documents]

[0030] [Patent Document 1] WO2020 / 151636 [Patent Document 2] WO2020 / 143626

Patent document 3

Patent document 4

Patent document 5

Patent document 6

Patent document 7

Patent document 8

Patent document 9

Patent document 10

Non-licensed literature

[0031] [Non-licensed document 1] Eichmann and Lass, Cell Mol Life Sci. 2015; 72: 3931 [Non-licensed document 2] Krishna and Zhong, Front. Immunol 2013, 4, 178 [Non-licensed document 3] Quann et al., Nat Immunol 2011(7), 647

Non-licensed Document 4

Non-licensed Document 5

Non-licensed Document 6

Non-licensed Document 7

Non-licensed literature 9

Non-licensed literature 10

Non-licensed Document 11

Non-licensed Document 12

Non-licensed Document 13

Non-licensed Document 14

Non-licensed Document 15

Non-licensed Document 16

Non-licensed Document 17

Non-licensed Document 18

Non-licensed Document 19

Non-licensed Document 20

Non-licensed Document 21

Non-licensed Document 22

Non-licensed Document 23

Non-licensed Document 24

Non-licensed Document 25

Non-licensed Document 26

Non-licensed Document 27

Non-licensed Document 28

Non-licensed Document 29

Non-licensed Document 30

Non-licensed Document 31

Non-licensed Document 32

[0032] However, the latest technology is Specific substituted amino groups of the general formula (I) of the present invention as described and defined herein. Nolon compounds, i.e., A methyl or ethyl group at position 1, Cyano, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, or or an alkoxycarbonyl group or an alkoxycarbonyl group, in position 4, a pyrrolidinyl, piperidinyl or azepanyl group; and The substituent of the pyrrolidinyl, piperidinyl or azepanyl group may be phenyl, naphthalene, or phenyl. butyl group or 5-10 membered heteroaryl group compounds having a 2-oxo-1,2-dihydroquinoline core having the formula or its stereoisomers, tautomers, N-oxides, hydrates, solvates, salts, or and mixtures thereof, as described and defined herein and hereinafter referred to as "general formula (I) "Compounds of" or "Compounds of the Invention" or its pharmacological activity is not stated.

[0033] It is desirable to provide novel compounds that have prophylactic and therapeutic properties.

[0034] Therefore, the object of the present invention is to provide a T cell immunostimulatory or immunomodulatory agent for DGKα dysregulation. The present invention provides compounds for prophylactic and therapeutic use and pharmaceutical compositions containing these compounds. DGKα regulation disorders are particularly prevalent in cancer, autoimmune diseases, viral infections, and Other disorders associated with abnormal DGKα signaling, such as immunologically suppressed fibrotic diseases, The compounds may be used as single agents in the treatment of conditions involving dysregulated immune responses in a compromised tumor microenvironment. It can be used as such or in combination with other active ingredients.

[0035] It has now been found that the compounds of the present invention have surprising and advantageous properties, form the basis of the present invention.

[0036] In particular, the compounds of the present invention surprisingly effectively inhibit DGKα protein and inhibit T These compounds have been found to enhance cell-mediated immunity. The present invention provides novel structures for the treatment of disorders of the body, particularly cancer, and therefore For example, they can be used to treat or prevent hyperproliferative disorders such as cancer. [Means for solving the problem]

[0037] According to a first aspect, the present invention provides compounds of the following general formula (I) and their stereoisomers, antonyms, and the like: This includes variants, N-oxides, hydrates, solvates and salts, and mixtures thereof. [ka] During the ceremony, R 1 is cyano, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N (H)C2H5, -C(=O)N(CH3)2 and -C(=O)OR 15 Selected from represents a group, R 2 represents a group selected from phenyl, naphthyl, and 5- to 10-membered heteroaryl; The 5- to 10-membered heteroaryl group is a 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, naphthyl and 5- to 10-membered heteroaryl groups are substituted 1, 2, 3 or 4 times Each substituent may be a halogen atom or C1-C6-Alkyl, C3-C6-Cycloalkyl, C1-C6-Hydroxyalkan alkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkoxy) (C1-C2 alkoxy)-(C1-C6-alkoxy)-, C1-C6-alkoxy (Si)-, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy , -SR 14 , -S(=O)R 14 , -S(=O)2R 14 , -P(=O)(R 14 )2 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 ) 2, 4 to 7 membered complex Cyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl and 5- or 6-membered heteroaryl; or when two substituents of said phenyl group are attached to adjacent ring atoms, they are Together, -(CH2)3-, -CH2-CH(OH)-CH2-, -(CH2)4-, -O- (CH2)2-, -(CH2)2-O-, -CH2-CH(CH3)-O-, -CH2- O-CH2-, -O-(CH2)3-, -(CH2)3-O-, -CH2-O-(CH2 )2-, -(CH2)2-O-CH2-, -O-CH2-O-, -OC(CH3)2- O-, -O-(CH2)2-O-, -N(R 18 )-C(=O)-(C(R 18 )(R 1 9 )) m -, -N(R 18 )-C(=O)-(C(CH2)3)-, -N(R 18 )-( C(R 18 )(R 19 )) m -, -N(R 18 )-C(=O)-O- and -N(R 18 ) -C(=O)-N(R 18 )-, and Also good, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are The remainder of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups It is connected to The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The cycloalkyloxy group may be substituted one, two or three times, and each substituent may be a halogen atom. atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R9 )(R 10 ) and oxo are independently selected from the group The C1-C6-alkyl and C1-C6-alkoxy groups are It may be substituted with a group selected from alkyl, phenyl and 4- to 7-membered heterocyclic alkyl. Ku, The 4- to 7-membered heterocyclic alkyl group is a group in which the carbon atom of the 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice or three times, and each The substituents are halogen atoms or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from groups selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups A C3-C4-cycloalkyl group may be substituted once or twice, and each substituent The substituent is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C6-cycloalkyl group may be substituted once or twice, and each the substituents are independently selected from halogen atoms or C1-C4-alkyl groups, The phenyl, phenoxy and 5- or 6-membered heteroaryl groups are 1 or 2 may be substituted five times, and each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups R 3 is a hydrogen atom or a halogen atom or C1-C6-Alkyl, C2-C6-Alkenyl, C2-C6-Alkynyl, C3-C 6-Cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl , C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl) -, C1-C6-alkoxy, (C1-C2 alkoxy)-(C1-C6-alkoxy) -, C1-C4-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, - SR 14 , -S(=O)R 14 , -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 1 2 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 1 4 )2, -N=S(=O)(R 14 ) 2、 -P(=O)(R 14 ) 2, 4 to 7 membered heterocyclic rings alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl, and represents a group selected from 5- or 6-membered heteroaryl, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, each of the substituents being a halogen. Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups are Selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocyclic alkyl may be substituted with a group, The 4- to 7-membered heterocyclic alkyl group is a 4- to 7-membered heterocyclic alkyl group having a carbon atom. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups A C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C2-C6-alkenyl group may be substituted with a C1-C4-haloalkyl group. Ku, The C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups may be one or more may be substituted twice, each substituent being a halogen atom or a C1-C4-alkyl and independently selected from groups selected from C1-C4-haloalkyl; The phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be It may be substituted, and each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 4 is a hydrogen atom or a halogen atom or C1-C6-Alkyl, C2-C6-Alkenyl, C2-C6-Alkynyl, C3-C 6-Cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl , C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl) -, C1-C6-alkoxy, (C1-C2 alkoxy)-(C1-C6-alkoxy) -, C1-C4-haloalkoxy, -O-(C1-C4-alkyl)-C(=O)OR 1 5, -O-(C1-C4-alkyl)-C(=O)N(R 9 )(R 10 ), C3-C6- Cycloalkyloxy, -S(=O)R 14 , -S(=O)2R 14 , cyano, nitro, Hydroxy, -N(R 9 )(R 10 ), -N(R 16 )(R 17 ), -N(R 16 )(R 20 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C( =O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 )2, -P(=O)(R 14 ) 2, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl, and 5 or represents a group selected from 6-membered heteroaryl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, each of the substituents being a halogen. Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is a 4- to 7-membered heterocyclic alkyl group having a carbon atom. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups A C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; the C1-C6-alkoxy group may be substituted with an oxiran-2-yl group, The C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups may be one or more is optionally substituted twice, each substituent independently being a halogen atom or a C1-C4-alkyl is selected from the group The phenyl and 5- or 6-membered heteroaryl groups may be mono- or disubstituted. Each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 5 is a hydrogen atom or a halogen atom or C1-C6-Alkyl, C2-C6-Alkenyl, C2-C6-Alkynyl, C3-C 6-Cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl , C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl) -, C1-C6-alkoxy, (C1-C2 alkoxy)-(C2-C6-alkoxy) -, C1-C4-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, - SR 14 , -S(=O)R 14 , -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 1 2 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 1 4 )2, -N=S(=O)(R 14 ) 2、 -P(=O)(R 14 ) 2, 4 to 7 membered heterocyclic rings alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl, and represents a group selected from 5- or 6-membered heteroaryl, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, each of the substituents being a halogen. Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups are Selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocyclic alkyl may be substituted with a group, The 4- to 7-membered heterocyclic alkyl group is a 4- to 7-membered heterocyclic alkyl group having a carbon atom. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups A C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups may be one or more is optionally substituted twice, each substituent independently being a halogen atom or a C1-C4-alkyl is selected from the group The phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be It may be substituted, and each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 6 is a hydrogen atom, a fluorine atom, or C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, represents a group selected from hydroxy and oxo, R 7 is a hydrogen atom or a halogen atom or selected from C1-C4-alkyl, C1-C4-alkoxy, hydroxy and cyano represents a group R 8 represents a group selected from methyl and ethyl, R 9 and R 10 is, independently in each occurrence, hydrogen, or C1-C4-Alkyl, C2-C4-Hydroxyalkyl, N≡C-(C1-C4-Alkyl) (C1-C4-alkoxy)-(C2-C4-alkyl)-, C3-C4- represents a group selected from cycloalkyl and C2-C4-haloalkyl, or R 9 and R 10 However, together with the nitrogen to which they are attached, they form a nitrogen-containing 4- to 7-membered heterocyclic alkane. represents a alkyl group, The nitrogen-containing 4- to 7-membered heterocycloalkyl group may be substituted one, two, or three times. , each substituent is a halogen atom or Selected from C1-C4-alkyl, C3-C4-cycloalkyl, hydroxy and oxo are independently selected from the groups or Two substituents bonded to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocyclic alkyl group together with the carbon atom to which they are attached represent a 4- to 7-membered heterocycloalkyl group; The 4- to 7-membered heterocyclic alkyl group may be substituted once or twice, and each substitution The group is a halogen atom or C1-C4-Alkyl, C3-C4-Cycloalkyl, C1-C4-Haloalkyl independently selected from the group consisting of hydroxy and oxo; R 11 is a hydrogen atom or C1-C4-alkyl, C1-C4-hydroxyalkyl, C a group selected from 1-C4-haloalkyl, phenyl and 5- or 6-membered heteroaryl represents The phenyl and 5- or 6-membered heteroaryl groups are mono- or disubstituted. Each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R9 )(R 10 ) are selected from are independently selected from the group R 12 represents a hydrogen atom or a C1-C4-alkyl group, R 13 is a hydrogen atom or A group selected from C1-C6-alkyl, phenyl and 5- or 6-membered heteroaryl represents The phenyl and 5- or 6-membered heteroaryl groups are mono- or disubstituted. Each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 14 is C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl represents a group selected from alkyl, phenyl and 5- or 6-membered heteroaryl; The phenyl and 5- or 6-membered heteroaryl groups are mono- or disubstituted. Each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 15 represents a hydrogen atom or a C1-C4-alkyl group, R 16 is a hydrogen atom or C1-C4-alkyl, C3-C4-cycloalkyl and C2-C4-haloalkyl represents a group selected from R 17represents a 4- to 7-membered heterocyclic alkyl group, The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice or three times, and each substitution The group is a halogen atom or C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-alkoxy, hydroxypropyl independently selected from the group consisting of hydroxy and oxo; The 4- to 7-membered heterocyclic alkyl group is a 4- to 7-membered heterocyclic alkyl group having a carbon atom. is connected to the rest of the molecule via R 18 represents a hydrogen atom or a group selected from methyl and ethyl, R 19 represents a hydrogen atom or a group selected from methyl and ethyl, R 20 represents a (4- to 7-membered heterocyclylalkyl)-(C1-C4-alkyl)- group, The (4- to 7-membered heterocycloalkyl) portion of the group is substituted one, two, or three times. Each substituent may be a halogen atom or C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-alkoxy, hydroxypropyl independently selected from the group consisting of hydroxy and oxo; m represents an integer selected from 1, 2 and 3; n represents an integer selected from 1, 2 and 3;

[0038] According to a variant of the first aspect, the present invention provides a method for manufacturing a semiconductor device comprising: R 1 cyano, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N (H)C2H5, -C(=O)N(CH3)2 and -C(=O)OR 15 Selected from represents a group, R 2 represents a group selected from phenyl, naphthyl, and 5- to 10-membered heteroaryl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, naphthyl and 5-10 membered heteroaryl groups substituted 1, 2, 3 or 4 times Each substituent may be a halogen atom or C1-C6-Alkyl, C3-C6-Cycloalkyl, C1-C6-Hydroxyalkan alkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkoxy) (C1-C2 alkoxy)-(C1-C6-alkoxy)-, C1-C6-alkoxy (Si)-, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy , -SR 14 , -S(=O)R 14 , -S(=O)2R 14 , -P(=O)(R 14 )2 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 ) 2, 4 to 7 membered complex Cyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl and 5- or 6-membered heteroaryl; or when two substituents of said phenyl group are attached to adjacent ring atoms, they are Together, -(CH2)3-, -(CH2)4-, -O-(CH2)2-, -(CH2)2-O -, -CH2-O-CH2-, -O-(CH2)3-, -(CH2)3-O-, -CH2 -O-(CH2)2-, -(CH2)2-O-CH2-, -O-CH2-O- and -O- (CH2)2-O-, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are The remainder of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups It is connected to The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The cyclic alkyloxy group may be substituted one, two or three times, and each substituent may be a halogen atom. atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group The C1-C6-alkyl and C1-C6-alkoxy groups are preferably C3-C4-cyclo It may be substituted with a group selected from alkyl, phenyl and 4- to 7-membered heterocyclic alkyl. Ku, The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from groups selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substituent The substituent is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C6-cycloalkyl group may be substituted once or twice, the substituents are independently selected from halogen atoms or C1-C4-alkyl groups, The phenyl, phenoxy and 5- or 6-membered heteroaryl groups are 1 or 2 may be substituted three times, and each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups R 3 is a hydrogen atom or a halogen atom or C1-C6-Alkyl, C2-C6-Alkenyl, C2-C6-Alkynyl, C3-C 6-Cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl , C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl) -, C1-C6-alkoxy, (C1-C2 alkoxy)-(C1-C6-alkoxy) -, C1-C4-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, - SR 14 , -S(=O)R 14 , -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 1 2 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 1 4 )2, -N=S(=O)(R 14 ) 2、 -P(=O)(R 14 ) 2, 4 to 7 membered heterocyclic rings alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl, and represents a group selected from 5- or 6-membered heteroaryl, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups, Selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocyclic alkyl may be substituted with a group, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups may be one or more may be substituted twice, each substituent being selected from a halogen atom or a C1-C4-alkyl group. are independently selected from The phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be present one or two times. It may be substituted, and each substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 4 is a hydrogen atom or a halogen atom or C1-C6-Alkyl, C2-C6-Alkenyl, C2-C6-Alkynyl, C3-C 6-Cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl , C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl) -, C1-C6-alkoxy, (C1-C2 alkoxy)-(C1-C6-alkoxy) -, C1-C4-haloalkoxy, C3-C6-cycloalkyloxy, -S(=O)R 14 , -S(=O)2R 14 , cyano, nitro, hydroxy, -N(R 9 )(R 10 ), -N(R 16 )(R 17 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=N H)(R 14 )2, -N=S(=O)(R 14 )2, -P(=O)(R 14 )2, 4-7 5- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, represents a group selected from phenyl and 5- or 6-membered heteroaryl, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups, substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups may be one or more is optionally substituted twice, each substituent independently being a halogen atom or a C1-C4-alkyl is selected from the group The phenyl and 5- or 6-membered heteroaryl groups are substituted one or two times. each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 5 is a hydrogen atom or a halogen atom or C1-C6-Alkyl, C2-C6-Alkenyl, C2-C6-Alkynyl, C3-C 6-Cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl , C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl) -, C1-C6-alkoxy, (C1-C2 alkoxy)-(C2-C6-alkoxy) -, C1-C4-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, - SR 14 , -S(=O)R 14 , -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 1 2 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R1 4 )2, -N=S(=O)(R 14 ) 2、 -P(=O)(R 14 ) 2, 4 to 7 membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl, and represents a group selected from 5- or 6-membered heteroaryl, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups, Selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocyclic alkyl may be substituted with a group, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups C3-C4-cycloalkyl may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups may be one or more is optionally substituted twice, each substituent independently being a halogen atom or a C1-C4-alkyl is selected from the group The phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be present one or two times. It may be substituted, and each substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 6 is a hydrogen atom, or a fluorine atom, or C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, represents a group selected from hydroxy and oxo, R 7 is a hydrogen atom or a halogen atom or selected from C1-C4-alkyl, C1-C4-alkoxy, hydroxy and cyano represents a group R 8 represents a group selected from methyl and ethyl, R 9 and R 10 is, independently in each occurrence, hydrogen, or C1-C4-alkyl, (C1-C4-alkoxy)-(C2-C4-alkyl)-, represents a group selected from C3-C4-cycloalkyl and C2-C4-haloalkyl, or R 9 and R 10 However, together with the nitrogen to which they are attached, they form a nitrogen-containing 4- to 7-membered heterocyclic alkane. represents a alkyl group, The nitrogen-containing 4- to 7-membered heterocyclic alkyl group may be substituted one, two, or three times. , each substituent is a halogen atom or Selected from C1-C4-alkyl, C3-C4-cycloalkyl, hydroxy and oxo are independently selected from the groups or Two substituents bonded to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocyclic alkyl group together with the carbon atom to which they are attached represent a 4- to 7-membered heterocycloalkyl group; The 4- to 7-membered heterocyclic alkyl group may be substituted once or twice, and each substitution The group is a halogen atom or C1-C4-Alkyl, C3-C4-Cycloalkyl, C1-C4-Haloalkyl independently selected from the group consisting of hydroxy and oxo; R 11 is a hydrogen atom or a C1-C4-alkyl, C1-C4-hydroxyalkyl, C a group selected from 1-C4-haloalkyl, phenyl and 5- or 6-membered heteroaryl represents The phenyl and 5- or 6-membered heteroaryl groups are substituted one or two times. Each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 12 represents a hydrogen atom or a C1-C4-alkyl group, R 13 is a hydrogen atom or A group selected from C1-C6-alkyl, phenyl and 5- or 6-membered heteroaryl represents The phenyl and 5- or 6-membered heteroaryl groups are substituted one or two times. Each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 14 C1-C6-alkyl, C1-C6-haloalkyl, C3-C6-cycloalkyl represents a group selected from alkyl, phenyl and 5- or 6-membered heteroaryl; The phenyl and 5- or 6-membered heteroaryl groups are substituted one or two times. Each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 15represents a hydrogen atom or a C1-C4-alkyl group, R 16 is a hydrogen atom or C1-C4-alkyl, C3-C4-cycloalkyl and C2-C4-haloalkyl represents a group selected from R 17 represents a 4- to 7-membered heterocyclic alkyl group; The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The group is a halogen atom or C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-alkoxy, hydroxypropyl independently selected from the group consisting of hydroxy and oxo; The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via n represents an integer selected from 1, 2 and 3; The compounds of the above general formula (I) and their stereoisomers, tautomers, N-oxides and hydrates , solvates and salts, and mixtures thereof. [Brief explanation of the drawings]

[0039] [Figure 1-1] This is human DGKa M1-S735+C-terminal flag tag, DGKa_hu_1, as shown under SEQ ID NO: 1. [Figure 1-2] This is human DGKa M1-S735+C-terminal flag tag, DGKa_hu_1, as shown under SEQ ID NO: 1. [Figure 2-1] Human DGKa M1-S735 shown under SEQ ID NO: 2 plus N-terminal Avi tag and C-terminal flag tag, DGKa_hu_1Avi. [Figure 2-2] Human DGKa M1-S735 shown under SEQ ID NO: 2 plus N-terminal Avi tag and C-terminal flag tag, DGKa_hu_1Avi. [Figure 3] The SIINFEKL amino acid sequence is set forth under SEQ ID NO:3. [Figure 4] GCCACC DNA sequence. [Figure 5] This is the flag tag sequence shown under SEQ ID NO:4. [Figure 6] OVA-30 peptide sequence set forth under SEQ ID NO:5. DETAILED DESCRIPTION OF THE INVENTION

[0040] definition The term "substituted" means that one or more hydrogen atoms on a specified atom or group has been substituted with a specified group. means that the value is replaced by a value selected from the The normal valence of a given atom is not exceeded. Combinations of substituents and / or variables are permitted. .

[0041] The term "optionally substituted" refers to a group having a number of substituents equal to or different from zero. Unless otherwise specified, an optionally substituted group may be Replacement of a hydrogen atom with a non-hydrogen substituent on any available carbon or nitrogen atom It can be substituted with as many suitable substituents as are available in Optional substituents, if present, are 1, 2, 3 or 4, in particular 1, 2 or 3. It is possible.

[0042] When groups in the compounds according to the invention are substituted, the groups are substituted unless otherwise specified. Within the scope of the present invention, the repeating groups may be mono- or polysubstituted with substituents. The meanings of all radicals occurring in each case are independent of one another. by one, two or three identical or different substituents, in particular by one substituent It can be replaced by

[0043] As used herein, an oxo substituent is an oxo group that is bonded to a carbon atom or sulfur through a double bond. Represents an oxygen atom bonded to an atom.

[0044] When a compound substituent is composed of multiple moieties, for example, (C1-C2-alkoxy)-(C In the case of (1-C6-alkyl)-, a moiety may be attached at any suitable position of the compound substituent. For example, the C1-C2-alkoxy moiety can be Any of the C1-C6-alkyl moieties of the (C1-C6-alkoxy)-(C1-C6-alkyl)- group The starting point or the suitable carbon atom of such a compound substituent can be The hyphen at the end indicates the point of attachment of the compound substituent to the rest of the molecule. carbon atoms and optionally one or more heteroatoms, such as nitrogen, oxygen or sulfur atoms; When the ring containing the compound is substituted with a substituent, the substituent may be bonded to any suitable position on the ring. It can be bonded to a suitable carbon atom and / or a suitable heteroatom. are.

[0045] As used herein, the term "comprising" is inclusive of "consisting of."

[0046] Within this description, when something is referred to as "mentioned herein," it is This means that the item may be mentioned anywhere in this document. There are.

[0047] The terms mentioned in this description have the following meanings:

[0048] The term "halogen atom" means a fluorine, chlorine, bromine or iodine atom, in particular fluorine, It means a chlorine or bromine atom.

[0049] The term "C1-C6-alkyl" refers to alkyl groups having 1, 2, 3, 4, 5 or 6 carbon atoms. and the like. It means a linear or branched saturated monovalent hydrocarbon group having the following structure: Pyrrole, isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl Isopentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2 -dimethylpropyl, neo-pentyl, 1,1-dimethylpropyl, hexyl, 1-methyl 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylpentyl butyl, 2-ethylbutyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3, 3-dimethylbutyl, 2,3-dimethylbutyl, 1,2-dimethylbutyl, or 1,3- dimethylbutyl group, or an isomer thereof. In particular, said group is 1, 2, 3, 4 or 5 carbon atoms (“C1-C5-alkyl”), such as methyl, ethyl, propyl, Isopropyl, butyl, sec-butyl, isobutyl, tert-butyl, pentyl, iso Pentyl, 2-methylbutyl, 1-methylbutyl, 1-ethylpropyl, 1,2-dimethyl propyl, neo-pentyl, 1,1-dimethylpropyl groups. In particular, the groups are , having 1, 2, 3 or 4 carbon atoms (“C1-C4-alkyl”), such as methyl, Ethyl, propyl, isopropyl, butyl, sec-butyl isobutyl, or tert- butyl groups, more particularly alkyl groups of 1, 2 or 3 carbon atoms ("C1-C3-alkyl") and having, for example, a methyl, ethyl, n-propyl or isopropyl group, more particularly 1 or having two carbon atoms ("C1-C2-alkyl"), e.g., a methyl or ethyl group .

[0050] The term "C2-C4-alkyl" refers to a straight-chain or straight-chain alkyl group having 2, 3 or 4 carbon atoms. means a branched saturated monovalent hydrocarbon radical, such as ethyl, propyl, isopropyl, butyl, The alkyl group is a butyl, sec-butyl, isobutyl or tert-butyl group.

[0051] The term "C1-C6-hydroxyalkyl" is used interchangeably with "C1-C6-alkyl". where the term is defined above and one or two hydrogen atoms are replaced by a hydroxy group. means a linear or branched saturated monovalent hydrocarbon radical, e.g., hydroxymethyl, 1-hydroxymethyl, hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 3-hydroxypropyl Pill, 2-hydroxypropyl, 1-hydroxypropyl, 1-hydroxypropane-2 -yl, 2-hydroxypropan-2-yl, 2,3-dihydroxypropyl, 1,3- Dihydroxypropan-2-yl, 3-hydroxy-2-methyl-propyl, 2-hydroxy hydroxy-2-methyl-propyl, 1-hydroxy-2-methyl-propyl, 1-hydroxy Butyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl group, 1- Hydroxypentyl, 2-hydroxypentyl, 3-hydroxypentyl, 4-hydroxy Dipentyl, 5-hydroxypentyl, 1-hydroxyhexyl, 2-hydroxyhexyl 3-hydroxyhexyl, 4-hydroxyhexyl, 5-hydroxyhexyl, 6- hydroxyhexyl group or an isomer thereof. In particular, said group may be one, two, three or four carbon atoms ("C1-C4-hydroxyalkyl"), such as hydroxymethyl, -hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 3-hydroxyethyl hydroxypropyl, 2-hydroxypropyl, 1-hydroxypropyl, 1-hydroxypropyl 2-hydroxypropan-2-yl, 2,3-dihydroxypropyl, 1,3-Dihydroxypropan-2-yl, 3-hydroxy-2-methyl-propyl, 2 -hydroxy-2-methyl-propyl, 1-hydroxy-2-methyl-propyl, 1-hydroxy-2-methyl-propyl Hydroxybutyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl groups, or isomers thereof.

[0052] The term "C2-C4-hydroxyalkyl" is used interchangeably with "C2-C4-alkyl". where the term is defined above and one or two hydrogen atoms are replaced by a hydroxy group. means a linear or branched saturated monovalent hydrocarbon radical having 2, 3 or 4 carbon atoms, For example, 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 3 -hydroxypropyl, 2-hydroxypropyl, 1-hydroxypropyl, 1-hydroxypropyl 2-hydroxypropan-2-yl, 2,3-dihydroxypropan-2-yl Propyl, 1,3-dihydroxypropan-2-yl, 3-hydroxy-2-methyl-propan Pill, 2-hydroxy-2-methyl-propyl, 1-hydroxy-2-methyl-propyl , 1-hydroxybutyl, 2-hydroxybutyl, 3-hydroxybutyl or 4-hydroxybutyl butyl group, or an isomer thereof.

[0053] The term "C1-C6-haloalkyl" means any alkyl group defined as "C1-C6" above. wherein one or more hydrogen atoms are replaced by the same or different halogen atoms; The halogen atom is a saturated monovalent hydrocarbon group, which may be linear or branched. The C1-C6-haloalkyl group is, for example, fluoromethyl, difluoromethyl, ethyl, trifluoromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2, 2-trifluoroethyl, pentafluoroethyl, 3,3,3-trifluoropropyl, 1,3-Difluoropropan-2-yl, 4,4,4-trifluorobutyl, 5,5,5 -trifluoropentyl or 6,6,6-trifluorohexyl. In particular, said groups are , 1, 2, 3 or 4 carbon atoms (“C1-C4-haloalkyl”), e.g., fulve Fluoromethyl, difluoromethyl, trifluoromethyl, 2-fluoroethyl, 2,2-difluoromethyl Fluoroethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, 3,3,3 -trifluoropropyl, 1,3-difluoropropan-2-yl or 4,4,4-trifluoropropyl It is a fluorobutyl group.

[0054] The term "C1-C6-alkoxy" refers to the term "C1-C6-alkyl" a linear or branched saturated alkyl group of the formula (C1-C6-alkyl)-O-, as defined above; means a hydroxyl group, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy oxy, sec-butoxy, isobutoxy, tert-butoxy, pentyloxy, isopentoxy In particular, the group is an n-butyloxy or n-hexyloxy group or an isomer thereof. , having 2, 3 or 4 carbon atoms (“C1-C4-alkoxy”), such as methoxy, Ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, isobutoxy The aryl group is a tert-butoxy or tert-butoxy group.

[0055] The term "C1-C6-haloalkoxy" means that one or more of the hydrogen atoms are the same or different. Linear or branched, saturated, monovalent C1- as defined above, substituted with halogen atoms In particular, the halogen atom is a fluorine atom. The -C6-haloalkoxy group is, for example, fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy or pentafluoroethoxy .

[0056] The term "C2-C6-alkenyl" includes one or two double bonds, means a linear or branched monovalent hydrocarbon radical having 3, 4, 5, or 6 carbon atoms When the alkenyl group contains two double bonds, the double bonds are conjugated to each other or It is understood that the alkenyl group may form an allene. Thenyl (or "vinyl"), prop-2-en-1-yl (or "allyl"), prop- 1-en-1-yl, but-3-enyl, but-2-enyl, but-1-enyl, Penta-4-enyl, Penta-3-enyl, Penta-2-enyl, Penta-1-enyl Hexa-5-enyl, Hexa-4-enyl, Hexa-3-enyl, Hexa -2-enyl, hex-1-enyl, prop-1-en-2-yl (or "isopropyl 2-methylprop-2-enyl, 1-methylprop-2-enyl, 2- Methylprop-1-enyl, 1-methylprop-1-enyl, 3-methylbut-3- Enyl, 2-methylbut-3-enyl, 1-methylbut-3-enyl, 3-methyl But-2-enyl, 2-methylbut-2-enyl, 1-methylbut-2-enyl, 3-Methylbut-1-enyl, 2-Methylbut-1-enyl, 1-Methylbut-1- Enyl, 1,1-dimethylprop-2-enyl, 1-ethylprop-1-enyl, 1-Propyl vinyl, 1-Isopropyl vinyl, 4-Methylpent-4-enyl, 3- Methylpent-4-enyl, 2-methylpent-4-enyl, 1-methylpent-4 -enyl, 4-methylpent-3-enyl, 3-methylpent-3-enyl, 2- Methylpent-3-enyl, 1-methylpent-3-enyl, 4-methylpent-2 -enyl, 3-methylpent-2-enyl, 2-methylpent-2-enyl, 1- Methylpent-2-enyl, 4-methylpent-1-enyl, 3-methylpent-1 -enyl, 2-methylpent-1-enyl, 1-methylpent-1-enyl, 3- Ethylbut-3-enyl, 2-ethylbut-3-enyl, 1-ethylbut-3-ene yl, 3-ethylbut-2-enyl, 2-ethylbut-2-enyl, 1-ethylbut- -2-enyl, 3-ethylbut-1-enyl, 2-ethylbut-1-enyl, 1- Ethylbut-1-enyl, 2-propylprop-2-enyl, 1-propylprop- 2-enyl, 2-isopropylprop-2-enyl, 1-isopropylprop-2- Enyl, 2-propylprop-1-enyl, 1-propylprop-1-enyl, 2 -Isopropylprop-1-enyl, 1-Isopropylprop-1-enyl, 3,3 -Dimethylprop-1-enyl, 1-(1,1-dimethylethyl)ethenyl, buta-1 ,3-dienyl, penta-1,4-dienyl or hexa-1,5-dienyl group.

[0057] The term "C2-C6-alkynyl" includes one triple bond and includes 2, 3, 4, 5 or has 6 carbon atoms, especially 2, 3 or 4 carbon atoms ("C2-C4-alkynyl"). The term "alkenyl group" refers to a linear or branched monovalent hydrocarbon group having two double bonds. When it contains a bond, the C2-C6-alkynyl group can be, for example, ethynyl, propionyl, prop-2-ynyl (or "propargyl"), but-1-ynyl, but- 2-ynyl, but-3-ynyl, pent-1-ynyl, pent-2-ynyl, pen- Penta-3-ynyl, pent-4-ynyl, hex-1-ynyl, hex-2-ynyl yl, hex-3-ynyl, hex-4-ynyl, hex-5-ynyl, 1-methyl 2-methylbut-3-ynyl, 1-methylbut-3-ynyl, 2-methylbut-3-ynyl 1-methylbut-2-ynyl, 3-methylbut-1-ynyl, 1-ethylpropanol -2-ynyl, 3-methylpent-4-ynyl, 2-methylpent-4-ynyl, 1-methylpent-4-ynyl, 2-methylpent-3-ynyl, 1-methylpenta -3-ynyl, 4-methylpent-2-ynyl, 1-methylpent-2-ynyl, 4-Methylpent-1-ynyl, 3-methylpent-1-ynyl, 2-ethylbut- 3-ynyl, 1-ethylbut-3-ynyl, 1-ethylbut-2-ynyl, 1-propyl 1-Isopropylprop-2-ynyl, 2,2-dimethylprop-2-ynyl 1,1-dimethylbut-3-ynyl, 1,1-dimethylbut-3-ynyl, 1,1-dimethylbut- 2-ynyl or 3,3-dimethylbut-1-ynyl group.

[0058] The term "C3-C6-cycloalkyl" refers to a group containing 3, 4, 5 or 6 carbon atoms. The C3-C6-cycloalkyl group is, for example, a saturated monovalent monocyclic hydrocarbon ring. It is a cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group. The group has 3, 4 or 5 carbon atoms ("C3-C5-cycloalkyl"), e.g. A cyclopropyl, cyclobutyl or cyclopentyl group. In particular, said group is a 3 or 4 carbon atoms (“C3-C4-cycloalkyl”), such as cyclopropyl or cyclopropyl; It is a cyclobutyl group.

[0059] The term "C4-C6-cycloalkenyl" refers to an alkenyl group having 4, 5 or 6 carbon atoms and 1 In particular, the ring has 5 or 6 carbon atoms. ("C5-C6-cycloalkenyl"). The C4-C6-cycloalkenyl group is , for example, monocyclic hydrocarbon rings, such as cyclobutenyl, cyclopentenyl, cyclohexene It is a cycloheptenyl or cycloheptenyl group.

[0060] The term "C3-C6-cycloalkyloxy" means "C3-C6-cycloalkyl " is a saturated alkyl group of the formula (C3-C6-cycloalkyl)-O-, as defined above. means a monovalent group, for example, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy or cyclohexyloxy.

[0061] The term "4- to 7-membered heterocycloalkyl" refers to one or two of the series N, O and S. having a total of 4, 5, 6 or 7 ring atoms, including the same or different ring heteroatoms from means a monocyclic saturated heterocycle.

[0062] The heterocycloalkyl group may be a four-membered ring, such as azetidinyl, oxetanyl, or thietanyl. or 5-membered rings, such as tetrahydrofuranyl, 1,3-dioxolanyl, thiolanyl , pyrrolidinyl, imidazolidinyl, pyrazolidinyl, 1,1-dioxidethiolanyl, 1,2-oxazolidinyl, 1,3-oxazolidinyl or 1,3-thiazolidinyl; or is a six-membered ring, e.g., tetrahydropyranyl, tetrahydrothiopyranyl, piperazinyl, molybdenum, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, 1,3-dioxanyl, 1 ,4-dioxanyl or 1,2-oxazinanyl, for example, or a seven-membered ring, for example azepanyl It can be 1,4-diazepanyl, 1,4-oxazepanyl, It is not limited to:

[0063] The term "5- to 7-membered heterocyclic alkenyl" refers to a heterocyclic ring having one or two double bonds and one or more or two identical or different ring heteroatoms from the series N, O and S, means a monocyclic unsaturated non-aromatic heterocycle having 5, 6 or 7 ring atoms.

[0064] The heterocyclic alkenyl group includes, for example, 4H-pyranyl, 2H-pyranyl, 2,5-dihydropyranyl, and the like. Doro-1H-pyrrolyl, [1,3]dioxolyl, 4H-[1,3,4]thiadiazinyl , 2,5-dihydrofuranyl, 2,3-dihydrofuranyl, 2,5-dihydrothiophene 2,3-dihydrothiophenyl, 4,5-dihydrooxazolyl or 4H-[1,4 ]Tiadinil.

[0065] The term "(4- to 7-membered heterocycloalkyl)oxy" is understood to mean "4- to 7-membered heterocycloalkyl". (4-7 membered heterocycloalkyl)-O-, wherein the term is as defined above. Heterocyclic alkyl means a heterocyclic alkyl.

[0066] The term "nitrogen-containing 4- to 7-membered heterocycloalkyl group" refers to a group consisting of one ring nitrogen atom and an optional silyl group. a total of 4, 5, 6 or 7 ring heteroatoms, including one additional ring heteroatom from each of the rings N, O and S means a monocyclic, saturated heterocycle having ring atoms of

[0067] The nitrogen-containing 4- to 7-membered heterocycloalkyl group may be a 4-membered ring, such as azetidinyl; or a 5-membered ring , for example pyrrolidinyl, imidazolidinyl, pyrazolidinyl, 1,2-oxazolidinyl , 1,3-oxazolidinyl or 1,3-thiazolidinyl; or a 6-membered ring, such as piperidinyl nyl, morpholinyl, thiomorpholinyl, piperazinyl or 1,2-oxazinanyl, e.g. For example, or a seven-membered ring, such as azepanyl, 1,4-diazepanyl or 1,4-oxazepanyl The present invention is not limited to the above.

[0068] The term "heteroaryl" refers to at least one ring heteroatom and optionally a series of heteroaryls. containing 1, 2 or 3 additional ring heteroatoms from N, O and / or S, monovalent monocyclic or bicyclic rings having 5, 6, 8, 9 or 10 ring atoms, linked via a bond It refers to a cyclic aromatic ring (a "5- to 10-membered heteroaryl" group).

[0069] The heteroaryl group may be a 5-membered heteroaryl group, such as thienyl, furanyl, pyrrolidinyl, or the like. aryl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, iso thiazolyl, oxadiazolyl, triazolyl, thiadiazolyl or tetrazolyl; or 6-membered heteroaryl groups, such as pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl or is triazinyl; or a 9-membered heteroaryl group, e.g., benzofuranyl, benzothienyl , benzoxazolyl, benzisoxazolyl, benzimidazolyl, benzothiazolyl benzotriazolyl, thiazolopyridinyl, indazolyl, indolyl, isoindo aryl, indolizinyl or purinyl; or a 10-membered heteroaryl group, such as quinolinyl , quinazolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinoxalinyl or propyl It can be theridinyl.

[0070] Generally, and unless otherwise specified, a heteroaryl or heteroarylene group is All possible isomeric forms of, e.g., tautomers and with respect to the point of attachment to the rest of the molecule. Thus, some illustrative, non-limiting examples include pyridinyl. The term includes pyridin-2-yl, pyridin-3-yl and pyridin-4-yl; The term thienyl includes thien-2-yl and thien-3-yl.

[0071] For example, "C1-C6-alkyl", "C1-C6-haloalkyl", "C1-C6-hydroxyalkyl", "C1-C6-alkoxy" or "C1-C6-haloalkoxy" In the context of the definition of "C1-C6" as used herein, the term "C1-C6" refers to 1 to 6 Alkyl groups having a finite number of carbon atoms, i.e., 1, 2, 3, 4, 5, or 6 carbon atoms means.

[0072] Additionally, as used herein, for example, within the definition of "C3-C6-cycloalkyl" In context, the term "C3-C8" as used herein refers to a finite number of amino acids between 3 and 6. means a cycloalkyl group having 3, 4, 5 or 6 carbon atoms. do.

[0073] Where a range of values ​​is provided, the range includes each value and subrange within the range. It is something that

[0074] for example, "C1-C6" means C1, C2, C3, C4, C5, C6, C1-C6, C1-C5, C1-C4, C1-C3, C1-C2, C2-C6, C2-C5, C2-C4, C2-C 3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and C5-C6 Includes; "C2-C6" means C2, C3, C4, C5, C6, C2-C6, C2-C5, C2- C4, C2-C3, C3-C6, C3-C5, C3-C4, C4-C6, C4-C5, and and C5-C6; "C3-C6" means C3, C4, C5, C6, C3-C6, C3-C5, C3-C4, Includes C4-C6, C4-C5, and C5-C6.

[0075] As used herein, the term "leaving group" refers to a stable group that takes the bonding electrons with it. As a chemical species, it means an atom or group of atoms that are displaced in a chemical reaction. Leaving groups include halides, especially fluoride, chloride, bromide or iodide, (methyl sulfide, nyl)oxy, [(trifluoromethyl)sulfonyl]oxy, [(nonafluorobutyl )sulfonyl]oxy, (phenylsulfonyl)oxy, [(4-methylphenyl)sulfonyl]oxy phenyl]oxy, [(4-bromophenyl)sulfonyl]oxy, [(4-nitrophenyl [(2-nitrophenyl)sulfonyl]oxy, [(4-isopropyl)sulfonyl]oxy propylphenyl)sulfonyl]oxy, [(2,4,6-triisopropylphenyl) sulfonyl]oxy, [(2,4,6-trimethylphenyl)sulfonyl]oxy, [( 4-tert-butylphenyl)sulfonyl]oxy and [(4-methoxyphenyl)sulfonyl]oxy The hydroxy group is selected from the group consisting of hydroxy and hydroxy.

[0076] It is possible for compounds of general formula (I) to exist in isotopic forms. Accordingly, the present invention provides One or more isotopic forms of the compounds of general formula (I), particularly deuterium-containing compounds of general formula (I), nothing.

[0077] The term "isotopic form" of a compound or reagent refers to one of the isotopes that constitute such compound. It is defined as a compound that exhibits an unnatural ratio of more than 100%.

[0078] The term "isotopic forms of compounds of general formula (I)" refers to the isotopic forms of such compounds. is defined as a compound of general formula (I) that exhibits one or more unnatural proportions of the

[0079] The expression "unnatural proportion" means the proportion of such isotopes that is higher than their natural abundance. The natural abundance of an isotope as applied in this context is referred to as “Isotopic Composition.” itions of the Elements 1997″,Pure Appl. Chem., 70(1), 217-235, 1998.

[0080] Examples of such isotopes include hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and bromine. Stable and radioactive isotopes of iodine and iodine, e.g., 2 H (deuterium), 3 H(tritium ), 11 C. 13 C. 14 C. 15 N, 17 O. 18 O. 32 P, 33 P, 33 S, 34 S, 35 S, 36 S, 18 F, 36 Cl, 82 Br, 123 I, 124 I, 125 I, 1 29 I and 131 I and others.

[0081] For the treatment and / or prevention of the disorders specified herein, isotopes of compounds of general formula (I) The form preferably contains deuterium ("deuterium-containing compound of general formula (I)"). Sex isotopes, e.g. 3 H or 14 The isotopic forms of compounds of general formula (I) incorporating C are e.g. For example, these isotopes are useful in drug and / or substrate tissue distribution studies. It is particularly preferred for its ease of incorporation and detectability. 18 F or 11 Positron emission such as C Isotopes can be incorporated into compounds of general formula (I). These isotopic forms are useful in in vivo imaging applications. Beauty 13 C-containing compounds can be used in mass spectrometry in the context of preclinical or clinical trials.

[0082] The isotopic form of the compound of general formula (I) is usually obtained by substituting the isotopic form of the reagent. and preferably by using a deuterium-containing reagent, The desired deuterium can be prepared by methods known to those skilled in the art, such as those described in Depending on the site of deuterium oxidation, in some cases deuterium from DO is added directly to the compound or to other compounds such as Deuterium gas can also be incorporated into useful reagents for synthesizing compounds. Catalytic deuteration of olefinic bonds is a useful reagent for incorporating deuterium. It is a rapid route to the synthesis of hydroxybenzoates using metal catalysts (i.e., Pd, Pt, and Rh) in the presence of deuterium gas. In this way, hydrogen in hydrocarbon-containing functional groups can be directly exchanged for deuterium. Deuterated reagents and synthetic building blocks are available from, for example, C / D / NIsotopes, Quebec , Canada;Cambridge Isotope Laboratories Inc., Andover, MA, USA; and CombiPhos Catal Commercially available from companies such as Systems, Inc., Princeton, NJ, USA. It is being done.

[0083] The term "deuterium-containing compound of general formula (I)" refers to a compound in which one or more hydrogen atoms are replaced by one or more deuterium atoms. The deuterium at each deuteration position of the compound of general formula (I) is replaced by a hydrogen atom. The compound is defined as a compound of general formula (I) having an abundance higher than the natural abundance of deuterium, which is about 0.015%. In particular, in the deuterium-containing compound of general formula (I), each of the compounds of general formula (I) The abundance ratio of deuterium at the deuteration position is 10%, 20%, 30%, 40%, 5% at the position. Higher than 0%, 60%, 70% or 80%, preferably 90%, 95%, 96% or 97% %, and even more preferably, greater than 98% or 99%. It is clear that the abundance of deuterium at the other deuteration positions is independent of the abundance of deuterium at the other deuteration positions. .

[0084] The selective incorporation of one or more deuterium atoms into the compounds of general formula (I) improves the physical properties of the molecules. Chemical properties (e.g., acidity [CL Perrin, et al., J. Am . Chem. Soc., 2007, 129, 4490], basicity [C. L . Perrin et al., J. Am. Chem. Soc., 2005 , 127, 9641], lipophilic [B. Testa et al., Int. J Pharm., 1984, 19(3), 271]) and / or metabolic profile The ratio of the parent compound to the metabolites or the amount of metabolites produced may change. Such changes may result in certain therapeutic benefits. Therefore, metabolic switching, which changes metabolism and the ratio of metabolites, may be preferable in some circumstances. A slowdown in the rate of replacement has been reported (AE Mutlib et al., To xicol. Appl. Pharmacol., 2000, 169, 102) These changes in exposure to the parent drug and metabolites result in deuterium-containing compounds of general formula (I). This can have important consequences for the pharmacodynamics, tolerability, and efficacy of the compound. Deuterium substitution reduces or eliminates the production of unwanted or toxic metabolites, resulting in the production of desired The production of metabolites is promoted (e.g., Nevirapine: AM Sharm a et al., Chem. Res. Toxicol., 2013, 26, 410;Efavirenz: AE Mutlib et al., Tox icol. Appl. Pharmacol., 2000, 169, 102). In other cases, the primary effect of deuteration is to reduce the rate of systemic clearance. As a result, the biological half-life of the compound is extended. Potential clinical benefits include peak These include the ability to maintain similar systemic exposure with reduced levels and elevated trough levels. This allows for the reduction of side effects and the development of new drugs depending on the pharmacokinetic / pharmacodynamic relationship of a particular compound. ML-337 (CJ Wenthur et al. l., J. Med. Chem., 2013, 56, 5208) and Odanaka Tiv (K. Kassahun et al., WO2012 / 112363) This is an example of the deuterium effect. The reduced metabolic rate leads to changes in the rate of total body clearance. Additional cases of increased drug exposure without adverse effects have been reported (e.g., rofecoxib). Schib: F. Schneider et al., Arzneim. Forsch. / Drug. Res., 2006, 56, 295;Telaprevir:F. Mal tais et al., J. Med. Chem., 2009, 52, 79 93) Deuterated drugs that exhibit this effect may reduce dosage requirements (e.g., (e.g., less frequent administration and reduced dose to achieve the desired effect) and / or metabolic burden. may be reduced.

[0085] Compounds of general formula (I) may have multiple possible sites of metabolic attack. To optimize the above effects on metabolic profiles, one or more species of deuterium-hydrogen exchange may be used. It is possible to select a deuterium-containing compound of general formula (I) having the following pattern. The deuterium atom of the deuterium-containing compound of general formula (I) is bonded to a carbon atom, and the ... 450 The compound of general formula (I) is located at a position that is the attack site of metabolic enzymes such as

[0086] In another embodiment, the present invention provides a compound having 1, 2, 3 or 4 deuterium atoms, particularly 1, The present invention relates to deuterium-containing compounds of general formula (I) having two or three deuterium atoms.

[0087] Plural forms of terms such as compounds, salts, polymorphs, hydrates, solvates, etc. are used herein. When used herein, it also refers to the singular compound, salt, polymorph, isomer, hydrate, solvate, etc. It is understood as something.

[0088] A "stable compound" or "stable structure" can be obtained by isolation to a useful degree of purity from a reaction mixture, and compounds that are sufficiently robust to survive formulation into an effective therapeutic agent.

[0089] The compounds of the present invention may contain one or more asymmetric centers, depending on the location and nature of the various substituents desired. One or more asymmetric carbon atoms may be present in either the (R) or (S) configuration. This produces a racemic mixture in the case of a single chiral center, and a diastereomeric mixture in the case of multiple chiral centers. In some cases, a given bond, e.g., two of a particular compound, may be present. Asymmetric structures due to restricted rotation around the central bond adjacent to the substituted aromatic ring It is also possible that there exists

[0090] Preferred compounds are those that produce the more desirable biological activity. , pure or partially purified isomers and stereoisomers or racemic or diastereomeric forms Mixtures of such materials are also included within the scope of this invention. Purification and separation of such materials are well known in the art. This can be done by standard techniques.

[0091] Preferred compounds are those that produce the more desirable biological activity. pure or partially pure isomers and stereoisomers or racemic or diastereoisomers Rheomeric mixtures are also included within the scope of the present invention. Purification and separation of such materials is well known in the art. This can be done by standard techniques known in the art.

[0092] The optical isomers can be obtained by resolution of the racemic mixtures according to conventional methods, e.g., from optically active acids or or formation of diastereoisomeric salts with bases, or formation of covalent diastereomers Examples of suitable acids are tartaric acid, diacetyltartaric acid, ditoluoyl Mixtures of diastereoisomers are known in the art. Physical and chemical separation can be carried out by known methods, for example by chromatography or fractional crystallization. can be separated into their individual diastereomers based on their molecular and / or chemical differences. The optically active bases or acids are then liberated from the separated diastereomeric salts. A different method for separating optical isomers is chiral chromatography (e.g., using a chiral phase). HPLC column), with or without conventional derivatization. The chiral phase may be selected optimally to maximize the separation of the enantiomers. Suitable HPLC columns using are commercially available, for example, in particular, Daicel products such as Chiracel OD and Chiracel Chiracel OJ is also useful. Enzyme isolation, which may involve derivatives, is also useful. Optically active compounds can also be obtained by chiral syntheses using optically active starting materials.

[0093] To distinguish different types of isomers from each other, see IUPAC Rules Section E (Pure Appl Chem 45, 11-30, 1976).

[0094] The present invention relates to benzophenone as a single stereoisomer or a mixture of said stereoisomers in any ratio. All possible stereoisomers of the compounds of the present invention, e.g., (R)- or (S)- The present invention also includes single stereoisomers of the compounds of the present invention, e.g., single enantiomers or Isolation of the single diastereomers can be achieved by any suitable modern method, e.g., chromatographic separation. The separation is carried out by, for example, chiral chromatography, in particular.

[0095] Additionally, compounds of the present invention may exist as tautomers. The compound may contain an amide moiety and may be an amide, or an imidic acid, or one of the two tautomers. They may be present as mixtures in any amount, namely: [ka]

[0096] The present invention relates to tautomers of the compounds of formula (I) as single tautomers or as mixtures of said tautomers in any ratio. The invention includes all possible tautomers of the compounds of the invention.

[0097] Additionally, the compounds of the present invention may be prepared by oxidizing at least one nitrogen of the compounds of the present invention. The present invention provides all such N-oxides. This includes possible N-oxides such as:

[0098] The present invention also relates to metabolites, hydrates, solvates, prodrugs, salts, particularly pharmaceutically acceptable salts. Also included are useful forms of the compounds of the present invention, such as salts and / or coprecipitates.

[0099] The compounds of the present invention can be dissolved in polar solvents, particularly solvents such as water, methanol or ethanol. as a hydrate or as a solvate containing the alcohol as a structural element of the crystal lattice of the compound. The amount of polar solvent, especially water, can be present in a stoichiometric or non-stoichiometric ratio. In the case of stoichiometric solvates, such as hydrates, the solvates may be half, ( Semi-, mono-, sesqui-, di-, tri-, tetra-, penta-, etc. solvates or water Solvates are possible and the present invention includes all such hydrates or solvates.

[0100] Additionally, the compounds of the present invention may be used in free form, e.g., as a free base, or as a free acid, or It can exist as a zwitterion or in the form of a salt. The salts may be any organic or inorganic salts, in particular those commonly used in pharmacy. or used, for example, to isolate or purify the compounds of the invention. It can be an organic or inorganic addition salt.

[0101] The term "pharmaceutically acceptable salt" refers to an inorganic or organic acid addition salt of a compound of the present invention. For example, SM Berge et al., "Pharmaceuti cal Salts,″ J. Pharm. Sci. 1977, 66, 1-1 See 9.

[0102] Suitable pharmaceutically acceptable salts of the compounds of the invention are, for example, sufficiently basic The compound may be an acid addition salt of a compound of the present invention having a nitrogen atom in a chain or in a ring, for example Inorganic or "mineral acids", such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, sulfamic acid, Acid addition salts with bisulfuric acid, phosphoric acid, or nitric acid, or organic acids such as formic acid, acetic acid, acetonitrile, Acetic acid, pyruvic acid, trifluoroacetic acid, propionic acid, butyric acid, hexanoic acid, heptanoic acid, Undecanoic acid, lauric acid, benzoic acid, salicylic acid, 2-(4-hydroxybenzoyl) -Benzoic acid, camphoric acid, cinnamic acid, cyclopentanepropionic acid, digluconic acid, 3-hydroxybenzoic acid 2-Naphthoic acid, Nicotinic acid, Pamoic acid, Pectinic acid, 3-Phenylpropionic acid Acid, pivalic acid, 2-hydroxyethanesulfonic acid, itaconic acid, trifluoromethanesulfonic acid sulfonic acid, dodecyl sulfuric acid, ethanesulfonic acid, benzenesulfonic acid, para-toluenesulfonic acid Sulfonic acid, methanesulfonic acid, 2-naphthalenesulfonic acid, naphthalenedisulfonic acid, camphor sulfonic acid, citric acid, tartaric acid, stearic acid, lactic acid, oxalic acid, malonic acid, amber Acid, malic acid, adipic acid, alginic acid, maleic acid, fumaric acid, D-gluconic acid, mannitol Derivatives, Ascorbic Acid, Glucoheptanoic Acid, Glycerophosphate, Aspartic Acid, Sulfo Examples include acid addition salts with salicylic acid, hemisulfuric acid, or thiocyanic acid.

[0103] Additionally, another suitable pharmaceutically acceptable salt of a compound of the present invention that is sufficiently acidic is alkaline metal salts, such as sodium salts or potassium salts; alkaline earth metal salts, such as calcium salts; ammonium salts, magnesium salts or strontium salts, or aluminum or zinc salts, or from ammonia or an organic primary, secondary or tertiary amine having 1 to 20 carbon atoms amines, such as ethylamine, diethylamine, triethylamine, ethyldiisopropylamine amine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexane Xylamine, dimethylaminoethanol, diethylaminoethanol, tris(hydrogen (oxymethyl)aminomethane, procaine, dibenzylamine, N-methylmorpholine, Arginine, Lysine, 1,2-Ethylenediamine, N-Methylpiperidine, N-Methyl- Glucamine, N,N-dimethyl-glucamine, N-ethyl-glucamine, 1,6-hexane Diamine, glucosamine, sarcosine, serinol, 2-amino-1,3-propanedioic acid 3-amino-1,2-propanediol, 4-amino-1,2,3-butanetriol Ammonium salts derived from ammonium nitrate or quaternary ammonium salts having 1 to 20 carbon atoms ammonium ions, such as tetramethylammonium, tetraethylammonium, tetra(n- propyl)ammonium, tetra(n-butylammonium), N-benzyl-N,N, It is a salt with N-trimethylammonium, choline or benzalkonium.

[0104] Those skilled in the art will further appreciate that acid addition salts of the claimed compounds are readily available. by reaction of the compound with a suitable inorganic or organic acid via any of the known methods described above. Alternatively, it is understood that the alkali metal salts of the acidic compounds of the present invention can be prepared. The salts and alkaline earth metal salts can be prepared by reacting the compounds of the present invention with a suitable base through various known methods. It is produced by reacting

[0105] The present invention relates to the preparation of hydroxybenzoates of the present invention as a single salt or as any mixture of said salts in any ratio. All possible salts of the compounds are included.

[0106] In this specification, particularly in the "Experimental Section", there are some descriptions relating to the synthesis of intermediates or examples of the present invention. Therefore, when a compound is referred to as a salt form with a corresponding base or acid, the individual preparation and / or The exact stoichiometry of the salt form obtained by the purification method is often unknown. It is clear.

[0107] Unless otherwise specified, for example, "hydrochloride salt," "trifluoroacetate salt," "sodium salt," " or "xHCl", "xCF3COOH", "xNa + " and other salt-related chemical names or The term added to the structural formula indicates the salt form, and the stoichiometry of the salt form is No mention of it.

[0108] This means that the synthetic intermediates or example compounds or salts thereof are not subject to the manufacturing and / or purification procedures described. Depending on the preparation method, as a solvate, e.g., a hydrate of unknown stoichiometry (if defined) This also applies when it is obtained as a physical object.

[0109] Additionally, the present invention provides compounds of the present invention as a single polymorph or as a mixture of multiple polymorphs in any ratio. The present invention includes all possible crystalline forms or polymorphs of the compounds of the present invention as such.

[0110] Furthermore, the present invention also includes prodrugs of the compounds according to the present invention. The term "tag" refers to a substance that may itself be physiologically active or inactive. While in the body, they are converted (e.g., metabolically or hydrolytically) into compounds according to the invention. It refers to a compound that is

[0111] The present invention further relates to all possible cyclodextrin inclusion complexes, i.e., α-, β- or γ- -Cyclodextrins, hydroxypropyl-β-cyclodextrins, methyl β-cyclodextrins Contains chlorodextrins.

[0112] According to a second embodiment of the first aspect, the present invention provides a method for manufacturing a semiconductor device comprising: R 1 cyano, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N (H)C2H5, -C(=O)N(CH3)2 and -C(=O)OR 15 Selected from represents a group, R 2 represents a group selected from phenyl, naphthyl, and 5- to 10-membered heteroaryl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, naphthyl and 5-10 membered heteroaryl groups substituted 1, 2, 3 or 4 times Each substituent may be a halogen atom or C1-C6-Alkyl, C3-C5-Cycloalkyl, C1-C6-Hydroxyalkan alkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkoxy) (C1-C2 alkoxy)-(C1-C4 alkoxy)-, C1-C4 alkoxy (Si)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy , -SR 14 , -S(=O)R 14 , -S(=O)2R 14 , -P(=O)(R 14 )2 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12)S(=O)2R 14 , -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 ) 2, 4 to 7 membered complex Cyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl and 5- or 6-membered heteroaryl; or when two substituents of said phenyl group are attached to adjacent ring atoms, they are Together, -(CH2)3-, -CH2-CH(OH)-CH2-, -(CH2)4-, -O- (CH2)2-, -(CH2)2-O-, -CH2-CH(CH3)-O-, -CH2- O-CH2-, -O-(CH2)3-, -(CH2)3-O-, -CH2-O-(CH2 )2-, -(CH2)2-O-CH2-, -O-CH2-O-, -OC(CH3)2- O-, -O-(CH2)2-O-, -N(R 18 )-C(=O)-(C(R 18 )(R 1 9 )) m -, -N(R 18 )-C(=O)-(C(CH2)3)-, -N(R 18 )-( C(R 18 )(R 19 )) m -, -N(R 18 )-C(=O)-O- and -N(R 18 ) -C(=O)-N(R 18 )-, and Also good, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are The remainder of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups It is connected to The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The cyclic alkyloxy group may be substituted one, two or three times, and each substituent may be a halogen atom. atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group The C1-C6-alkyl and C1-C4-alkoxy groups are preferably C3-C4-cyclo It may be substituted with a group selected from alkyl, phenyl and 4- to 7-membered heterocyclic alkyl. Ku, The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from groups selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substituent The substituent is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl group may be substituted once or twice, and each the substituents are independently selected from halogen atoms or C1-C4-alkyl groups, The phenyl, phenoxy and 5- or 6-membered heteroaryl groups are 1 or 2 may be substituted three times, and each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups R 3 is a hydrogen atom or a halogen atom or C1-C6-Alkyl, C2-C4-Alkenyl, C2-C4-Alkynyl, C3-C 5-Cycloalkyl, C4-C5-cycloalkenyl, C1-C4-hydroxyalkyl , C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl) -, C1-C4-alkoxy, (C1-C2 alkoxy)-(C1-C4-alkoxy) -, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, - SR 14 , -S(=O)R 14 , -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 1 2 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 1 4 )2, -N=S(=O)(R 14 ) 2、 -P(=O)(R 14 ) 2, 4 to 7 membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl, and represents a group selected from 5- or 6-membered heteroaryl, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups, Selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocyclic alkyl may be substituted with a group, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R10 ) and oxo are independently selected from the group selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C2-C4-alkenyl group may be substituted with a C1-C4-haloalkyl group. Ku, The C3-C5-cycloalkyl and C4-C5-cycloalkenyl groups are may be substituted twice, each substituent being a halogen atom or a C1-C4-alkyl and independently selected from groups selected from C1-C4-haloalkyl; The phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be present one or two times. It may be substituted, and each substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 4 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C1-C6-haloalkyl, C2-C4-alkenyl, C2- C4-alkynyl, C3-C5-cycloalkyl, C4-C5-cycloalkenyl, C1 -C5-hydroxyalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy) -(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2 alkoxy)- (C1-C4-alkoxy)-, C1-C4-haloalkoxy, -O-(C1-C4-alkoxy)-, C1-C4-haloalkoxy, rukil)-C(=O)OR 15 , -O-(C1-C4-alkyl)-C(=O)N(R 9 )(R 10 ), C3-C5-cycloalkyloxy, -S(=O)R 14 , -S(=O) 2nd Round 14 , cyano, nitro, hydroxy, -N(R 9 )(R 10 ), -N(R 16 )(R 17 ), -N(R 16 )(R 20 ), -C(=O)N(R 9 )(R 10 ), -C(=O) R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N= S(=NH)(R 14 )2, -N=S(=O)(R 14 )2, -P(=O)(R 14 )2 , 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl) represents a group selected from oxy, phenyl and 5- or 6-membered heteroaryl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups, substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; the C1-C4-alkoxy group may be substituted with an oxiran-2-yl group, The C3-C5-cycloalkyl and C4-C6-cycloalkenyl groups may be one or more is optionally substituted twice, each substituent independently being a halogen atom or a C1-C4-alkyl is selected from the group The phenyl and 5- or 6-membered heteroaryl groups are substituted one or two times. each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 5 is a hydrogen atom or a halogen atom or C1-C5-Alkyl, C2-C4-Alkenyl, C2-C4-Alkynyl, C3-C 5-Cycloalkyl, C4-C5-cycloalkenyl, C1-C4-hydroxyalkyl , C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl) -, C1-C4-alkoxy, (C1-C2 alkoxy)-(C2-C4-alkoxy) -, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, - SR 14 , -S(=O)R 14 , -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 1 2 )C(=O)R 13, -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 1 4 )2, -N=S(=O)(R 14 ) 2、 -P(=O)(R 14 ) 2, 4 to 7 membered heterocyclic rings alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl, and represents a group selected from 5- or 6-membered heteroaryl, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C5-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups, Selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocyclic alkyl may be substituted with a group, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl and C4-C5-cycloalkenyl groups are is optionally substituted twice, each substituent independently being a halogen atom or a C1-C4-alkyl is selected from the group The phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be present one or two times. It may be substituted, and each substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 6 is a hydrogen atom, or a fluorine atom, or C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, represents a group selected from hydroxy and oxo, R 7is a hydrogen atom or a halogen atom or selected from C1-C4-alkyl, C1-C4-alkoxy, hydroxy and cyano represents a group R 8 represents a group selected from methyl and ethyl, R 9 and R 10 is, independently in each occurrence, hydrogen, or C1-C4-Alkyl, C2-C4-Hydroxyalkyl, N≡C-(C1-C4-Alkyl) (C1-C4-alkoxy)-(C2-C4-alkyl)-, C3-C4- represents a group selected from cycloalkyl and C2-C4-haloalkyl, or R 9 and R 10 However, together with the nitrogen to which they are attached, they form a nitrogen-containing 4- to 7-membered heterocyclic alkane. represents a alkyl group, The nitrogen-containing 4- to 7-membered heterocyclic alkyl group may be substituted one, two, or three times. , each substituent is a halogen atom or Selected from C1-C4-alkyl, C3-C4-cycloalkyl, hydroxy and oxo are independently selected from the groups or Two substituents bonded to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocyclic alkyl group together with the carbon atom to which they are attached represent a 4- to 7-membered heterocycloalkyl group; The 4- to 7-membered heterocyclic alkyl group may be substituted once or twice, and each substitution The group is a halogen atom or C1-C4-Alkyl, C3-C4-Cycloalkyl, C1-C4-Haloalkyl independently selected from the group consisting of hydroxy and oxo; R 11 is a hydrogen atom or a C1-C4-alkyl, C1-C4-hydroxyalkyl, C a group selected from 1-C4-haloalkyl, phenyl and 5- or 6-membered heteroaryl represents The phenyl and 5- or 6-membered heteroaryl groups are substituted one or two times. Each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 12 represents a hydrogen atom or a C1-C4-alkyl group, R 13 is a hydrogen atom or A group selected from C1-C4-alkyl, phenyl and 5- or 6-membered heteroaryl represents The phenyl and 5- or 6-membered heteroaryl groups are substituted one or two times. Each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 14 C1-C4-alkyl, C1-C4-haloalkyl, C3-C5-cycloalkyl represents a group selected from alkyl, phenyl and 5- or 6-membered heteroaryl; The phenyl and 5- or 6-membered heteroaryl groups are substituted one or two times. Each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10) are selected from are independently selected from the group R 15 represents a hydrogen atom or a C1-C4-alkyl group, R 16 is a hydrogen atom or C1-C4-alkyl, C3-C4-cycloalkyl and C2-C4-haloalkyl represents a group selected from R 17 represents a 4- to 7-membered heterocyclic alkyl group; The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The group is a halogen atom or C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-alkoxy, hydroxypropyl independently selected from the group consisting of hydroxy and oxo; The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via R 18 represents a hydrogen atom or a group selected from methyl and ethyl, R 19 represents a hydrogen atom or a group selected from methyl and ethyl, R 20 represents a (4- to 7-membered heterocyclylalkyl)-(C1-C4-alkyl)- group; The (4- to 7-membered heterocyclic alkyl) portion of the group is substituted one, two, or three times. each substituent may be a halogen atom or C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-alkoxy, hydroxypropyl independently selected from the group consisting of hydroxy and oxo; m represents an integer selected from 1, 2 and 3; n represents an integer selected from 1, 2 and 3; The compounds of the above general formula (I) and their stereoisomers, tautomers, N-oxides and hydrates , solvates and salts, and mixtures thereof.

[0113] According to a variant of the second embodiment of the first aspect, the present invention provides a method for manufacturing a semiconductor device comprising: R 1 cyano, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N (H)C2H5, -C(=O)N(CH3)2 and -C(=O)OR 15 Selected from represents a group, R 2 represents a group selected from phenyl, naphthyl, and 5- to 10-membered heteroaryl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, naphthyl and 5-10 membered heteroaryl groups substituted 1, 2, 3 or 4 times Each substituent may be a halogen atom or C1-C6-Alkyl, C3-C5-Cycloalkyl, C1-C6-Hydroxyalkan alkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkoxy) (C1-C2 alkoxy)-(C1-C4 alkoxy)-, C1-C4 alkoxy (Si)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy , -SR 14 , -S(=O)R 14 , -S(=O)2R 14 , -P(=O)(R 14 )2 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 14 )2, -N=S(=O)(R14 ) 2, 4 to 7 membered complex Cyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl and 5- or 6-membered heteroaryl; or when two substituents of said phenyl group are attached to adjacent ring atoms, they are Together, -(CH2)3-, -(CH2)4-, -O-(CH2)2-, -(CH2)2-O -, -CH2-O-CH2-, -O-(CH2)3-, -(CH2)3-O-, -CH2 -O-(CH2)2-, -(CH2)2-O-CH2-, -O-CH2-O- and -O- (CH2)2-O-, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are The remainder of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups It is connected to The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The cyclic alkyloxy group may be substituted one, two or three times, and each substituent may be a halogen atom. atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The C1-C6-alkyl and C1-C4-alkoxy groups are preferably C3-C4-cyclo It may be substituted with a group selected from alkyl, phenyl and 4- to 7-membered heterocyclic alkyl. Ku, The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from groups selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substituent The substituent is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl group may be substituted once or twice, and each the substituents are independently selected from halogen atoms or C1-C4-alkyl groups, The phenyl, phenoxy and 5- or 6-membered heteroaryl groups are 1 or 2 may be substituted three times, and each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups R 3 is a hydrogen atom or a halogen atom or C1-C6-Alkyl, C2-C4-Alkenyl, C2-C4-Alkynyl, C3-C 5-Cycloalkyl, C4-C5-cycloalkenyl, C1-C4-hydroxyalkyl , C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl) -, C1-C4-alkoxy, (C1-C2 alkoxy)-(C1-C4-alkoxy) -, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, - SR 14 , -S(=O)R 14 , -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 1 2 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 1 4 )2, -N=S(=O)(R 14 ) 2、 -P(=O)(R 14 ) 2, 4 to 7 membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl, and represents a group selected from 5- or 6-membered heteroaryl, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups, Selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocyclic alkyl may be substituted with a group, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl and C4-C5-cycloalkenyl groups are may be substituted twice, each substituent being selected from a halogen atom or a C1-C4-alkyl group. are independently selected from The phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be present one or two times. It may be substituted, and each substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 4 is a hydrogen atom or a halogen atom or C1-C6-Alkyl, C2-C4-Alkenyl, C2-C4-Alkynyl, C3-C 5-Cycloalkyl, C4-C5-cycloalkenyl, C1-C5-hydroxyalkyl , C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl) -, C1-C4-alkoxy, (C1-C2 alkoxy)-(C1-C4-alkoxy) -, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, -S(=O)R 14 , -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), -N(R 16 )(R 17 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 14)2, -N=S(=O)(R 14 )2, -P(=O)(R 14 ) 2, 4- to 7-membered heterocycles Alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl, and and 5- or 6-membered heteroaryl, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups, substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl and C4-C6-cycloalkenyl groups may be one or more is optionally substituted twice, each substituent independently being a halogen atom or a C1-C4-alkyl is selected from the group The phenyl and 5- or 6-membered heteroaryl groups are substituted one or two times. each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 5 is a hydrogen atom or a halogen atom or C1-C5-Alkyl, C2-C4-Alkenyl, C2-C4-Alkynyl, C3-C 5-Cycloalkyl, C4-C5-cycloalkenyl, C1-C4-hydroxyalkyl , C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl) -, C1-C4-alkoxy, (C1-C2 alkoxy)-(C2-C4-alkoxy) -, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, - SR 14 , -S(=O)R 14 , -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 1 2 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 1 4 )2, -N=S(=O)(R 14 ) 2、 -P(=O)(R 14 ) 2, 4 to 7 membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl, and represents a group selected from 5- or 6-membered heteroaryl, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C5-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups, Selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocyclic alkyl may be substituted with a group, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl and C4-C5-cycloalkenyl groups are is optionally substituted twice, each substituent independently being a halogen atom or a C1-C4-alkyl is selected from the group The phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be present one or two times. It may be substituted, and each substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 6 is a hydrogen atom, or a fluorine atom, or C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, represents a group selected from hydroxy and oxo, R 7 is a hydrogen atom or a halogen atom or selected from C1-C4-alkyl, C1-C4-alkoxy, hydroxy and cyano represents a group R 8 represents a group selected from methyl and ethyl, R 9 and R 10 is, independently in each occurrence, hydrogen, or C1-C4-alkyl, (C1-C4-alkoxy)-(C2-C4-alkyl)-, represents a group selected from C3-C4-cycloalkyl and C2-C4-haloalkyl, or R 9 and R 10 However, together with the nitrogen to which they are attached, they form a nitrogen-containing 4- to 7-membered heterocyclic alkane. represents a alkyl group, The nitrogen-containing 4- to 7-membered heterocyclic alkyl group may be substituted one, two, or three times. , each substituent is a halogen atom or Selected from C1-C4-alkyl, C3-C4-cycloalkyl, hydroxy and oxo are independently selected from the groups or Two substituents bonded to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocyclic alkyl group together with the carbon atom to which they are attached represent a 4- to 7-membered heterocycloalkyl group; The 4- to 7-membered heterocyclic alkyl group may be substituted once or twice, and each substitution The group is a halogen atom or C1-C4-Alkyl, C3-C4-Cycloalkyl, C1-C4-Haloalkyl independently selected from the group consisting of hydroxy and oxo; R 11 is a hydrogen atom or a C1-C4-alkyl, C1-C4-hydroxyalkyl, C a group selected from 1-C4-haloalkyl, phenyl and 5- or 6-membered heteroaryl represents The phenyl and 5- or 6-membered heteroaryl groups are substituted one or two times. Each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 12 represents a hydrogen atom or a C1-C4-alkyl group, R 13 is a hydrogen atom or A group selected from C1-C4-alkyl, phenyl and 5- or 6-membered heteroaryl represents The phenyl and 5- or 6-membered heteroaryl groups are substituted one or two times. Each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 14 C1-C4-alkyl, C1-C4-haloalkyl, C3-C5-cycloalkyl represents a group selected from alkyl, phenyl and 5- or 6-membered heteroaryl; The phenyl and 5- or 6-membered heteroaryl groups are substituted one or two times. Each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 15 represents a hydrogen atom or a C1-C4-alkyl group, R 16 is a hydrogen atom or C1-C4-alkyl, C3-C4-cycloalkyl and C2-C4-haloalkyl represents a group selected from R 17 represents a 4- to 7-membered heterocyclic alkyl group; The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The group is a halogen atom or C1-C4-alkyl, C3-C4-cycloalkyl, C1-C4-alkoxy, hydroxypropyl independently selected from the group consisting of hydroxy and oxo; The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via n represents an integer selected from 1, 2 and 3; The compounds of the above general formula (I) and their stereoisomers, tautomers, N-oxides and hydrates , solvates and salts, and mixtures thereof.

[0114] According to a third embodiment of the first aspect, the present invention provides a method for manufacturing a semiconductor device comprising: R 1 cyano, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N (H)C2H5, -C(=O)N(CH3)2 and -C(=O)OR 15 Selected from represents a group, R 2 represents a group selected from phenyl, naphthyl, and 5- to 10-membered heteroaryl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, naphthyl and 5-10 membered heteroaryl groups substituted 1, 2, 3 or 4 times Each substituent may be a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C2-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 1 4 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 1 0 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O )2R 14 , -N=S(=O)(R 14 ) 2, 4 to 7 membered heterocyclic alkyl, phenyl and 5 or 6-membered heteroaryl; or when two substituents of said phenyl group are attached to adjacent ring atoms, they are Together, -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC( CH3)2-O-, -N(R 18 )-C(=O)-(C(R18 )(R 19 )) m -,- N(R 18 )-C(=O)-(C(CH2)3)-, -N(R 18 )-(C(R 18 )( R 19 )) m -, -N(R 18 )-C(=O)-O- and -N(R 18 )-C(=O)- N(R 18 )-, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C1-C4-alkoxy group is selected from phenyl and 4- to 7-membered heterocyclic alkyl. may be substituted with a group The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The phenyl, phenoxy and 5- or 6-membered heteroaryl groups are 1 or 2 may be substituted three times, and each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups R 3 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C2-C4-alkenyl, C3-C5-cycloalkyl, (C 1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C1 -C4-haloalkoxy, C3-C5-cycloalkyloxy, -S(=O)2R 14 , Cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), - P(=O)(R 14 )2, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- represents a group selected from 7-membered heterocyclic alkyl)oxy and phenyl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C2-C4-alkenyl group may be substituted with a C1-C4-haloalkyl group. Ku, The C3-C5-cycloalkyl group may be substituted once or twice, and each substitution The substituents are selected from halogen atoms or C1-C4-alkyl and C1-C4-haloalkyl. are independently selected from the groups R 4 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C1-C6-haloalkyl, C3-C5-cycloalkyl, ( C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, ( C1-C2 alkoxy)-(C1-C4 alkoxy)-, -O-(C1-C4 alkoxy)- (=O)-C(=O)OR 15 , -O-(C1-C4-alkyl)-C(=O)N(R 9 )( R 10 ), C3-C5-cycloalkyloxy, -S(=O)2R 14 , cyano, nitro , hydroxy, -N(R 9 )(R 10 ), -N(R 16 )(R 17), -N(R 16 )( R 20 ), -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 )2, -P(= O)(R 14 ) 2, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic represents a group selected from the group consisting of (heterocyclic alkyl)oxy and phenyl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10) and oxo are independently selected from the group The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; the C1-C4-alkoxy group may be substituted with an oxiran-2-yl group, The C3-C5-cycloalkyl group may be substituted once or twice, and each substitution the substituents are independently selected from halogen atoms or C1-C4-alkyl groups; The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 5 is a hydrogen atom or a halogen atom or C1-C5-alkyl, C3-C5-cycloalkyl, C1-C4-alkoxy, C3 -C5-cycloalkyloxy, -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 1 2 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 1 4 )2, -N=S(=O)(R 14 ) 2、 -P(=O)(R 14) 2, 4 to 7 membered heterocyclic rings represents a group selected from alkyl and (4- to 7-membered heterocyclic alkyl)oxy; The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C5-alkyl and C1-C4-alkoxy groups are Selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocyclic alkyl may be substituted with a group, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl group may be substituted once or twice, and each substitution the substituents are independently selected from halogen atoms or C1-C4-alkyl groups; R 6 is a hydrogen atom or C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, represents a group selected from hydroxy and oxo, R 7 is a hydrogen atom or a halogen atom or represents a group selected from C1-C4-alkyl, C1-C4-alkoxy and hydroxy death, R 8 represents a group selected from methyl and ethyl, R 9 and R 10 is, independently in each occurrence, hydrogen, or C1-C4-Alkyl, C2-C4-Hydroxyalkyl, N≡C-(C1-C4-Alkyl) (C1-C4-alkoxy)-(C2-C4-alkyl)- and C3-C4 -cycloalkyl, or R 9 and R 10 However, together with the nitrogen to which they are attached, they form a nitrogen-containing 4- to 7-membered heterocyclic alkane. represents a alkyl group, The nitrogen-containing 4- to 7-membered heterocyclic alkyl group may be substituted one, two, or three times. , each substituent is a halogen atom or Selected from C1-C4-alkyl, C3-C4-cycloalkyl, hydroxy and oxo are independently selected from the groups or Two substituents bonded to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocyclic alkyl group together with the carbon atom to which they are attached represent a 4- to 7-membered heterocycloalkyl group; The 4- to 7-membered heterocyclic alkyl group may be substituted once or twice, and each substitution The group is a halogen atom or C1-C4-Alkyl, C3-C4-Cycloalkyl, C1-C4-Haloalkyl independently selected from the group consisting of hydroxy and oxo; R 11 is selected from a hydrogen atom or C1-C4-alkyl and C1-C4-haloalkyl represents a group R 12 represents a hydrogen atom, R 13 represents a phenyl group, R 14 represents a group selected from C1-C4-alkyl and phenyl, The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 15 represents a hydrogen atom or a C1-C4-alkyl group, R 16 represents a hydrogen atom or a C1-C4-alkyl group, R 17 represents a 4- to 7-membered heterocyclic alkyl group; The 4- to 7-membered heterocyclic alkyl group is substituted once or twice with a C1-C4 alkyl group. It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via R 18 represents a hydrogen atom or a methyl group; R 19 represents a hydrogen atom or a methyl group; R 20 represents a (4- to 7-membered heterocyclylalkyl)-(C1-C4-alkyl)- group; The (4- to 7-membered heterocyclic alkyl) portion of the group is at least one C1-C4 alkyl group. may be substituted at most twice, m represents an integer selected from 1 and 2; n represents an integer selected from 1, 2 and 3; The compounds of the above general formula (I) and their stereoisomers, tautomers, N-oxides and hydrates , solvates and salts, and mixtures thereof.

[0115] According to a variant of the third embodiment of the first aspect, the present invention provides a method for manufacturing a semiconductor device comprising: R 1 cyano, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N (H)C2H5, -C(=O)N(CH3)2 and -C(=O)OR 15 Selected from represents a group, R 2 represents a group selected from phenyl, naphthyl, and 5- to 10-membered heteroaryl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, naphthyl and 5-10 membered heteroaryl groups substituted 1, 2, 3 or 4 times Each substituent may be a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 14 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C (=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=O)(R 14 )2 and phenyl independently selected from the groups the C1-C4-alkoxy group may be substituted with a phenyl group, The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups R 3 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)- (C1-C4-alkyl)-, C1-C4-alkoxy, C3-C5-cycloalkyl Oxygen, -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), -P(= O)(R 14 ) 2, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic represents a group selected from the group consisting of (heterocyclic alkyl)oxy and phenyl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl group may be substituted once or twice, and each substitution the substituents are independently selected from halogen atoms or C1-C4-alkyl groups, R 4 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)- (C1-C4-alkyl)-, C1-C4-alkoxy, C3-C5-cycloalkyl Oxygen, -S(=O)2R 14 , cyano, -N(R 9 )(R 10 ), -N(R 16 )(R 1 7 ), -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 )2, -P(=O) (R 14 )2, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic represents a group selected from alkyl)oxy and phenyl, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl group may be substituted once or twice, and each substitution the substituents are independently selected from halogen atoms or C1-C4-alkyl groups; The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 5 is a hydrogen atom or a halogen atom or C1-C5-alkyl, C3-C5-cycloalkyl, C1-C4-alkoxy, C3 -C5-cycloalkyloxy, -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R11 , -N(R 1 2 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 1 4 )2, -N=S(=O)(R 14 ) 2、 -P(=O)(R 14 ) 2, 4 to 7 membered heterocyclic rings represents a group selected from alkyl and (4- to 7-membered heterocyclic alkyl)oxy; The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via The 4- to 7-membered heterocyclic alkyl group and the (4- to 7-membered heterocyclic alkyl)oxy group are each independently selected from the group consisting of 1, 2 or more. It may be substituted three times or three times, each of the substituents being a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C5-alkyl and C1-C4-alkoxy groups are Selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocyclic alkyl may be substituted with a group, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R10 ) and oxo are independently selected from the group selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl group may be substituted once or twice, and each substitution the substituents are independently selected from halogen atoms or C1-C4-alkyl groups; R 6 is a hydrogen atom or C1-C4-alkyl, C1-C4-hydroxyalkyl, C1-C4-alkoxy, represents a group selected from hydroxy and oxo, R 7 is a hydrogen atom or a halogen atom or represents a group selected from C1-C4-alkyl and hydroxy, R 8 represents a group selected from methyl and ethyl, R 9 and R 10 represents independently in each case hydrogen or a C-C-alkyl group, or R 9 and R 10 However, together with the nitrogen to which they are attached, they form a nitrogen-containing 4- to 7-membered heterocyclic alkane. represents a alkyl group, The nitrogen-containing 4- to 7-membered heterocyclic alkyl group may be substituted one, two, or three times. , each substituent is a halogen atom or Selected from C1-C4-alkyl, C3-C4-cycloalkyl, hydroxy and oxo are independently selected from the groups or Two substituents bonded to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocyclic alkyl group together with the carbon atom to which they are attached represent a 4- to 7-membered heterocycloalkyl group; The 4- to 7-membered heterocyclic alkyl group may be substituted once or twice, and each substitution The group is a halogen atom or C1-C4-Alkyl, C3-C4-Cycloalkyl, C1-C4-Haloalkyl independently selected from the group consisting of hydroxy and oxo; R 11 represents a hydrogen atom or a C1-C4-haloalkyl group, R 12 represents a hydrogen atom, R 13 represents a phenyl group, R 14 represents a group selected from C1-C4-alkyl and phenyl, The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from are independently selected from the group R 15 represents a hydrogen atom or a C1-C4-alkyl group, R 16 represents a hydrogen atom or a C1-C4-alkyl group, R 17 represents a 4- to 7-membered heterocyclic alkyl group; The 4- to 7-membered heterocyclic alkyl group is substituted once or twice with a C1-C4 alkyl group. It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via n represents an integer selected from 1, 2 and 3; The compounds of the above general formula (I) and their stereoisomers, tautomers, N-oxides and hydrates , solvates and salts, and mixtures thereof.

[0116] According to a fourth embodiment of the first aspect, the present invention provides a method for manufacturing a semiconductor device comprising: R 1 cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O) N(CH3)2, R 2 represents a group selected from phenyl, naphthyl, and 5- to 10-membered heteroaryl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, naphthyl and 5-10 membered heteroaryl groups substituted 1, 2, 3 or 4 times Each substituent may be a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C2-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 1 4 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 1 0 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O )2R14 , -N=S(=O)(R 14 ) 2, 4 to 7 membered heterocyclic alkyl, phenyl and 5 or 6-membered heteroaryl; or when two substituents of said phenyl group are attached to adjacent ring atoms, they are Together, -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC (CH3)2-O-, -N(R 18 )-C(=O)-(C(R 18 )(R 19 )) m -, -N(R 18 )-C(=O)-(C(CH2)3)-, -N(R 18 )-(C(R 18 ) (R 19 )) m -, -N(R 18 )-C(=O)-O- and -N(R 18 )-C(=O) -N(R 18 )-, wherein the The 4- to 7-membered heterocyclic alkyl group is connected to the end of the molecule via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. It is connected to the rest of the The C1-C4-alkoxy group is selected from 4- to 7-membered heterocyclic alkyl and phenyl. may be substituted with a group The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The phenyl and 5- or 6-membered heteroaryl groups are mono- or disubstituted. Each substituent may be a halogen atom or C1-C2-alkyl, C1-C2-haloalkyl and C1-C2-alkoxy are independently selected from the group selected from R 3is a hydrogen atom or a halogen atom or C1-C6-alkyl, C2-C4-alkenyl, C3-C5-cycloalkyl, (C 1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C1 -C4-haloalkoxy, C3-C5-cycloalkyloxy, -S(=O)2R 14 , Cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), - P(=O)(R 14 )2, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- represents a group selected from 7-membered heterocyclic alkyl)oxy and phenyl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C3-C4-cycloalkyl group may be substituted once or twice with a cyano group. Ku, The C2-C4-alkenyl group may be substituted with a C1-C4-haloalkyl group. Ku, The C3-C5-cycloalkyl group may be substituted once or twice, and each substitution The substituents are independently selected from halogen atoms or C1-C4-alkyl and C1-C4-haloalkyl is selected from the group selected from R 4is a hydrogen atom or a halogen atom or C1-C6-alkyl, C1-C6-haloalkyl, C3-C5-cycloalkyl, ( C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, ( C1-C2 alkoxy)-(C1-C4 alkoxy)-, -O-(C1-C4 alkoxy)- (=O)-C(=O)OR 15 , -O-(C1-C4-alkyl)-C(=O)N(R 9 )( R 10 ), C3-C5-cycloalkyloxy, -S(=O)2R 14 , cyano, nitro , hydroxy, -N(R 9 )(R 10 ), -N(R 16 )(R 17 ), -N(R 16 )( R 20 ), -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 )2, -P(= O)(R 14 ) 2, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic represents a group selected from the group consisting of (heterocyclic alkyl)oxy and phenyl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; the C1-C4-alkoxy group may be substituted with an oxiran-2-yl group, The C3-C5-cycloalkyl may be substituted once or twice, and each substitution groups are independently selected from halogen atoms or C1-C4-alkyl groups, R 5 is a hydrogen atom or a halogen atom or C1-C5-alkyl, C3-C5-cycloalkyl, C1-C4-alkoxy, C3 -C5-cycloalkyloxy, -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), 4- to 7-membered heterocyclic alkyl, and (4- to 7-membered heterocyclic alkyl)oxy. represents a group selected from The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via R 6 is a hydrogen atom or represents a group selected from C1-C4-alkyl and C1-C4-hydroxyalkyl , R 7 is a hydrogen atom or a halogen atom or a group selected from C1-C4-alkyl, C1-C4-alkoxy and hydroxy; Represents, R 8 represents a group selected from methyl and ethyl, R 9 and R 10 is, independently in each occurrence, a hydrogen atom or C1-C4-alkyl, C2- C4-hydroxyalkyl, N≡C-(C1-C4-alkyl)-, (C1-C4-alkanol C2-C4-cycloalkyl)- and C3-C4-cycloalkyl represents a group, or R 9 and R 10 However, together with the nitrogen to which they are attached, they form a nitrogen-containing 4- to 7-membered heterocyclic alkane. represents a alkyl group, The nitrogen-containing 4- to 7-membered heterocycloalkyl group may be substituted one, two, or three times. each substituent being selected from halogen atoms or C1-C4-alkyl, hydroxy and oxo; are independently selected from the groups or Two substituents bonded to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocyclic alkyl group together with the carbon atom to which they are attached, represent a 4- to 7-membered heterocyclic alkyl group. The 4- to 7-membered heterocyclic alkyl group is substituted once or twice with a C1-C4 alkyl group. It may be R 11 represents a group selected from C1-C4-alkyl and C1-C4-haloalkyl; death, R 12 represents a hydrogen atom, R 13 represents a phenyl group, R 14 represents a group selected from C1-C4-alkyl and phenyl, R 15 represents a hydrogen atom or a C1-C4-alkyl group, R 16 represents a hydrogen atom or a C1-C4-alkyl group, R 17 represents a 4- to 7-membered heterocyclic alkyl group; The 4- to 7-membered heterocyclic alkyl group is substituted once or twice with a C1-C4 alkyl group. It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via R 18 represents a hydrogen atom or a methyl group; R19 represents a hydrogen atom or a methyl group; R 20 represents a (4- to 7-membered heterocyclylalkyl)-(C1-C4-alkyl)- group; The (4- to 7-membered heterocyclic alkyl) portion of the group is at least one C1-C4 alkyl group. may be substituted at most twice, m represents an integer selected from 1 and 2; n represents an integer selected from 1, 2 and 3; The compounds of the above general formula (I) and their stereoisomers, tautomers, N-oxides and hydrates , solvates and salts, and mixtures thereof.

[0117] According to a variant of the fourth embodiment of the first aspect, the present invention provides a method for manufacturing a semiconductor device comprising: R 1 cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O) N(CH3)2, R 2 represents a group selected from phenyl, naphthyl, and 5- to 10-membered heteroaryl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, naphthyl and 5-10 membered heteroaryl groups substituted 1, 2, 3 or 4 times Each substituent may be a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 14 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C (=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=O)(R 14 )2 and phenyl independently selected from the groups the C1-C4-alkoxy group may be substituted with a phenyl group, R 3 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)- (C1-C4-alkyl)-, C1-C4-alkoxy, C3-C5-cycloalkyl Oxygen, -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), 4-7 members Heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy and fluoro represents a group selected from the group consisting of phenyl, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C3-C4-cycloalkyl group may be substituted once or twice with a cyano group. Ku, The C3-C5-cycloalkyl group is substituted one or two times with a halogen atom. It is also good to R 4is a hydrogen atom or a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)- (C1-C4-alkyl)-, C1-C4-alkoxy, C3-C5-cycloalkyl Oxygen, -S(=O)2R 14 , cyano, -N(R 9 )(R 10 ), -N(R 16 )(R 1 7 ), -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 ) 2, 4 to 7 membered complex Heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy and phenyl represents a group selected from The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl may be substituted once or twice, and each substitution groups are independently selected from halogen atoms or C1-C4-alkyl groups, R 5 is a hydrogen atom or a halogen atom or C1-C5-alkyl, C3-C5-cycloalkyl, C1-C4-alkoxy, C3 -C5-cycloalkyloxy, -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), 4- to 7-membered heterocyclic alkyl, and (4- to 7-membered heterocyclic alkyl)oxy. represents a group selected from The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via R 6 is a hydrogen atom or represents a group selected from C1-C4-alkyl and C1-C4-hydroxyalkyl , R 7 is a hydrogen atom or a halogen atom or represents a group selected from C1-C4-alkyl and hydroxy, R 8 represents a group selected from methyl and ethyl, R 9 and R 10 represents, independently in each case, a hydrogen atom or a C1-C4-alkyl group, or R 9 and R 10 However, together with the nitrogen to which they are attached, they form a nitrogen-containing 4- to 7-membered heterocyclic alkane. represents a alkyl group, The nitrogen-containing 4- to 7-membered heterocycloalkyl group may be substituted one, two, or three times. each substituent being selected from halogen atoms or C1-C4-alkyl, hydroxy and oxo; are independently selected from the groups or Two substituents bonded to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocyclic alkyl group together with the carbon atom to which they are attached, represent a 4- to 7-membered heterocyclic alkyl group. The 4- to 7-membered heterocyclic alkyl group is substituted once or twice with a C1-C4 alkyl group. It may be R 11 represents a C1-C4-haloalkyl group, R 12 represents a hydrogen atom, R 13 represents a phenyl group, R 14 represents a group selected from C1-C4-alkyl and phenyl, R 16 represents a hydrogen atom or a C1-C4-alkyl group, R 17 represents a 4- to 7-membered heterocyclic alkyl group; The 4- to 7-membered heterocyclic alkyl group is substituted once or twice with a C1-C4 alkyl group. It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via n represents an integer selected from 1, 2 and 3; The compounds of the above general formula (I) and their stereoisomers, tautomers, N-oxides and hydrates , solvates and salts, and mixtures thereof.

[0118] According to a fifth embodiment of the first aspect, the present invention provides a method for manufacturing a semiconductor device comprising: R 1 cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O) N(CH3)2, R 2 is selected from phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl represents a group selected from The 5- to 10-membered heteroaryl group is selected from the group consisting of pyrazolyl, 1,2,4-oxadiazole, 1, 3,4-Oxadiazole, 1H-1,2,3-Triazolyl, 2H-1,2,3-Triazolyl Azolyl, 1,3-thiazolyl, pyridinyl, pyrazinyl, indolyl, benzothiophene nyl, benzofuranyl, 1,3-benzoxazolyl, indazolyl, benzimidazolyl benzothiazolyl, 1,3-benzothiazolyl, pyrrolo[2,3-b]pyridinyl, quinolinyl, isoxa quinoxalinyl, quinoxalinyl, and 1,3-thiazolo[5,4-b]pyridinyl. , The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl groups are 1, 2, It may be substituted 3 or 4 times, each of the substituents being a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C2-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 1 4 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 1 0 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O )2R 14 , -N=S(=O)(R 14 ) 2, 4- to 7-membered heterocyclic alkyl, phenyl and phenyl lysinyl; or when two substituents of said phenyl group are attached to adjacent ring atoms, they are Together, -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC( CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O )-C(CH3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2- C(CH3)2-, -N(CH3)-C(=O)-O- and -N(CH3)-C(=O) may be linked together to form a group selected from -N(CH3)-, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C1-C4-alkoxy group is selected from 4- to 7-membered heterocyclic alkyl and phenyl. may be substituted with a group The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The phenyl group may be substituted one or two times, each substituent being a halogen. Atom or C1-C2-alkyl, C1-C2-haloalkyl and C1-C2-alkoxy are independently selected from the group selected from R 3 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C2-C4-alkenyl, C3-C5-cycloalkyl, (C 1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C1 -C4-haloalkoxy, C3-C5-cycloalkyloxy, -S(=O)2R 14 , Cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), - P(=O)(R 14 )2, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- represents a group selected from 7-membered heterocyclic alkyl)oxy and phenyl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C3-C4-cycloalkyl group may be substituted once or twice with a cyano group. Ku, The C2-C4-alkenyl group may be substituted with a C1-C4-haloalkyl group. Ku, The C3-C5-cycloalkyl group is selected from the group consisting of halogen atoms and C1-C4-alkyl and may be substituted one or two times with a group selected from C1-C4-haloalkyl, R 4 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C1-C6-haloalkyl, C3-C5-cycloalkyl, ( C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, ( C1-C2 alkoxy)-(C1-C4 alkoxy)-, -O-CH2-C(=O)O R 15 , -O-CH2-C(=O)N(R 9 )(R 10 ), C3-C5-cycloalkyl Oxy, -S(=O)2R 14 , cyano, nitro, hydroxy, -N(R 9 )(R 10 ) , -N(R 16 )(R17 ), -N(R 16 )(R 20 ), -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 )2, -P(=O)(R 14 ) 2, 4- to 7-membered heterocyclic alkane alkyl, 5-7 membered heterocyclic alkenyl, (4-7 membered heterocyclic alkyl)oxy and phenyl represents a group selected from The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; the C1-C4-alkoxy group may be substituted with an oxiran-2-yl group, The C3-C5-cycloalkyl group may be substituted once or twice, and each substitution the substituents are independently selected from halogen atoms or C1-C4-alkyl groups; R 5 is a hydrogen atom or a halogen atom or C1-C5-alkyl, C3-C5-cycloalkyl, C1-C4-alkoxy, C3 -C5-cycloalkyloxy, -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R10 ), 4- to 7-membered heterocyclic alkyl, and (4- to 7-membered heterocyclic alkyl)oxy. represents a group selected from The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via R 6 is a hydrogen atom or represents a group selected from C1-C4-alkyl and C1-C4-hydroxyalkyl , R 7 is a hydrogen atom or a halogen atom or a group selected from C1-C4-alkyl, C1-C4-alkoxy and hydroxy; Represents, R 8 represents a group selected from methyl and ethyl, R 9 and R 10 is, independently in each occurrence, a hydrogen atom or C1-C4-alkyl, C2- C4-hydroxyalkyl, N≡C-(C1-C4-alkyl)-, (C1-C4-alkanol C2-C4-cycloalkyl)- and C3-C4-cycloalkyl represents a group, or R 9 and R 10 However, together with the nitrogen to which they are attached, they form a nitrogen-containing 4- to 7-membered heterocyclic alkane. represents a alkyl group, The nitrogen-containing 4- to 7-membered heterocycloalkyl group may be substituted one, two, or three times. each substituent being selected from halogen atoms or C1-C4-alkyl, hydroxy and oxo; are independently selected from the groups or Two substituents bonded to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocyclic alkyl group together with the carbon atom to which they are attached, represent a 4- to 7-membered heterocyclic alkyl group. The 4- to 7-membered heterocyclic alkyl group is substituted once or twice with a C1-C4 alkyl group. It may be R 11 represents a group selected from C1-C4-alkyl and C1-C4-haloalkyl; death, R 12 represents a hydrogen atom, R 13 represents a phenyl group, R 14 represents a group selected from C1-C4-alkyl and phenyl, R 15 represents a hydrogen atom or a C1-C4-alkyl group, R 16 represents a hydrogen atom or a C1-C4-alkyl group, R 17 represents a 4- to 7-membered heterocyclic alkyl group; The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via R 20 represents a (4- to 7-membered heterocyclylalkyl)-(C1-C4-alkyl)- group; n represents an integer selected from 1, 2 and 3; The compounds of the above general formula (I) and their stereoisomers, tautomers, N-oxides and hydrates , solvates and salts, and mixtures thereof.

[0119] According to a variant of the fifth embodiment of the first aspect, the present invention provides a method for manufacturing a semiconductor device comprising: R 1 cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O) N(CH3)2, R 2 is selected from phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl represents a group selected from The 5- to 10-membered heteroaryl group is selected from the group consisting of pyrazolyl, 1,2,4-oxadiazole, 1, 3,4-Oxadiazole, 1,3-Thiazolyl, Pyridinyl, Pyrazinyl, Indolyl , benzothiophenyl, benzofuranyl, 1,3-benzoxazolyl, indazolyl, Benzimidazolyl, 1,3-benzothiazolyl, pyrrolo[2,3-b]pyridinyl, quinolinyl, isoquinolinyl, quinoxalinyl and 1,3-thiazolo[5,4-b]pyridinyl Selected from Nil, The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl groups are 1, 2, It may be substituted 3 or 4 times, each of the substituents being a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C2-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 1 4 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 1 0 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O )2R 14 , -N=S(=O)(R 14 ) 2, 4- to 7-membered heterocyclic alkyl, phenyl and phenyl lysinyl; or when two substituents of said phenyl group are attached to adjacent ring atoms, they are Together, -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC( CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O )-C(CH3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2- C(CH3)2-, -N(CH3)-C(=O)-O- and -N(CH3)-C(=O) may be linked together to form a group selected from -N(CH3)-, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C1-C4-alkoxy group is selected from 4- to 7-membered heterocyclic alkyl and phenyl. may be substituted with a group The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The phenyl group may be substituted one or two times, each substituent being a halogen. Atom or C1-C2-alkyl, C1-C2-haloalkyl and C1-C2-alkoxy are independently selected from the group R 3 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C2-C4-alkenyl, C3-C5-cycloalkyl, (C 1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C1 -C4-haloalkoxy, C3-C5-cycloalkyloxy, -S(=O)2R 14 , Cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), - P(=O)(R 14)2, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- represents a group selected from 7-membered heterocyclic alkyl)oxy and phenyl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C3-C4-cycloalkyl group may be substituted once or twice with a cyano group. Ku, The C2-C4-alkenyl group may be substituted with a C1-C4-haloalkyl group. Ku, The C3-C5-cycloalkyl group is selected from the group consisting of halogen atoms and C1-C4-alkyl and may be substituted one or two times with a group selected from C1-C4-haloalkyl, R 4 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C1-C6-haloalkyl, C3-C5-cycloalkyl, ( C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, ( C1-C2 alkoxy)-(C1-C4 alkoxy)-, -O-CH2-C(=O)O R 15 , -O-CH2-C(=O)N(R 9 )(R 10 ), C3-C5-cycloalkyl Oxy, -S(=O)2R 14 , cyano, nitro, hydroxy, -N(R 9 )(R 10) , -N(R 16 )(R 17 ), -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 )2, -P(=O)(R 14 ) 2, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkene represents a group selected from yl, (4- to 7-membered heterocyclylalkyl)oxy, and phenyl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; the C1-C4-alkoxy group may be substituted with an oxiran-2-yl group, The C3-C5-cycloalkyl group may be substituted once or twice, and each substitution the substituents are independently selected from halogen atoms or C1-C4-alkyl groups; R 5 is a hydrogen atom or a halogen atom or C1-C5-alkyl, C3-C5-cycloalkyl, C1-C4-alkoxy, C3 -C5-cycloalkyloxy, -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10), 4- to 7-membered heterocyclic alkyl, and (4- to 7-membered heterocyclic alkyl)oxy. represents a group selected from The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via R 6 is a hydrogen atom or represents a group selected from C1-C4-alkyl and C1-C4-hydroxyalkyl , R 7 is a hydrogen atom or a halogen atom or a group selected from C1-C4-alkyl, C1-C4-alkoxy and hydroxy; Represents, R 8 represents a group selected from methyl and ethyl, R 9 and R 10 is, independently in each occurrence, a hydrogen atom or C1-C4-alkyl, C2- C4-hydroxyalkyl, N≡C-(C1-C4-alkyl)-, (C1-C4-alkanol C2-C4-cycloalkyl)- and C3-C4-cycloalkyl represents a group, or R 9 and R 10 However, together with the nitrogen to which they are attached, they form a nitrogen-containing 4- to 7-membered heterocyclic alkane. represents a alkyl group, The nitrogen-containing 4- to 7-membered heterocycloalkyl group may be substituted one, two, or three times. each substituent being selected from halogen atoms or C1-C4-alkyl, hydroxy and oxo; are independently selected from the groups or Two substituents bonded to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocyclic alkyl group together with the carbon atom to which they are attached, represent a 4- to 7-membered heterocyclic alkyl group. The 4- to 7-membered heterocyclic alkyl group is substituted once or twice with a C1-C4 alkyl group. It may be R 11 represents a group selected from C1-C4-alkyl and C1-C4-haloalkyl; death, R 12 represents a hydrogen atom, R 13 represents a phenyl group, R 14 represents a group selected from C1-C4-alkyl and phenyl, R 15 represents a hydrogen atom or a C1-C4-alkyl group, R 16 represents a hydrogen atom or a C1-C4-alkyl group, R 17 represents a 4- to 7-membered heterocyclic alkyl group; The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via n represents an integer selected from 1, 2 and 3; The compounds of the above general formula (I) and their stereoisomers, tautomers, N-oxides and hydrates , solvates and salts, and mixtures thereof.

[0120] According to a further variant of the fifth embodiment of the first aspect, the present invention provides a method for manufacturing a semiconductor device comprising: R 1 cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O) N(CH3)2, R 2 represents a group selected from phenyl, 1-naphthyl and 5- to 10-membered heteroaryl; death, The 5- to 10-membered heteroaryl group is selected from the group consisting of pyrazolyl, 1,2,4-oxadiazole, 1, 3-thiazolyl, pyridinyl, pyrazinyl, indolyl, benzofuranyl, 1,3-benzoyl benzoxazolyl, benzimidazolyl, 1,3-benzothiazolyl, pyrrolo[2,3-b ]pyridinyl, quinolinyl, isoquinolinyl, quinoxalinyl and 1,3-thiazolo[5 ,4-b]pyridinyl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, 1-naphthyl and 5-10 membered heteroaryl groups occurring 1, 2, 3 or 4 times It may be substituted, and each substituent is a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 14 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C (=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=O)(R 14 )2 and phenyl groups are independently selected from the C1-C4-alkoxy group may be substituted with a phenyl group, R 3 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)- (C1-C4-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, -S(=O)2R 14 , cyano, hydroxy, -N (R 9)(R 10 ), 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered represents a group selected from heterocycloalkyl)oxy and phenyl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C3-C4-cycloalkyl group may be substituted once or twice with a cyano group. Ku, The C3-C5-cycloalkyl group is substituted one or two times with a halogen atom. It is also good to R 4 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)- (C1-C4-alkyl)-, C1-C4-alkoxy, C3-C5-cycloalkyl Oxygen, -S(=O)2R 14 , cyano, -N(R 9 )(R 10 ), -N(R 16 )(R 1 7 ), -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 ) 2, 4 to 7 membered complex Heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy and phenyl represents a group selected from The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl group may be substituted once or twice, and each substitution the substituents are independently selected from halogen atoms or C1-C4-alkyl groups; R 5 is a hydrogen atom or a halogen atom or C1-C5-alkyl, C3-C5-cycloalkyl, C1-C4-alkoxy, C3 -C5-cycloalkyloxy, -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), 4- to 7-membered heterocyclic alkyl, and (4- to 7-membered heterocyclic alkyl)oxy. represents a group selected from The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via R 6 is a hydrogen atom or represents a group selected from C1-C4-alkyl and C1-C4-hydroxyalkyl , R 7 is a hydrogen atom or a halogen atom or represents a group selected from C1-C4-alkyl and hydroxy, R 8 represents a group selected from methyl and ethyl, R 9 and R 10 represents, independently in each case, a hydrogen atom or a C1-C4-alkyl group, or R 9 and R 10 However, together with the nitrogen to which they are attached, they form a nitrogen-containing 4- to 7-membered heterocyclic alkane. represents a alkyl group, The nitrogen-containing 4- to 7-membered heterocycloalkyl group may be substituted one, two, or three times. each substituent being selected from halogen atoms or C1-C4-alkyl, hydroxy and oxo; are independently selected from the groups or Two substituents bonded to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocyclic alkyl group together with the carbon atom to which they are attached, represent a 4- to 7-membered heterocyclic alkyl group. The 4- to 7-membered heterocyclic alkyl group is substituted once or twice with a C1-C4 alkyl group. It may be R 11 represents a C1-C4-haloalkyl group, R 12 represents a hydrogen atom, R 13 represents a phenyl group, R 14 represents a group selected from C1-C4-alkyl and phenyl, R 16 represents a hydrogen atom or a C1-C4-alkyl group, R 17 represents a 4- to 7-membered heterocyclic alkyl group; The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via n represents an integer selected from 1, 2 and 3; The compounds of the above general formula (I) and their stereoisomers, tautomers, N-oxides and hydrates , solvates and salts, and mixtures thereof.

[0121] According to a sixth embodiment of the first aspect, the present invention provides a method for manufacturing a semiconductor device comprising: R 1 cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O) N(CH3)2, R 2 Phenyl, 1-naphthyl, 2-naphthyl, 1H-pyrazol-3-yl, 1H -pyrazol-4-yl, 1H-pyrazol-5-yl, 1,2,4-oxadiazole -5-yl, 1,3,4-oxadiazol-2-yl, 1H-1,2,3-triazol- 2H-1,2,3-triazol-4-yl, 1,3-thiazol-2-yl yl, pyridin-3-yl, pyrazin-2-yl, 1H-indol-5-yl, 1-benzyl 1-benzofuran-4-yl, 1-benzofuran-7-yl, 1H-indol-6-yl, benzothiophen-2-yl, 1,3-benzoxazol-2-yl, 1,3-benzo 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl, 1,3-benzoxazol- 1H-indazol-7-yl, 1H-indazol-5-yl, 1H-benzimidazol-2-yl 1H-benzimidazol-4-yl, 1,3-benzothiazol-2-yl, 1, 3-benzothiazol-4-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol- benzothiazol-6-yl, 1,3-benzothiazol-7-yl, 1H-pyrrolo[2,3 -b]pyridin-3-yl, quinolin-2-yl, quinolin-4-yl, quinolin-6- yl, quinolin-7-yl, isoquinolin-5-yl, isoquinolin-7-yl, isoquinolin quinoxalin-8-yl, quinoxalin-2-yl, quinoxalin-5-yl and 1,3-thiazol-2-yl represents a group selected from the group consisting of 2-azolo[5,4-b]pyridin-2-yl, The group may be substituted one or two times, each substituent independently being fluorine, chlorine or is a bromine atom or Methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoro Methyl, trifluoromethyl, methoxy, ethoxy, propoxy, (propan-2-yl )oxy, methoxymethyl, 2-methoxyethyl, benzyloxy, trifluoromethoxy 2,2,2-trifluoroethoxy, phenoxy, (oxolan-2-yl)methoxy (tetrahydrofuran-2-yl)methoxy, methanesulfonyl, dimethylphosphoryl aryl, cyano, hydroxy, dimethylamino, oxetan-3-yl, 2-oxopyrrolidine 4-methyl-2-oxopiperazin-1-yl, 4-methyl-3-oxo Piperazin-1-yl, morpholin-4-yl, 7-oxo-2-oxa-6-azaspirillum 2,8-Diazapiro[3,4]octan-6-yl, 8-methyl-3-oxo-2,8-diazaspiro[4 .5]Decan-2-yl, carbamoyl, acetyl, trifluoroacetyl, benzamido , benzenesulfonamide, [dimethyl(oxide)-λ 6 -sulfanilidene]amine phenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl 4-methylphenyl, 3-trifluoromethylphenyl, 2-methoxyphenyl selected from phenyl, 3-methoxyphenyl, 4-methoxyphenyl and pyridin-3-yl is selected from the group or When two substituents of the phenyl group are attached to adjacent ring atoms, they Together, -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC( CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O )-C(CH3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2- C(CH3)2-, -N(CH3)-C(=O)-O- and -N(CH3)-C(=O) -N(CH3)-, R 3 is a hydrogen atom or a fluorine, chlorine or bromine atom or a methyl, sec-butyl, (oxy) cetan-3-yl)methyl, 3,3,3-trifluoroprop-1-en-2-yl, Cyclopropyl, (trifluoromethyl)cyclopropyl, cyclobutyl, 2,2-dimethyl cyclobutyl, 3,3-difluorocyclobutyl, methoxymethyl, methoxy, ethoxy cyclopropoxy, 2,2-difluoroethoxy, 2,2-difluoropropoxy Propylmethoxy, (1-cyanocyclopropyl)methoxy, cyclopropyloxy, cyano Chlorobutyloxy, methanesulfonyl, cyano, hydroxy, 4-hydroxy-2-oxo 7-oxo-2-oxa-6-azaspiro[3.4]octaiso-pyrrolidin-1-yl benzoyl, carbamoyl, dimethylphosphoryl, oxetan-3-yl, 3,6-di selected from hydro-2H-pyran-4-yl, (oxetan-3-yl)oxy and phenyl represents a group selected from R 4 is a hydrogen atom or a fluorine, chlorine or bromine atom or a methyl, sec-butyl, (oxy) (cetan-3-yl)methyl, trifluoromethyl, cyclopropyl, 3,3-difluoro Cyclobutyl, methoxymethyl, methoxy, propoxy, 2-methoxyethoxy, (1- (hydroxycyclopropyl)methoxy, (1-cyanocyclopropyl)methoxy, (oxy Silane-2-yl)methoxy, carboxymethoxy, 2-tert-butoxy-2-ox 2-ethoxy, 2-amino-2-oxo-ethoxy, cyclopropyloxy, cyclobutyloxy hydroxy, methanesulfonyl, dimethylphosphoryl, cyano, nitro, hydroxy, (silyl) (aminomethyl)(methyl)amino, (2-hydroxyethyl)amino, (2-hydroxyethyl)amino (2-methoxyethyl)(methyl)amino, (2-methoxyethyl)(methyl)amino, (2-methoxyethyl)(methyl)amino (oxetan-3-yl)amino, cyclopropylamino, (oxetan-3-yl)amino, methyl(oxetan-3-yl)amino (cetan-3-yl)amino, methyl(oxolan-3-yl)amino, 3-hydroxya Zetidin-1-yl, 2-oxopyrrolidin-1-yl, morpholino, 1,1-dioxy Dothiomorpholin-4-yl, 4-hydroxy-2-oxo-pyrrolidin-1-yl, 7 -Oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, 2,2-dimethyl Lu-2λ 6 -diazathia-1,2-dien-1-yl, [dimethyl(oxide)-λ 6 - sulfanylidene]amino, methyl(tetrahydrofuran-3-yl)amino, tetrahydrofuran-3-yl Tetrahydrofuran-3-ylmethoxy, (tetrahydrofuran-3-ylmethyl)amino, oxy Cetan-3-yl, 3,6-dihydro-2H-pyran-4-yl, (oxetan-3-yl (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran (tetrahydro-2H-pyran-4-yl)oxy and phenyl represents a group selected from R 5 is a hydrogen atom, a fluorine, chlorine or bromine atom, or a methyl, cyclopropyl, methoxy si, propoxy, cyclopropyloxy, methanesulfonyl, cyano, hydroxy, oxy represents a group selected from cetane-3-yl and oxetan-3-yloxy, R 6 represents a hydrogen atom or a group selected from methyl and hydroxymethyl, R 7 is selected from a hydrogen atom, a fluorine atom, methyl, ethyl, methoxy and hydroxy represents a group selected from R 8 represents a group selected from methyl and ethyl, n represents an integer selected from 1, 2 and 3 The compounds of the above general formula (I) and their stereoisomers, tautomers, N-oxides and hydrates , solvates and salts, and mixtures thereof.

[0122] According to a variant of the sixth embodiment of the first aspect, the present invention provides a method for manufacturing a semiconductor device comprising: R 1 cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O) N(CH3)2, R 2 Phenyl, 1-naphthyl, 2-naphthyl, 1H-pyrazol-3-yl, 1H -pyrazol-4-yl, 1H-pyrazol-5-yl, 1,2,4-oxadiazole -5-yl, 1,3,4-oxadiazol-2-yl, 1,3-thiazol-2-yl , pyridin-3-yl, pyrazin-2-yl, 1H-indol-5-yl, 1-benzoyl Furan-4-yl, 1-benzofuran-7-yl, 1H-indol-6-yl, benzo Thiophen-2-yl, 1,3-benzoxazol-2-yl, 1,3-benzoxazol 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl, 1,3-benzoxazol- 1H-indazol-7-yl, 1H-indazol-5-yl, 1H-benzimidazol-2-yl, 1H-Benzimidazol-4-yl, 1,3-benzothiazol-2-yl, 1,3- Benzothiazol-4-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol Azol-6-yl, 1,3-benzothiazol-7-yl, 1H-pyrrolo[2,3-b ]pyridin-3-yl, quinolin-2-yl, quinolin-4-yl, quinolin-6-yl , quinolin-7-yl, isoquinolin-5-yl, isoquinolin-7-yl, isoquinolin quinoxalin-8-yl, quinoxalin-2-yl, quinoxalin-5-yl and 1,3-thiazolo [5,4-b]pyridin-2-yl, The group may be substituted one or two times, each substituent independently being fluorine, chlorine, or a bromine atom or Methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoro Methyl, trifluoromethyl, methoxy, ethoxy, propoxy, (propan-2-yl )oxy, methoxymethyl, 2-methoxyethyl, benzyloxy, trifluoromethoxy 2,2,2-trifluoroethoxy, phenoxy, (oxolan-2-yl)methoxy (tetrahydrofuran-2-yl)methoxy, methanesulfonyl, dimethylphosphoryl aryl, cyano, hydroxy, dimethylamino, oxetan-3-yl, 2-oxopyrrolidine 4-methyl-2-oxopiperazin-1-yl, 4-methyl-3-oxo Piperazin-1-yl, morpholin-4-yl, 7-oxo-2-oxa-6-azaspirillum 2,8-Diazapiro[3,4]octan-6-yl, 8-methyl-3-oxo-2,8-diazaspiro[4 .5]Decan-2-yl, carbamoyl, acetyl, trifluoroacetyl, benzamido , benzenesulfonamide, [dimethyl(oxide)-λ 6 -sulfanylidene]amine phenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl 4-methylphenyl, 3-trifluoromethylphenyl, 2-methoxyphenyl selected from phenyl, 3-methoxyphenyl, 4-methoxyphenyl and pyridin-3-yl is selected from the group or When two substituents of the phenyl group are attached to adjacent ring atoms, they Together, -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC( CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O )-C(CH3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2- C(CH3)2-, -N(CH3)-C(=O)-O- and -N(CH3)-C(=O) -N(CH3)-, R 3 is a hydrogen atom or a fluorine, chlorine or bromine atom or a methyl, sec-butyl, (oxy) cetan-3-yl)methyl, 3,3,3-trifluoroprop-1-en-2-yl, Cyclopropyl, (trifluoromethyl)cyclopropyl, cyclobutyl, 2,2-dimethyl cyclobutyl, 3,3-difluorocyclobutyl, methoxymethyl, methoxy, ethoxy cyclopropoxy, 2,2-difluoroethoxy, 2,2-difluoropropoxy Propylmethoxy, (1-cyanocyclopropyl)methoxy, cyclopropyloxy, cyano Chlorobutyloxy, methanesulfonyl, cyano, hydroxy, 4-hydroxy-2-oxo 7-oxo-2-oxa-6-azaspiro[3.4]octaiso-pyrrolidin-1-yl benzoyl, carbamoyl, dimethylphosphoryl, oxetan-3-yl, 3,6-di selected from hydro-2H-pyran-4-yl, (oxetan-3-yl)oxy and phenyl represents a group selected from R 4 is a hydrogen atom or a fluorine, chlorine or bromine atom or a methyl, sec-butyl, (oxy) (cetan-3-yl)methyl, trifluoromethyl, cyclopropyl, 3,3-difluoro Cyclobutyl, methoxymethyl, methoxy, propoxy, 2-methoxyethoxy, (1- (hydroxycyclopropyl)methoxy, (1-cyanocyclopropyl)methoxy, (oxy Silane-2-yl)methoxy, carboxymethoxy, 2-tert-butoxy-2-ox 2-ethoxy, 2-amino-2-oxo-ethoxy, cyclopropyloxy, cyclobutyloxy hydroxy, methanesulfonyl, dimethylphosphoryl, cyano, nitro, hydroxy, (silyl) (aminomethyl)(methyl)amino, (2-hydroxyethyl)amino, (2-hydroxyethyl)amino (2-methoxyethyl)(methyl)amino, (2-methoxyethyl)(methyl)amino, (2-methoxyethyl)(methyl)amino (oxetan-3-yl)amino, cyclopropylamino, (oxetan-3-yl)amino, methyl(oxetan-3-yl)amino (cetan-3-yl)amino, methyl(oxolan-3-yl)amino, 3-hydroxya Zetidin-1-yl, 2-oxopyrrolidin-1-yl, morpholino, 1,1-dioxy Dothiomorpholin-4-yl, 4-hydroxy-2-oxo-pyrrolidin-1-yl, 7 -Oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, 2,2-dimethyl Lu-2λ6 -diazathia-1,2-dien-1-yl, [dimethyl(oxide)-λ 6 - sulfanylidene]amino, methyl(tetrahydrofuran-3-yl)amino, oxetane 3,6-dihydro-2H-pyran-4-yl, (oxetan-3-yl) Oxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3 (tetrahydro-2H-pyran-4-yl)oxy and phenyl represents a group selected from R 5 is a hydrogen atom, a fluorine, chlorine or bromine atom, or a methyl, cyclopropyl, methoxy si, propoxy, cyclopropyloxy, methanesulfonyl, cyano, hydroxy, oxy represents a group selected from cetane-3-yl and oxetan-3-yloxy, R 6 represents a hydrogen atom or a group selected from methyl and hydroxymethyl, R 7 is selected from a hydrogen atom, a fluorine atom, methyl, ethyl, methoxy and hydroxy represents a group selected from R 8 represents a group selected from methyl and ethyl, n represents an integer selected from 1, 2 and 3 The compounds of the above general formula (I) and their stereoisomers, tautomers, N-oxides and hydrates , solvates and salts, and mixtures thereof.

[0123] According to a further variant of the sixth embodiment of the first aspect, the present invention provides a method for manufacturing a semiconductor device comprising: R 1 cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O) N(CH3)2, R 2Phenyl, 1-naphthyl, 1H-pyrazol-5-yl, 1,2,4-oxa Diazol-5-yl, 1,3-thiazol-2-yl, pyridin-3-yl, pyrazine -2-yl, 1H-indol-5-yl, 1-benzofuran-4-yl, 1-benzofuran-4-yl, Ran-7-yl, 1,3-benzoxazol-2-yl, 1,3-benzoxazole -5-yl, 1,3-benzoxazol-7-yl, 1H-benzimidazol-2- yl, 1H-benzimidazol-4-yl, 1,3-benzothiazol-2-yl, 1 ,3-benzothiazol-4-yl, 1,3-benzothiazol-7-yl, 1H-pyro 2,3-b]pyridin-3-yl, quinolin-4-yl, isoquinolin-5-yl, Isoquinolin-7-yl, isoquinolin-8-yl, quinoxalin-2-yl, quinoxa thiazolo[5,4-b]pyridin-2-yl and 1,3-thiazolo[5,4-b]pyridin-2-yl represents a group, The group may be substituted one or two times, each substituent independently being fluorine, chlorine or Bromine atom or methyl, propyl, isopropyl, tert-butyl, cyclopropyl, dipropyl Fluoromethyl, trifluoromethyl, methoxy, ethoxy, propoxy, (propane- 2-yl)oxy, benzyloxy, trifluoromethoxy, 2,2,2-trifluoro Ethoxy, phenoxy, methanesulfonyl, dimethylphosphoryl, cyano, hydroxy, Dimethylamino, 2-oxopyrrolidin-1-yl, 4-methyl-2-oxopiperazine -1-yl, 4-methyl-3-oxopiperazin-1-yl, morpholino-4-yl, 7 -oxo-2-oxa-6-azaspiro[3.4]octan-6-yl,8-methyl-3 -oxo-2,8-diazaspiro[4.5]decan-2-yl, carbamoyl, triflate Oroacetyl, benzamide, benzenesulfonamide, [dimethyl(oxide)-λ 6 -sulfanylidene]amino and phenyl, R 3 is a hydrogen atom or a fluorine, chlorine or bromine atom or a methyl, sec-butyl, (oxy) (cetan-3-yl)methyl, cyclopropyl, 3,3-difluorocyclobutyl, methoxy Dimethyl, methoxy, propoxy, (1-cyanocyclopropyl) methoxy, cyclopropyl Pyroxy, cyclobutyloxy, methanesulfonyl, cyano, hydroxy, 4-hydroxy 2-oxo-pyrrolidin-1-yl, 7-oxo-2-oxa-6-azaspiro[ 3.4]octan-6-yl, oxetan-3-yl, 3,6-dihydro-2H-pyran represents a group selected from oxetan-4-yl, (oxetan-3-yl)oxy and phenyl, R 4 is a hydrogen atom or a fluorine, chlorine or bromine atom or a methyl, sec-butyl, (oxy) (cetan-3-yl)methyl, cyclopropyl, 3,3-difluorocyclobutyl, methoxy Dimethyl, methoxy, propoxy, (1-hydroxycyclopropyl)methoxy, (1- Cyanocyclopropyl)methoxy, cyclopropyloxy, cyclobutyloxy, methane Sulfonyl, cyano, 2-oxopyrrolidin-1-yl, morpholino, 1,1-dioxy Dothiomorpholin-4-yl, 4-hydroxy-2-oxo-pyrrolidin-1-yl, 7 -Oxo-2-oxa-6-azaspiro[3.4]octan-6-yl, 2,2-dimethyl Lu-2λ 6 -diazathia-1,2-dien-1-yl, [dimethyl(oxide)-λ 6 - sulfanylidene]amino, methyl(tetrahydrofuran-3-yl)amino, oxetane 3,6-dihydro-2H-pyran-4-yl, (oxetan-3-yl) Oxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3 (tetrahydro-2H-pyran-4-yl)oxy and phenyl represents a group selected from R 5 is a hydrogen atom, a fluorine, chlorine or bromine atom, or a methyl, cyclopropyl, methoxy si, propoxy, cyclopropyloxy, methanesulfonyl, cyano, hydroxy, oxy represents a group selected from cetane-3-yl and oxetan-3-yloxy, R 6 represents a hydrogen atom or a group selected from methyl and hydroxymethyl, R 7 is a hydrogen atom, a fluorine atom, or a group selected from methyl, ethyl, and hydroxy represents R 8 represents a group selected from methyl and ethyl, n represents an integer selected from 1, 2 and 3 The compounds of the above general formula (I) and their stereoisomers, tautomers, N-oxides and hydrates , solvates and salts, and mixtures thereof.

[0124] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 1 cyano, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N (H)C2H5, -C(=O)N(CH3)2 and -C(=O)OR 15 Selected from The compounds of formula (I) above and their stereoisomers, tautomers, N-oxides, This includes hydrates, solvates and salts, and mixtures thereof.

[0125] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 1 cyano, -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N (H) represents a group selected from C2H5 and -C(=O)N(CH3)2, ) and its stereoisomers, tautomers, N-oxides, hydrates, solvates and salts , as well as mixtures thereof.

[0126] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 1 cyano, -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O) N(CH3)2, , tautomers, N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0127] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 1 represents a cyano group and stereoisomers, tautomers thereof, This includes N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0128] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 1 is -C(=O)NH2, -C(=O)N(H)CH3, -C(=O)N(H)C 2H5 and -C(=O)N(CH3)2, and its stereoisomers, tautomers, N-oxides, hydrates, solvates and salts, This includes mixtures thereof.

[0129] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R1 -C(=O)NH2, -C(=O)N(H)CH3 and -C(=O)N(CH 3) Compounds of the above formula (I) and their stereoisomers, tautomers, etc., which represent a group selected from 2 This includes the hydroxybenzoates, N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0130] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a group selected from phenyl, naphthyl, and 5- to 10-membered heteroaryl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, naphthyl and 5-10 membered heteroaryl groups substituted 1, 2, 3 or 4 times Each substituent may be a halogen atom or C1-C6-Alkyl, C3-C6-Cycloalkyl, C1-C6-Hydroxyalkan alkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkoxy) (C1-C2 alkoxy)-(C1-C6 alkoxy)-, C1-C6 alkoxy (Si)-, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy , -SR 14 , -S(=O)R 14 , -S(=O)2R 14 , -P(=O)(R 14 )2 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 14)2, -N=S(=O)(R 14 ) 2, 4 to 7 membered complex Cyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl and 5- or 6-membered heteroaryl; or when two substituents of said phenyl group are attached to adjacent ring atoms, they are Together, -(CH2)3-, -CH2-CH(OH)-CH2-, -(CH2)4-, -O- (CH2)2-, -(CH2)2-O-, -CH2-CH(CH3)-O-, -CH2- O-CH2-, -O-(CH2)3-, -(CH2)3-O-, -CH2-O-(CH2 )2-, -(CH2)2-O-CH2-, -O-CH2-O-, -OC(CH3)2- O-, -O-(CH2)2-O-, -N(R 18 )-C(=O)-(C(R 18 )(R 1 9 )) m -, -N(R 18 )-C(=O)-(C(CH2)3)-, -N(R 18 )-( C(R 18 )(R 19 )) m -, -N(R 18 )-C(=O)-O- and -N(R 18 ) -C(=O)-N(R 18 )-, and Also good, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are The remainder of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups It is connected to The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The cyclic alkyloxy group may be substituted one, two or three times, and each substituent may be a halogen atom. atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The C1-C6-alkyl and C1-C6-alkoxy groups are preferably C3-C4-cyclo It may be substituted with a group selected from alkyl, phenyl and 4- to 7-membered heterocyclic alkyl. Ku, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C6-cycloalkyl group may be substituted once or twice, and each substituent the substituents are independently selected from halogen atoms or C1-C4-alkyl groups; The phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be present one or two times. It may be substituted, each substituent being a halogen atom or a C1-C2-alkyl, C1-C 2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cyclo Alkyl and -N(R 9 )(R 10 ) independently selected from groups selected from the above formula Compounds of (I) and their stereoisomers, tautomers, N-oxides, hydrates, solvates and and salts, and mixtures thereof.

[0131] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a group selected from phenyl, naphthyl, and 5- to 10-membered heteroaryl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, naphthyl and 5-10 membered heteroaryl groups substituted 1, 2, 3 or 4 times Each substituent may be a halogen atom or C1-C6-Alkyl, C3-C5-Cycloalkyl, C1-C6-Hydroxyalkan alkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkoxy) (C1-C2 alkoxy)-(C1-C4 alkoxy)-, C1-C4 alkoxy (Si)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy , -SR 14 , -S(=O)R 14 , -S(=O)2R 14 , -P(=O)(R 14)2 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 ) 2, 4 to 7 membered complex Cyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl and 5- or 6-membered heteroaryl; or when two substituents of said phenyl group are attached to adjacent ring atoms, they are Together, -(CH2)3-, -CH2-CH(OH)-CH2-, -(CH2)4-, -O- (CH2)2-, -(CH2)2-O-, -CH2-CH(CH3)-O-, -CH2- O-CH2-, -O-(CH2)3-, -(CH2)3-O-, -CH2-O-(CH2 )2-, -(CH2)2-O-CH2-, -O-CH2-O-, -OC(CH3)2- O-, -O-(CH2)2-O-, -N(R 18 )-C(=O)-(C(R 18 )(R 1 9 )) m -, -N(R 18 )-C(=O)-(C(CH2)3)-, -N(R 18 )-( C(R 18 )(R 19 )) m -, -N(R 18 )-C(=O)-O- and -N(R 18 ) -C(=O)-N(R 18)-, and Also good, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are The remainder of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups It is connected to The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The cyclic alkyloxy group may be substituted one, two or three times, and each substituent may be a halogen atom. atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The C1-C6-alkyl and C1-C4-alkoxy groups are preferably C3-C4-cyclo It may be substituted with a group selected from alkyl, phenyl and 4- to 7-membered heterocyclic alkyl. Ku, The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from groups selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substituent The substituent is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl group may be substituted once or twice, and each the substituents are independently selected from halogen atoms or C1-C4-alkyl groups, The phenyl, phenoxy and 5- or 6-membered heteroaryl groups are 1 or 2 may be substituted three times, and each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) The compounds of formula (I) above and stereoisomers, tautomers thereof, independently selected from the groups , N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0132] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a group selected from phenyl, naphthyl, and 5- to 10-membered heteroaryl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, naphthyl and 5-10 membered heteroaryl groups substituted 1, 2, 3 or 4 times Each substituent may be a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C2-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 1 4 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 1 0 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O )2R 14 , -N=S(=O)(R 14 ) 2, 4 to 7 membered heterocyclic alkyl, phenyl and 5 or 6-membered heteroaryl; or when two substituents of said phenyl group are attached to adjacent ring atoms, they are Together, -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC (CH3)2-O-, -N(R 18 )-C(=O)-(C(R 18 )(R 19 )) m -, -N(R 18 )-C(=O)-(C(CH2)3)-, -N(R 18 )-(C(R 18 ) (R 19 )) m -, -N(R 18 )-C(=O)-O- and -N(R 18 )-C(=O) -N(R 18 )-, wherein the The 4- to 7-membered heterocyclic alkyl group is connected to the end of the molecule via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. It is connected to the rest of the The C1-C4-alkoxy group is selected from 4- to 7-membered heterocyclic alkyl and phenyl. may be substituted with a group The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The phenyl and 5- or 6-membered heteroaryl groups are mono- or disubstituted. Each substituent may be a halogen atom or C1-C2-alkyl, C1-C2-haloalkyl and C1-C2-alkoxy Compounds of formula (I) above and stereoisomers thereof, independently selected from the group selected from This includes tautomers, N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0133] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 is selected from phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl represents a group selected from The 5- to 10-membered heteroaryl group is Pyrazolyl, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1H -1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1,3-thiazolyl, Pyridinyl, pyrazinyl, indolyl, benzothiophenyl, benzofuranyl, 1,3- benzoxazolyl, indazolyl, benzimidazolyl, 1,3-benzothiazolyl, Pyrrolo[2,3-b]pyridinyl, quinolinyl, isoquinolinyl, quinoxalinyl and 1 ,3-thiazolo[5,4-b]pyridinyl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl groups are 1, 2, It may be substituted 3 or 4 times, each of the substituents being a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C2-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 1 4 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 1 0 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O )2R 14 , -N=S(=O)(R 14 ) 2, 4- to 7-membered heterocyclic alkyl, phenyl and phenyl lysinyl; or when two substituents of said phenyl group are attached to adjacent ring atoms, they are Together, -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC( CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O )-C(CH3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2- C(CH3)2-, -N(CH3)-C(=O)-O- and -N(CH3)-C(=O) may be linked together to form a group selected from -N(CH3)-, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C1-C4-alkoxy group is selected from 4- to 7-membered heterocyclic alkyl and phenyl. may be substituted with a group The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The phenyl group may be substituted one or two times, each substituent being a halogen. Atom or C1-C2-alkyl, C1-C2-haloalkyl and C1-C2-alkoxy Compounds of formula (I) above and stereoisomers thereof, independently selected from the group selected from This includes tautomers, N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0134] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a group selected from 5- to 10-membered heteroaryl; 5-10 membered heteroaryl group Pyrazolyl, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1H -1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1,3-thiazolyl, Pyridinyl, pyrazinyl, indolyl, benzothiophenyl, benzofuranyl, 1,3- benzoxazolyl, indazolyl, benzimidazolyl, 1,3-benzothiazolyl, Pyrrolo[2,3-b]pyridinyl, quinolinyl, isoquinolinyl, quinoxalinyl and 1 ,3-thiazolo[5,4-b]pyridinyl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via The 5- to 10-membered heteroaryl group may be substituted 1, 2, 3, or 4 times, and each substitution The substituent is a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C2-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 1 4 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 1 0 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O )2R 14 , -N=S(=O)(R 14 ) 2, 4- to 7-membered heterocyclic alkyl, phenyl and phenyl lysinyl; The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C1-C4-alkoxy group is selected from 4- to 7-membered heterocyclic alkyl and phenyl. may be substituted with a group The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The phenyl group may be substituted one or two times, each substituent being a halogen. Atom or C1-C2-alkyl, C1-C2-haloalkyl and C1-C2-alkoxy Compounds of formula (I) above and stereoisomers thereof, independently selected from the group selected from This includes tautomers, N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0135] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 is selected from phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl represents a group selected from 5-10 membered heteroaryl group Pyrazolyl, 1,2,4-oxadiazole, 1,3,4-oxadiazole 1,3 -Thiazolyl, pyridinyl, pyrazinyl, indolyl, benzothiophenyl, benzofuranoside nyl, 1,3-benzoxazolyl, indazolyl, benzimidazolyl, 1,3-benzoxazolyl Zothiazolyl, pyrrolo[2,3-b]pyridinyl, quinolinyl, isoquinolinyl, quinoxazolyl selected from salinyl and 1,3-thiazolo[5,4-b]pyridinyl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl groups are 1, 2, It may be substituted 3 or 4 times, each of the substituents being a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C2-alkyl)-, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 1 4 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 1 0 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O )2R 14 , -N=S(=O)(R 14 ) 2, 4- to 7-membered heterocyclic alkyl, phenyl and phenyl lysinyl; or when two substituents of said phenyl group are attached to adjacent ring atoms, they are Together, -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC( CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O )-C(CH3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2- C(CH3)2-, -N(CH3)-C(=O)-O- and -N(CH3)-C(=O) may be linked together to form a group selected from -N(CH3)-, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C1-C4-alkoxy group is selected from 4- to 7-membered heterocyclic alkyl and phenyl. may be substituted with a group The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The phenyl group may be substituted one or two times, each substituent being a halogen. Atom or C1-C2-alkyl, C1-C2-haloalkyl and C1-C2-alkoxy Compounds of formula (I) above and stereoisomers thereof, independently selected from the group selected from This includes tautomers, N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0136] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2Phenyl, 1-naphthyl, 2-naphthyl, 1H-pyrazol-3-yl, 1H -pyrazol-4-yl, 1H-pyrazol-5-yl, 1,2,4-oxadiazole -5-yl, 1,3,4-oxadiazol-2-yl, 1H-1,2,3-triazol- 2H-1,2,3-triazol-4-yl, 1,3-thiazol-2-yl yl, pyridin-3-yl, pyrazin-2-yl, 1H-indol-5-yl, 1-benzyl 1-benzofuran-4-yl, 1-benzofuran-7-yl, 1H-indol-6-yl, benzothiophen-2-yl, 1,3-benzoxazol-2-yl, 1,3-benzo 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl, 1,3-benzoxazol- 1H-indazol-7-yl, 1H-indazol-5-yl, 1H-benzimidazol-2-yl 1H-benzimidazol-4-yl, 1,3-benzothiazol-2-yl, 1, 3-benzothiazol-4-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol- benzothiazol-6-yl, 1,3-benzothiazol-7-yl, 1H-pyrrolo[2,3 -b]pyridin-3-yl, quinolin-2-yl, quinolin-4-yl, quinolin-6- yl, quinolin-7-yl, isoquinolin-5-yl, isoquinolin-7-yl, isoquinolin quinoxalin-8-yl, quinoxalin-2-yl, quinoxalin-5-yl and 1,3-thiazol-2-yl represents a group selected from the group consisting of 2-azolo[5,4-b]pyridin-2-yl, The group may be substituted one or two times, each substituent independently being fluorine, chlorine or is a bromine atom or Methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoro Methyl, trifluoromethyl, methoxy, ethoxy, propoxy, (propan-2-yl )oxy, methoxymethyl, 2-methoxyethyl, benzyloxy, trifluoromethoxy 2,2,2-trifluoroethoxy, phenoxy, (oxolan-2-yl)methoxy (tetrahydrofuran-2-yl)methoxy, methanesulfonyl, dimethylphosphoryl aryl, cyano, hydroxy, dimethylamino, oxetan-3-yl, 2-oxopyrrolidine 4-methyl-2-oxopiperazin-1-yl, 4-methyl-3-oxo Piperazin-1-yl, morpholin-4-yl, 7-oxo-2-oxa-6-azaspirillum 2,8-Diazapiro[3,4]octan-6-yl, 8-methyl-3-oxo-2,8-diazaspiro[4 .5]Decan-2-yl, carbamoyl, acetyl, trifluoroacetyl, benzamido , benzenesulfonamide, [dimethyl(oxide)-λ 6 -sulfanylidene]amine phenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl 4-methylphenyl, 3-trifluoromethylphenyl, 2-methoxyphenyl selected from phenyl, 3-methoxyphenyl, 4-methoxyphenyl and pyridin-3-yl is selected from the group or When two substituents of the phenyl group are attached to adjacent ring atoms, they Together, -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC( CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O )-C(CH3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2- C(CH3)2-, -N(CH3)-C(=O)-O- and -N(CH3)-C(=O) -N(CH3)-, Compounds of (I) and their stereoisomers, tautomers, N-oxides, hydrates, solvates and and salts, and mixtures thereof.

[0137] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 However, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazo 1,2,4-oxadiazol-5-yl, 1,3,4-oxadiazol-5-yl, 1H-1,2,3-triazol-2-yl, 1H-1,2,3-triazol-4-yl, 2H-1,2,3-triazol-4-yl 1,3-thiazol-4-yl, 1,3-thiazol-2-yl, pyridin-3-yl, pyrazine-2 -yl, 1H-indol-5-yl, 1-benzofuran-4-yl, 1-benzofuran -7-yl, 1H-indol-6-yl, benzothiophen-2-yl, 1,3-benzophen- benzoxazol-2-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol-2-yl 6-oxazol-yl, 1,3-benzoxazol-7-yl, 1H-indazole- 5-yl, 1H-benzimidazol-2-yl, 1H-benzimidazol-4-yl , 1,3-benzothiazol-2-yl, 1,3-benzothiazol-4-yl, 1,3 -benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 1,3-benzo Thiazol-7-yl, 1H-pyrrolo[2,3-b]pyridin-3-yl, quinoline-2 -yl, quinolin-4-yl, quinolin-6-yl, quinolin-7-yl, isoquinoline -5-yl, isoquinolin-7-yl, isoquinolin-8-yl, quinoxalin-2-yl quinoxalin-5-yl and 1,3-thiazolo[5,4-b]pyridin-2-yl represents a group selected from The group may be substituted one or two times, each substituent independently being fluorine, chlorine or is a bromine atom or Methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoro Methyl, trifluoromethyl, methoxy, ethoxy, propoxy, (propan-2-yl )oxy, methoxymethyl, 2-methoxyethyl, benzyloxy, trifluoromethoxy 2,2,2-trifluoroethoxy, phenoxy, (oxolan-2-yl)methoxy (tetrahydrofuran-2-yl)methoxy, methanesulfonyl, dimethylphosphoryl aryl, cyano, hydroxy, dimethylamino, oxetan-3-yl, 2-oxopyrrolidine 4-methyl-2-oxopiperazin-1-yl, 4-methyl-3-oxo Piperazin-1-yl, morpholin-4-yl, 7-oxo-2-oxa-6-azaspirillum 2,8-Diazapiro[3,4]octan-6-yl, 8-methyl-3-oxo-2,8-diazaspiro[4 .5]Decan-2-yl, carbamoyl, acetyl, trifluoroacetyl, benzamido , benzenesulfonamide, [dimethyl(oxide)-λ 6 -sulfanylidene]amine phenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl 4-methylphenyl, 3-trifluoromethylphenyl, 2-methoxyphenyl selected from phenyl, 3-methoxyphenyl, 4-methoxyphenyl and pyridin-3-yl is selected from the group or When two substituents of the phenyl group are attached to adjacent ring atoms, they Together, -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC( CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O )-C(CH3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2- C(CH3)2-, -N(CH3)-C(=O)-O- and -N(CH3)-C(=O) -N(CH3)-, Compounds of (I) and their stereoisomers, tautomers, N-oxides, hydrates, solvates and and salts, and mixtures thereof.

[0138] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 Phenyl, 1-naphthyl, 2-naphthyl, 1H-pyrazol-3-yl, 1H -pyrazol-4-yl, 1H-pyrazol-5-yl, 1,2,4-oxadiazole -5-yl, 1,3,4-oxadiazol-2-yl, 1,3-thiazol-2-yl , pyridin-3-yl, pyrazin-2-yl, 1H-indol-5-yl, 1-benzoyl Furan-4-yl, 1-benzofuran-7-yl, 1H-indol-6-yl, benzo Thiophen-2-yl, 1,3-benzoxazol-2-yl, 1,3-benzoxazol 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl, 1,3-benzoxazol- 1H-indazol-7-yl, 1H-indazol-5-yl, 1H-benzimidazol-2-yl, 1H-Benzimidazol-4-yl, 1,3-benzothiazol-2-yl, 1,3- Benzothiazol-4-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol Azol-6-yl, 1,3-benzothiazol-7-yl, 1H-pyrrolo[2,3-b ]pyridin-3-yl, quinolin-2-yl, quinolin-4-yl, quinolin-6-yl , quinolin-7-yl, isoquinolin-5-yl, isoquinolin-7-yl, isoquinolin quinoxalin-8-yl, quinoxalin-2-yl, quinoxalin-5-yl and 1,3-thiazolo [5,4-b]pyridin-2-yl, The group may be substituted one or two times, each substituent independently being fluorine, chlorine or is a bromine atom or Methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoro Methyl, trifluoromethyl, methoxy, ethoxy, propoxy, (propan-2-yl )oxy, methoxymethyl, 2-methoxyethyl, benzyloxy, trifluoromethoxy 2,2,2-trifluoroethoxy, phenoxy, (oxolan-2-yl)methoxy (tetrahydrofuran-2-yl)methoxy, methanesulfonyl, dimethylphosphoryl aryl, cyano, hydroxy, dimethylamino, oxetan-3-yl, 2-oxopyrrolidine 4-methyl-2-oxopiperazin-1-yl, 4-methyl-3-oxo Piperazin-1-yl, morpholin-4-yl, 7-oxo-2-oxa-6-azaspirillum 2,8-Diazapiro[3,4]octan-6-yl, 8-methyl-3-oxo-2,8-diazaspiro[4 .5]Decan-2-yl, carbamoyl, acetyl, trifluoroacetyl, benzamido , benzenesulfonamide, [dimethyl(oxide)-λ 6 -sulfanylidene]amine phenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl 4-methylphenyl, 3-trifluoromethylphenyl, 2-methoxyphenyl selected from phenyl, 3-methoxyphenyl, 4-methoxyphenyl and pyridin-3-yl is selected from the group or When two substituents of the phenyl group are attached to adjacent ring atoms, they Together, -CH2-CH(OH)-CH2-, -CH2-CH(CH3)-O-, -OC( CH3)2-O-, -NH-C(=O)-CH(CH3)-, -N(CH3)-C(=O )-C(CH3)2-, -NH-C(=O)-(C(CH2)3)-, -NH-CH2- C(CH3)2-, -N(CH3)-C(=O)-O- and -N(CH3)-C(=O) -N(CH3)-, Compounds of (I) and their stereoisomers, tautomers, N-oxides, hydrates, solvates and and salts, and mixtures thereof.

[0139] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a group selected from phenyl, naphthyl, and 5- to 10-membered heteroaryl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, naphthyl and 5-10 membered heteroaryl groups substituted 1, 2, 3 or 4 times Each substituent may be a halogen atom or C1-C6-Alkyl, C3-C6-Cycloalkyl, C1-C6-Hydroxyalkan alkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkoxy) (C1-C2 alkoxy)-(C1-C6 alkoxy)-, C1-C6 alkoxy (Si)-, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy , -SR 14 , -S(=O)R 14 , -S(=O)2R 14 , -P(=O)(R 14 )2 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 ) 2, 4 to 7 membered complex Cyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl and 5- or 6-membered heteroaryl; or when two substituents of said phenyl group are attached to adjacent ring atoms, they are Together, -(CH2)3-, -(CH2)4-, -O-(CH2)2-, -(CH2)2-O -, -CH2-O-CH2-, -O-(CH2)3-, -(CH2)3-O-, -CH2 -O-(CH2)2-, -(CH2)2-O-CH2-, -O-CH2-O- and -O- (CH2)2-O-, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are The remainder of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups It is connected to The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The cyclic alkyloxy group may be substituted one, two or three times, and each substituent may be a halogen atom. atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group The C1-C6-alkyl and C1-C6-alkoxy groups are preferably C3-C4-cyclo It may be substituted with a group selected from alkyl, phenyl and 4- to 7-membered heterocyclic alkyl. Ku, The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from groups selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substituent The substituent is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C6-cycloalkyl group may be substituted once or twice, the substituents are independently selected from halogen atoms or C1-C4-alkyl groups, The phenyl, phenoxy and 5- or 6-membered heteroaryl groups are 1 or 2 may be substituted three times, and each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) The compounds of formula (I) above and stereoisomers, tautomers thereof, independently selected from the groups , N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0140] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a group selected from phenyl, naphthyl, and 5- to 10-membered heteroaryl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, naphthyl and 5-10 membered heteroaryl groups substituted 1, 2, 3 or 4 times Each substituent may be a halogen atom or C1-C6-Alkyl, C3-C5-Cycloalkyl, C1-C6-Hydroxyalkan alkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkoxy) (C1-C2 alkoxy)-(C1-C4 alkoxy)-, C1-C4 alkoxy (Si)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy , -SR 14 , -S(=O)R 14 , -S(=O)2R 14 , -P(=O)(R 14 )2 , cyano, hydroxy, -N(R 9 )(R10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 ) 2, 4 to 7 membered complex Cyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl and 5- or 6-membered heteroaryl; or when two substituents of said phenyl group are attached to adjacent ring atoms, they are Together, -(CH2)3-, -(CH2)4-, -O-(CH2)2-, -(CH2)2-O -, -CH2-O-CH2-, -O-(CH2)3-, -(CH2)3-O-, -CH2 -O-(CH2)2-, -(CH2)2-O-CH2-, -O-CH2-O- and -O- (CH2)2-O-, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are The remainder of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups It is connected to The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The cyclic alkyloxy group may be substituted one, two or three times, and each substituent may be a halogen atom. atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The C1-C6-alkyl and C1-C4-alkoxy groups are preferably C3-C4-cyclo It may be substituted with a group selected from alkyl, phenyl and 4- to 7-membered heterocyclic alkyl. Ku, The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from groups selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substituent The substituent is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl group may be substituted once or twice, and each the substituents are independently selected from halogen atoms or C1-C4-alkyl groups, The phenyl, phenoxy and 5- or 6-membered heteroaryl groups are 1 or 2 may be substituted three times, and each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) The compounds of formula (I) above and stereoisomers, tautomers thereof, independently selected from the groups , N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0141] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a group selected from phenyl, naphthyl, and 5- to 10-membered heteroaryl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, naphthyl and 5-10 membered heteroaryl groups substituted 1, 2, 3 or 4 times Each substituent may be a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 14 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C (=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=O)(R 14 )2 and phenyl independently selected from the groups the C1-C4-alkoxy group may be substituted with a phenyl group, The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) The compounds of formula (I) above and stereoisomers, tautomers thereof, independently selected from the groups , N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0142] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a group selected from phenyl, naphthyl, and 5- to 10-membered heteroaryl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, naphthyl and 5-10 membered heteroaryl groups substituted 1, 2, 3 or 4 times Each substituent may be a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 14 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C (=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=O)(R 14 )2 and phenyl independently selected from the groups The C1-C4-alkoxy group may be substituted with a phenyl group. I) and its stereoisomers, tautomers, N-oxides, hydrates, solvates and This includes salts, as well as mixtures thereof.

[0143] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a group selected from phenyl, 1-naphthyl and 5- to 10-membered heteroaryl; death, The 5- to 10-membered heteroaryl group is pyrazolyl, 1,2,4-oxadiazole, 1,3 -Thiazolyl, pyridinyl, pyrazinyl, indolyl, benzofuranyl, 1,3-benzo Oxazolyl, benzimidazolyl, 1,3-benzothiazolyl, pyrrolo[2,3-b] Pyridinyl, quinolinyl, isoquinolinyl, quinoxalinyl and 1,3-thiazolo[5, 4-b]pyridinyl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via Phenyl, 1-naphthyl and 5-10 membered heteroaryl groups occurring 1, 2, 3 or 4 times It may be substituted, and each substituent is a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 14 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C (=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=O)(R 14 )2 and phenyl independently selected from the groups The C1-C4-alkoxy group may be substituted with a phenyl group. I) and its stereoisomers, tautomers, N-oxides, hydrates, solvates and This includes salts, as well as mixtures thereof.

[0144] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 Phenyl, 1-naphthyl, 1H-pyrazol-5-yl, 1,2,4-oxa Diazol-5-yl, 1,3-thiazol-2-yl, pyridin-3-yl, pyrazine -2-yl, 1H-indol-5-yl, 1-benzofuran-4-yl, 1-benzofuran-4-yl, Ran-7-yl, 1,3-benzoxazol-2-yl, 1,3-benzoxazole -5-yl, 1,3-benzoxazol-7-yl, 1H-benzimidazol-2- yl, 1H-benzimidazol-4-yl, 1,3-benzothiazol-2-yl, 1 ,3-benzothiazol-4-yl, 1,3-benzothiazol-7-yl, 1H-pyro 2,3-b]pyridin-3-yl, quinolin-4-yl, isoquinolin-5-yl, Isoquinolin-7-yl, isoquinolin-8-yl, quinoxalin-2-yl, quinoxa thiazolo[5,4-b]pyridin-2-yl and 1,3-thiazolo[5,4-b]pyridin-2-yl represents a group, The group may be substituted one or two times, each substituent independently being fluorine, chlorine or is a bromine atom or Methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoro Methyl, trifluoromethyl, methoxy, ethoxy, propoxy, (propan-2-yl )oxy, benzyloxy, trifluoromethoxy, 2,2,2-trifluoroethoxy , phenoxy, methanesulfonyl, dimethylphosphoryl, cyano, hydroxy, dimethyl Amino, 2-oxopyrrolidin-1-yl, 4-methyl-2-oxopiperazin-1-yl 4-methyl-3-oxopiperazin-1-yl, morpholin-4-yl, 7-oxo -2-oxa-6-azaspiro[3.4]octan-6-yl, 8-methyl-3-oxo -2,8-diazaspiro[4.5]decan-2-yl, carbamoyl, trifluoroacetate Benzamide, benzenesulfonamide, [dimethyl(oxide)-λ 6 -Sulf a group selected from the group consisting of phenyl, ... compounds and their stereoisomers, tautomers, N-oxides, hydrates, solvates and salts, This includes mixtures thereof.

[0145] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a 5- to 10-membered heteroaryl group; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via The 5- to 10-membered heteroaryl group may be substituted 1, 2, 3, or 4 times, and each substitution The substituent is a halogen atom or C1-C6-Alkyl, C3-C6-Cycloalkyl, C1-C6-Hydroxyalkan alkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkoxy) (C1-C2 alkoxy)-(C1-C6 alkoxy)-, C1-C6 alkoxy (Si)-, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy , -SR 14 , -S(=O)R 14 , -S(=O)2R 14 , -P(=O)(R 14 )2 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 ) 2, 4 to 7 membered complex Cyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl and 5- or 6-membered heteroaryl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are The remainder of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups It is connected to The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The cycloalkyloxy group may be substituted one, two or three times, and each substituent may be a halogen atom. atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The C1-C6-alkyl and C1-C6-alkoxy groups are preferably C3-C4-cyclo It may be substituted with a group selected from alkyl, phenyl and 4- to 7-membered heterocyclic alkyl. Ku, The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice or three times, and each The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from groups selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substituent The substituent is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C6-cycloalkyl group may be substituted once or twice, the substituents are independently selected from halogen atoms or C1-C4-alkyl groups, The phenyl, phenoxy and 5- or 6-membered heteroaryl groups are 1 or 2 may be substituted three times, and each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R10 ) The compounds of formula (I) above and stereoisomers, tautomers thereof, independently selected from the groups , N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0146] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a 5- to 10-membered heteroaryl group; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via The 5- to 10-membered heteroaryl group may be substituted 1, 2, 3, or 4 times, and each substitution The substituent is a halogen atom or C1-C6-Alkyl, C3-C5-Cycloalkyl, C1-C6-Hydroxyalkan alkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkoxy) (C1-C2 alkoxy)-(C1-C4 alkoxy)-, C1-C4 alkoxy (Si)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy , -SR 14 , -S(=O)R 14 , -S(=O)2R 14 , -P(=O)(R 14 )2 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 ) 2, 4 to 7 membered complex Cyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl and 5- or 6-membered heteroaryl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are The remainder of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups It is connected to The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The cyclic alkyloxy group may be substituted one, two or three times, and each substituent may be a halogen atom. atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The C1-C6-alkyl and C1-C4-alkoxy groups are preferably C3-C4-cyclo It may be substituted with a group selected from alkyl, phenyl and 4- to 7-membered heterocyclic alkyl. Ku, The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice or three times, and each The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from groups selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substituent The substituent is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl group may be substituted once or twice, and each the substituents are independently selected from halogen atoms or C1-C4-alkyl groups, The phenyl, phenoxy and 5- or 6-membered heteroaryl groups are 1 or 2 may be substituted twice, each substituent being a halogen atom or a C1-C2-alkyl, C1- C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cyclo -N(R 9 )(R 10 ) independently selected from the group Compounds of formula (I) and their stereoisomers, tautomers, N-oxides, hydrates and solvates and salts, and mixtures thereof.

[0147] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a 5- to 10-membered heteroaryl; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via The 5- to 10-membered heteroaryl group may be substituted 1, 2, 3, or 4 times, and each substitution The substituent is a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 14 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C (=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=O)(R 14 )2 and phenyl independently selected from the groups the C1-C4-alkoxy group may be substituted with a phenyl group, The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) The compounds of formula (I) above and stereoisomers, tautomers thereof, independently selected from the groups , N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0148] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a 5- to 10-membered heteroaryl group; The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via The 5- to 10-membered heteroaryl group may be substituted 1, 2, 3, or 4 times, and each substitution The substituent is a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 14 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C (=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=O)(R 14 )2 and phenyl independently selected from the groups The C1-C4-alkoxy group may be substituted with a phenyl group. I) and its stereoisomers, tautomers, N-oxides, hydrates, solvates and This includes salts, as well as mixtures thereof.

[0149] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a 5- to 10-membered heteroaryl group; 5-10 membered heteroaryl group Pyrazolyl, 1,2,4-oxadiazole, 1,3-thiazolyl, pyridinyl, pyridinyl Razinyl, indolyl, benzofuranyl, 1,3-benzoxazolyl, benzimidazolyl aryl, 1,3-benzothiazolyl, pyrrolo[2,3-b]pyridinyl, quinolinyl, iso quinolinyl, quinoxalinyl, and 1,3-thiazolo[5,4-b]pyridinyl; R, The 5- to 10-membered heteroaryl group is bonded to the carbon atom of the 5- to 10-membered heteroaryl group. is connected to the rest of the molecule via The 5- to 10-membered heteroaryl group may be substituted 1, 2, 3, or 4 times, and each substitution The substituent is a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 14 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C (=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=O)(R 14 )2 and phenyl independently selected from the groups The C1-C4-alkoxy group may be substituted with a phenyl group. I) and its stereoisomers, tautomers, N-oxides, hydrates, solvates and This includes salts, as well as mixtures thereof.

[0150] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 However, 1H-pyrazol-5-yl, 1,2,4-oxadiazol-5-yl, 1 ,3-thiazol-2-yl, pyridin-3-yl, pyrazin-2-yl, 1H-indo 1-benzofuran-5-yl, 1-benzofuran-4-yl, 1-benzofuran-7-yl, 1,3- Benzoxazol-2-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol- 1H-benzoxazol-7-yl, 1H-benzimidazol-2-yl, 1H-benzimidazole 1,3-benzothiazol-4-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazol- 4-yl, 1,3-benzothiazol-7-yl, 1H-pyrrolo[2,3-b]pyridine -3-yl, quinolin-4-yl, isoquinolin-5-yl, isoquinolin-7-yl, Isoquinolin-8-yl, quinoxalin-2-yl, quinoxalin-5-yl and 1,3 -thiazolo[5,4-b]pyridin-2-yl, The group may be substituted one or two times, each substituent independently being fluorine, chlorine or Bromine atom or Methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoromethyl methyl, trifluoromethyl, methoxy, ethoxy, propoxy, (propan-2-yl) Oxy, benzyloxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, Phenoxy, methanesulfonyl, dimethylphosphoryl, cyano, hydroxy, dimethyla 2-oxopyrrolidin-1-yl, 4-methyl-2-oxopiperazin-1-yl , 4-methyl-3-oxopiperazin-1-yl, morpholino-4-yl, 7-oxo- 2-oxa-6-azaspiro[3.4]octan-6-yl, 8-methyl-3-oxo- 2,8-diazaspiro[4.5]decan-2-yl, carbamoyl, trifluoroacetyl Benzamide, benzenesulfonamide, [dimethyl(oxide)-λ 6 -Sulfa a compound of formula (I) above, selected from the group consisting of phenyl, ... and its stereoisomers, tautomers, N-oxides, hydrates, solvates and salts, This includes mixtures thereof.

[0151] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a group selected from phenyl and naphthyl, The phenyl and naphthyl groups may be substituted one, two, three or four times, and each substituent is a halogen atom or C1-C6-Alkyl, C3-C6-Cycloalkyl, C1-C6-Hydroxyalkan alkyl, C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkoxy) (C1-C2 alkoxy)-(C1-C6 alkoxy)-, C1-C6 alkoxy (Si)-, C1-C6-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy , -SR 14 , -S(=O)R 14 , -S(=O)2R 14 , -P(=O)(R 14 )2 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 ) 2, 4 to 7 membered complex Cyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl and 5- or 6-membered heteroaryl; Or, when two substituents of the phenyl group are bonded to adjacent ring atoms, they are Together, -(CH2)3-, -(CH2)4-, -O-(CH2)2-, -(CH2)2-O -, -CH2-O-CH2-, -O-(CH2)3-, -(CH2)3-O-, -CH2 -O-(CH2)2-, -(CH2)2-O-CH2-, -O-CH2-O- and -O- (CH2)2-O-, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are The remainder of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups It is connected to The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The cyclic alkyloxy group may be substituted one, two or three times, and each substituent may be a halogen atom. atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group The C1-C6-alkyl and C1-C6-alkoxy groups are preferably C3-C4-cyclo It may be substituted with a group selected from alkyl, phenyl and 4- to 7-membered heterocyclic alkyl. Ku, The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice or three times, and each The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from groups selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substituent The substituent is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C6-cycloalkyl group may be substituted once or twice, the substituents are independently selected from halogen atoms or C1-C4-alkyl groups, The phenyl, phenoxy and 5- or 6-membered heteroaryl groups are 1 or 2 may be substituted three times, and each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) The compounds of formula (I) above and stereoisomers, tautomers thereof, independently selected from the groups , N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0152] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a group selected from phenyl and naphthyl, The phenyl and naphthyl groups may be substituted one, two, three or four times, and each substituent is a halogen atom or C1-C6-Alkyl, C3-C5-Cycloalkyl, C1-C6-Hydroxyalkan alkyl, C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkoxy) (C1-C2 alkoxy)-(C1-C4 alkoxy)-, C1-C4 alkoxy (Si)-, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy , -SR 14 , -S(=O)R 14 , -S(=O)2R 14 , -P(=O)(R 14 )2 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 ) 2, 4 to 7 membered complex Cyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl and 5- or 6-membered heteroaryl; or when two substituents of said phenyl group are attached to adjacent ring atoms, they are Together, -(CH2)3-, -(CH2)4-, -O-(CH2)2-, -(CH2)2-O -, -CH2-O-CH2-, -O-(CH2)3-, -(CH2)3-O-, -CH2 -O-(CH2)2-, -(CH2)2-O-CH2-, -O-CH2-O- and -O- (CH2)2-O-, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are The remainder of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups It is connected to The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The cyclic alkyloxy group may be substituted one, two or three times, and each substituent may be a halogen atom. atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group The C1-C6-alkyl and C1-C4-alkoxy groups are preferably C3-C4-cyclo It may be substituted with a group selected from alkyl, phenyl and 4- to 7-membered heterocyclic alkyl. Ku, The 4- to 7-membered heterocyclic alkyl group is is linked to the rest of the molecule via The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from groups selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1 -C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substituent The substituent is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl group may be substituted once or twice, and each the substituents are independently selected from halogen atoms or C1-C4-alkyl groups, The phenyl, phenoxy and 5- or 6-membered heteroaryl groups are 1 or 2 may be substituted twice, each substituent being a halogen atom or a C1-C2-alkyl, C1- C2-haloalkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cyclo -N(R 9 )(R 10 ) independently selected from the group Compounds of formula (I) and their stereoisomers, tautomers, N-oxides, hydrates and solvates and salts, and mixtures thereof.

[0153] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a group selected from phenyl and naphthyl, The phenyl and naphthyl groups may be substituted one, two, three or four times, and each substituent is a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 14 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C (=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14, -N=S(=O)(R 14 )2 and phenyl independently selected from the groups the C1-C4-alkoxy group may be substituted with a phenyl group, The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) The compounds of formula (I) above and stereoisomers, tautomers thereof, This includes N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0154] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a group selected from phenyl and naphthyl, The phenyl and naphthyl groups may be substituted one, two, three or four times, and each substituent is a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 14 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C (=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=O)(R 14 )2 and phenyl independently selected from the groups The C1-C4-alkoxy group may be substituted with a phenyl group. I) and its stereoisomers, tautomers, N-oxides, hydrates, solvates and This includes salts, as well as mixtures thereof.

[0155] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2 represents a group selected from phenyl and 1-naphthyl, The phenyl and 1-naphthyl groups may be substituted 1, 2, 3 or 4 times, and each substitution The substituent is a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, C1-C4-haloalkyl, C1-C4-alkoxy, C1-C4-haloalkoxy, phenoxy, -S(=O)2R 14 , -P(=O)(R 14 )2, cyano, hydroxy, -N(R 9 )(R 10 ), -C (=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=O)(R 14 )2 and phenyl independently selected from the groups The C1-C4-alkoxy group may be substituted with a phenyl group. I) and its stereoisomers, tautomers, N-oxides, hydrates, solvates and This includes salts, as well as mixtures thereof.

[0156] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 2represents a group selected from phenyl and 1-naphthyl, The phenyl and naphthyl groups may be substituted one or two times, and each substituent may independently be fluorine, chlorine or bromine atoms or Methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoro Methyl, trifluoromethyl, methoxy, ethoxy, propoxy, (propan-2-yl )oxy, benzyloxy, trifluoromethoxy, 2,2,2-trifluoroethoxy , phenoxy, methanesulfonyl, dimethylphosphoryl, cyano, hydroxy, dimethyl Amino, 2-oxopyrrolidin-1-yl, 4-methyl-2-oxopiperazin-1-yl 4-methyl-3-oxopiperazin-1-yl, morpholin-4-yl, 7-oxo -2-oxa-6-azaspiro[3.4]octan-6-yl, 8-methyl-3-oxo -2,8-diazaspiro[4.5]decan-2-yl, carbamoyl, trifluoroacetate Benzamide, benzenesulfonamide, [dimethyl(oxide)-λ 6 -Sulf a group selected from the group consisting of phenyl, ... compounds and their stereoisomers, tautomers, N-oxides, hydrates, solvates and salts, includes mixtures thereof.

[0157] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 3 is a hydrogen atom or a halogen atom or C1-C6-Alkyl, C2-C6-Alkenyl, C2-C6-Alkynyl, C3-C 6-Cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl , C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl) -, C1-C6-alkoxy, (C1-C2 alkoxy)-(C1-C6-alkoxy) -, C1-C4-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, - SR 14 , -S(=O)R 14 , -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 1 2 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 1 4 )2, -N=S(=O)(R 14 ) 2、 -P(=O)(R 14 ) 2, 4 to 7 membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl, and represents a group selected from 5- or 6-membered heteroaryl, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups, Selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocyclic alkyl may be substituted with a group, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C2-C6-alkenyl group may be substituted with a C1-C4-haloalkyl group. Ku, The C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups may be one or more may be substituted twice, each substituent being a halogen atom or a C1-C4-alkyl and independently selected from groups selected from C1-C4-haloalkyl; The phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be present one or two times. It may be substituted, and each substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from The compounds of formula (I) above and stereoisomers, tautomers, and the like thereof are independently selected from the group consisting of: This includes N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0158] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 3 is a hydrogen atom or a halogen atom or C1-C6-Alkyl, C2-C4-Alkenyl, C2-C4-Alkynyl, C3-C 5-Cycloalkyl, C4-C5-cycloalkenyl, C1-C4-hydroxyalkyl , C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl) -, C1-C4-alkoxy, (C1-C2 alkoxy)-(C1-C4-alkoxy) -, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, - SR 14 , -S(=O)R 14 , -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 1 2 )C(=O)R 13 , -N(R 12 )S(=O)2R14 , -N=S(=NH)(R 1 4 )2, -N=S(=O)(R 14 ) 2、 -P(=O)(R 14 ) 2, 4 to 7 membered heterocyclic rings alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl, and represents a group selected from 5- or 6-membered heteroaryl, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups, Selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocyclic alkyl may be substituted with a group, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C2-C4-alkenyl group may be substituted with a C1-C4-haloalkyl group. Ku, The C3-C5-cycloalkyl and C4-C5-cycloalkenyl groups are may be substituted twice, each substituent being a halogen atom or a C1-C4-alkyl and independently selected from groups selected from C1-C4-haloalkyl; The phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be present one or two times. It may be substituted, and each substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from The compounds of formula (I) above and stereoisomers, tautomers, and the like thereof are independently selected from the group consisting of: This includes N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0159] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 3 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C2-C4-alkenyl, C3-C5-cycloalkyl, (C 1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C1 -C4-haloalkoxy, C3-C5-cycloalkyloxy, -S(=O)2R 14 , Cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), - P(=O)(R 14 )2, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- represents a group selected from 7-membered heterocyclic alkyl)oxy and phenyl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl and C1-C4-alkoxy groups are and optionally substituted with a group selected from alkyl and 4- to 7-membered heterocyclic alkyl, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. is connected to the rest of the molecule via The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The group is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo, are independently selected from the group selected from The C3-C4-cycloalkyl group may be substituted once or twice, and each substituent is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C2-C4-alkenyl group may be substituted with a C1-C4-haloalkyl group. , The C3-C5-cycloalkyl group may be substituted once or twice, and each substitution The group is selected from halogen atoms or C1-C4-alkyl and C1-C4-haloalkyl. The compounds of formula (I) above and stereoisomers, tautomers thereof, independently selected from the groups , N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0160] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 3 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C2-C4-alkenyl, C3-C5-cycloalkyl, (C 1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C1 -C4-haloalkoxy, C3-C5-cycloalkyloxy, -S(=O)2R 14 , Cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9)(R 10 ), - P(=O)(R 14 )2, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- represents a group selected from 7-membered heterocyclic alkyl)oxy and phenyl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C3-C4-cycloalkyl group may be substituted once or twice with a cyano group. Ku, The C2-C4-alkenyl group may be substituted with a C1-C4-haloalkyl group. Ku, The C3-C5-cycloalkyl group may be substituted once or twice, and each substitution The substituents are independently selected from halogen atoms or C1-C4-alkyl and C1-C4-haloalkyl Compounds of formula (I) above and stereoisomers, tautomers thereof selected from the group , N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0161] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 3 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C2-C4-alkenyl, C3-C5-cycloalkyl, (C 1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, C1 -C4-haloalkoxy, C3-C5-cycloalkyloxy, -S(=O)2R 14 , Cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), - P(=O)(R 14 )2, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- represents a group selected from 7-membered heterocyclic alkyl)oxy and phenyl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C3-C4-cycloalkyl group may be substituted once or twice with a cyano group. Ku, The C2-C4-alkenyl group may be substituted with a C1-C4-haloalkyl group. Ku, The C3-C5-cycloalkyl group is selected from the group consisting of halogen atoms or C1-C4-alkyl and C 1-C4-haloalkyl, Compounds of formula (I) and their stereoisomers, tautomers, N-oxides, hydrates, solvates This includes compounds and salts, and mixtures thereof.

[0162] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 3is a hydrogen atom or a fluorine, chlorine or bromine atom or a methyl, sec-butyl, (oxy) cetan-3-yl)methyl, 3,3,3-trifluoroprop-1-en-2-yl, Cyclopropyl, (trifluoromethyl)cyclopropyl, cyclobutyl, 2,2-dimethyl cyclobutyl, 3,3-difluorocyclobutyl, methoxymethyl, methoxy, ethoxy cyclopropoxy, 2,2-difluoroethoxy, 2,2-difluoropropoxy Propylmethoxy, (1-cyanocyclopropyl)methoxy, cyclopropyloxy, cyano Chlorobutyloxy, methanesulfonyl, cyano, hydroxy, 4-hydroxy-2-oxo 7-oxo-2-oxa-6-azaspiro[3.4]octaiso-pyrrolidin-1-yl benzoyl, carbamoyl, dimethylphosphoryl, oxetan-3-yl, 3,6-di selected from hydro-2H-pyran-4-yl, (oxetan-3-yl)oxy and phenyl The compounds of formula (I) above and their stereoisomers, tautomers, N-oxo-N-methyl ... This includes sides, hydrates, solvates and salts, and mixtures thereof.

[0163] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 3 is a hydrogen atom or a halogen atom or C1-C6-Alkyl, C2-C6-Alkenyl, C2-C6-Alkynyl, C3-C 6-Cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl , C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl) -, C1-C6-alkoxy, (C1-C2 alkoxy)-(C1-C6-alkoxy) -, C1-C4-haloalkoxy, C3-C6-cycloalkyloxy, phenoxy, - SR14 , -S(=O)R 14 , -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 1 2 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 1 4 )2, -N=S(=O)(R 14 ) 2、 -P(=O)(R 14 ) 2, 4 to 7 membered heterocyclic rings alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl, and represents a group selected from 5- or 6-membered heteroaryl, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups, Selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocyclic alkyl may be substituted with a group, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups may be one or more is optionally substituted twice, each substituent independently being a halogen atom or a C1-C4-alkyl is selected from the group The phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be present one or two times. It may be substituted, and each substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from The compounds of formula (I) above and stereoisomers, tautomers, and the like thereof are independently selected from the group consisting of: This includes N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0164] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 3 is a hydrogen atom or a halogen atom or C1-C6-Alkyl, C2-C4-Alkenyl, C2-C4-Alkynyl, C3-C 5-Cycloalkyl, C4-C5-cycloalkenyl, C1-C4-hydroxyalkyl , C1-C4-haloalkyl, (C1-C2-alkoxy)-(C1-C4-alkyl) -, C1-C4-alkoxy, (C1-C2 alkoxy)-(C1-C4-alkoxy) -, C1-C4-haloalkoxy, C3-C5-cycloalkyloxy, phenoxy, - SR 14 , -S(=O)R 14 , -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 1 2 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 1 4 )2, -N=S(=O)(R 14 ) 2、 -P(=O)(R 14 ) 2, 4 to 7 membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl, and represents a group selected from 5- or 6-membered heteroaryl, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups, Selected from C3-C4-cycloalkyl, phenyl and 4- to 7-membered heterocyclic alkyl may be substituted with a group, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl and C4-C5-cycloalkenyl groups are is optionally substituted twice, each substituent independently being a halogen atom or a C1-C4-alkyl is selected from the group The phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be present one or two times. It may be substituted, and each substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from The compounds of formula (I) above and stereoisomers, tautomers, and the like thereof are independently selected from the group consisting of: This includes N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0165] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 3 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)- (C1-C4-alkyl)-, C1-C4-alkoxy, C3-C5-cycloalkyl Oxygen, -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R10 ), -P(= O)(R 14 ) 2, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic represents a group selected from the group consisting of (heterocyclic alkyl)oxy and phenyl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl and C1-C4-alkoxy groups are and optionally substituted with a group selected from alkyl and 4- to 7-membered heterocyclic alkyl, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; The C3-C5-cycloalkyl group may be substituted once or twice, and each substitution The substituents are independently selected from halogen atoms or C1-C4-alkyl groups of formula (I) above. and stereoisomers, tautomers, N-oxides, hydrates, solvates and salts thereof, and mixtures thereof.

[0166] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 3 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C3-C5-cycloalkyl, (C1-C2-alkoxy)- (C1-C4-alkyl)-, C1-C4-alkoxy, C3-C5-cycloalkyl Oxygen, -S(=O)2R 14 , cyano, hydroxy, -N(R 9 )(R 10 ), 4-7 members Heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy and fluoro represents a group selected from the group consisting of phenyl, The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C3-C4-cycloalkyl group may be substituted once or twice with a cyano group. Ku, The C3-C5-cycloalkyl group is substituted one or two times with a halogen atom. The compounds of formula (I) above and their stereoisomers, tautomers, N-oxides, This includes hydrates, solvates and salts, and mixtures thereof.

[0167] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 3 is a hydrogen atom or a fluorine, chlorine or bromine atom or a methyl, sec-butyl, (oxy) (cetan-3-yl)methyl, cyclopropyl, 3,3-difluorocyclobutyl, methoxy Dimethyl, methoxy, propoxy, (1-cyanocyclopropyl) methoxy, cyclopropyl Pyroxy, cyclobutyloxy, methanesulfonyl, cyano, hydroxy, 4-hydroxy 2-oxo-pyrrolidin-1-yl, 7-oxo-2-oxa-6-azaspiro[ 3.4]octan-6-yl, oxetan-3-yl, 3,6-dihydro-2H-pyran (oxetan-3-yl)oxy and phenyl. The compounds of formula (I) and their stereoisomers, tautomers, N-oxides, hydrates, and solvents This includes solvates and salts, and mixtures thereof.

[0168] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 4 is a hydrogen atom or a halogen atom or C1-C6-Alkyl, C2-C6-Alkenyl, C2-C6-Alkynyl, C3-C 6-Cycloalkyl, C4-C6-cycloalkenyl, C1-C6-hydroxyalkyl , C1-C6-haloalkyl, (C1-C2-alkoxy)-(C1-C6-alkyl) -, C1-C6-alkoxy, (C1-C2 alkoxy)-(C1-C6-alkoxy) -, C1-C4-haloalkoxy, -O-(C1-C4-alkyl)-C(=O)OR 1 5 , -O-(C1-C4-alkyl)-C(=O)N(R 9 )(R 10 ), C3-C6- Cycloalkyloxy, -S(=O)R 14 , -S(=O)2R 14 , cyano, nitro, Hydroxy, -N(R 9 )(R 10 ), -N(R 16 )(R 17 ), -N(R 16 )(R 20 ), -C(=O)N(R 9 )(R 10 ), -C(=O)R 11 , -N(R 12 )C( =O)R 13 , -N(R 12 )S(=O)2R 14 , -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 )2, -P(=O)(R 14 ) 2, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl)oxy, phenyl, and 5 or represents a group selected from 6-membered heteroaryl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl and C1-C6-alkoxy groups are C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl groups. may be substituted with a group selected from The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; the C1-C6-alkoxy group may be substituted with an oxiran-2-yl group, The C3-C6-cycloalkyl and C4-C6-cycloalkenyl groups may be one or more is optionally substituted twice, each substituent independently being a halogen atom or a C1-C4-alkyl is selected from the group The phenyl and 5- or 6-membered heteroaryl groups are substituted one or two times. Each substituent may be a halogen atom or a C1-C2-alkyl, C1-C2-haloalkenyl group. alkyl, cyano, hydroxy, C1-C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) independently selected from the group consisting of: and its stereoisomers, tautomers, N-oxides, hydrates, solvates and salts, This includes mixtures thereof.

[0169] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 4 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C1-C6-haloalkyl, C2-C4-alkenyl, C2- C4-alkynyl, C3-C5-cycloalkyl, C4-C5-cycloalkenyl, C1 -C5-hydroxyalkyl, C1-C4-haloalkyl, (C1-C2-alkoxy) -(C1-C4-alkyl)-, C1-C4-alkoxy, (C1-C2 alkoxy)- (C1-C4-alkoxy)-, C1-C4-haloalkoxy, -O-(C1-C4-alkoxy)-, C1-C4-haloalkoxy, rukil)-C(=O)OR 15 , -O-(C1-C4-alkyl)-C(=O)N(R 9 )(R 10 ), C3-C5-cycloalkyloxy, -S(=O)R 14 , -S(=O) 2nd Round 14 , cyano, nitro, hydroxy, -N(R 9 )(R 10 ), -N(R 16 )(R 17 ), -N(R 16 )(R 20 ), -C(=O)N(R 9 )(R 10 ), -C(=O) R 11 , -N(R 12 )C(=O)R 13 , -N(R 12 )S(=O)2R 14 , -N= S(=NH)(R 14 )2, -N=S(=O)(R 14 )2, -P(=O)(R 14 )2 , 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic alkyl) represents a group selected from oxy, phenyl and 5- or 6-membered heteroaryl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and C1-C4-alkoxy groups are C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl groups. may be substituted with a group selected from The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group The phenyl group may be substituted one or two times, each substituent being a halogen atom. or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are independently selected from the groups The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; the C1-C4-alkoxy group may be substituted with an oxiran-2-yl group, The C3-C5-cycloalkyl and C4-C6-cycloalkenyl groups may be one or more is optionally substituted twice, each substituent independently being a halogen atom or a C1-C4-alkyl is selected from the group The phenyl and 5- or 6-membered heteroaryl groups are substituted one or two times. each substituent may be a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from The compounds of formula (I) above and stereoisomers, tautomers, and the like thereof are independently selected from the group consisting of: This includes N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0170] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 4 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C1-C6-haloalkyl, C3-C5-cycloalkyl, ( C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, ( C1-C2 alkoxy)-(C1-C4 alkoxy)-, -O-(C1-C4 alkoxy)- (=O)-C(=O)OR 15 , -O-(C1-C4-alkyl)-C(=O)N(R 9 )( R 10 ), C3-C5-cycloalkyloxy, -S(=O)2R 14 , cyano, nitro , hydroxy, -N(R 9 )(R 10 ), -N(R 16 )(R 17 ), -N(R 16 )( R 20 ), -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 )2, -P(= O)(R 14 ) 2, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic represents a group selected from the group consisting of (heterocyclic alkyl)oxy and phenyl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The 4- to 7-membered heterocyclic alkyl group, the 5- to 7-membered heterocyclic alkenyl group, and the 4- to 7-membered heterocyclic The alkyl)oxy group may be substituted one, two or three times, and each substituent may be a halogen Atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo independently selected from the groups The C1-C6-alkyl and C1-C4-alkoxy groups are and optionally substituted with a group selected from alkyl and 4- to 7-membered heterocyclic alkyl, The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The 4- to 7-membered heterocyclic alkyl group may be substituted once, twice, or three times, and each substitution The substituent is a halogen atom or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1- C2-alkoxy, C3-C4-cycloalkyl, -N(R 9 )(R 10 ) and oxo are independently selected from the group selected from The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; the C1-C4-alkoxy group may be substituted with an oxiran-2-yl group, The C3-C5-cycloalkyl group may be substituted once or twice, and each substitution the substituents are independently selected from halogen atoms or C1-C4-alkyl groups; The phenyl group may be substituted one or two times, each substituent being a halogen atom. Child or C1-C2-Alkyl, C1-C2-Haloalkyl, Cyano, Hydroxy, C1-C 2-alkoxy, C3-C4-cycloalkyl and -N(R 9 )(R 10 ) are selected from The compounds of formula (I) above and stereoisomers, tautomers, and the like thereof are independently selected from the group consisting of: This includes N-oxides, hydrates, solvates and salts, and mixtures thereof.

[0171] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 4 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C1-C6-haloalkyl, C3-C5-cycloalkyl, ( C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, ( C1-C2 alkoxy)-(C1-C4 alkoxy)-, -O-(C1-C4 alkoxy)- (=O)-C(=O)OR 15 , -O-(C1-C4-alkyl)-C(=O)N(R 9 )( R 10 ), C3-C5-cycloalkyloxy, -S(=O)2R 14 , cyano, nitro , hydroxy, -N(R 9 )(R 10 ), -N(R 16 )(R 17 ), -N(R 16 )( R 20 ), -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 )2, -P(= O)(R 14 ) 2, 4- to 7-membered heterocyclic alkyl, 5- to 7-membered heterocyclic alkenyl, (4- to 7-membered heterocyclic represents a group selected from the group consisting of (heterocyclic alkyl)oxy and phenyl; The 4- to 7-membered heterocyclic alkyl group and the 5- to 7-membered heterocyclic alkenyl group are to the rest of the molecule via the carbon atoms of the heterocyclic alkyl and 5- to 7-membered heterocyclic alkenyl groups. It is connected, The C1-C6-alkyl and C1-C4-alkoxy groups are substituted with a group selected from C3-C4-cycloalkyl and 4- to 7-membered heterocyclic alkyl It may be The 4- to 7-membered heterocyclic alkyl group is bonded to the 4- to 7-membered heterocyclic alkyl group via a carbon atom of the 4- to 7-membered heterocyclic alkyl group. and connected to the rest of the molecule The C3-C4-cycloalkyl group may be substituted once or twice, and each substitution The group is a halogen atom or independently selected from groups selected from cyano and hydroxy; the C1-C4-alkoxy group may be substituted with an oxiran-2-yl group, The C3-C5-cycloalkyl may be substituted once or twice, and each substitution groups are independently selected from halogen atoms or C1-C4-alkyl groups of formula (I) above. Compounds and their stereoisomers, tautomers, N-oxides, hydrates, solvates and salts, as well as This includes allergens, cereals, and mixtures thereof.

[0172] In a further embodiment of the first aspect, the present invention provides a method for treating a cancer cell comprising: R 4 is a hydrogen atom or a halogen atom or C1-C6-alkyl, C1-C6-haloalkyl, C3-C5-cycloalkyl, ( C1-C2-alkoxy)-(C1-C4-alkyl)-, C1-C4-alkoxy, ( C1-C2 alkoxy)-(C1-C4 alkoxy)-, -O-CH2-C(=O)O R 15 , -O-CH2-C(=O)N(R 9 )(R 10 ), C3-C5-cycloalkyl Oxy, -S(=O)2R 14, cyano, nitro, hydroxy, -N(R 9 )(R 10 ) , -N(R 16 )(R 17 ), -N(R 16 )(R 20 ), -N=S(=NH)(R 14 )2, -N=S(=O)(R 14 )2, -P(=O)(R 14 ) 2, 4- to 7-membered heterocyclic alkane alkyl, 5-7 membered heterocyclic alkenyl, (4-7 membered heterocyclic alkyl)oxy and phenyl...

Claims

1. A compound of the following general formula (I), or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a mixture thereof: 【Chemistry 1】 [In the formula, R １ is cyano, -C(=O)NH ２ , -C(=O)N(H)CH ３ , -C(=O)N(H)C ２ H ５ , -C(=O)N(CH ３ ) ２ and -C(=O)OR １５ represents a group selected from R ２ represents a group selected from phenyl, naphthyl and 5- to 10-membered heteroaryl; wherein the 5- to 10-membered heteroaryl group is linked to the nitrogen-containing heterocycloalkyl group to which R 2 is attached via a carbon atom of said 5- to 10-membered heteroaryl group; and wherein the phenyl, naphthyl and 5- to 10-membered heteroaryl groups may be substituted one, two, three or four times, each substituent being a halogen atom or C １ -C ６ -Alkyl, C ３ -C ６ -cycloalkyl, C １ -C ６ -hydroxyalkyl, C １ -C ６ -haloalkyl, (C １ -C ２ -alkoxy)-(C １ -C ６ -alkyl)-, C １ -C ６ -alkoxy, (C １ -C ２ alkoxy)-(C １ -C ６ -alkoxy)-, C １ -C ６ -haloalkoxy, C ３ -C ６ -cycloalkyloxy, phenoxy, -SR １４ , -S(=O)R １４ , -S(=O) ２ R １４ , -P(=O)(R １４ ) ２ , cyano, hydroxy, -N(R ９ ) (R １０ ), -C(=O)N(R ９ ) (R １０ ), -C(=O)R １１ , -N(R １２ ) C(=O)R １３ , -N(R １２ ) S(=O) ２ R １４ , -N=S(=NH)(R １４ ) ２ , -N=S(=O)(R １４ ) ２ , 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl; Or, when two substituents of said phenyl group are attached to adjacent ring atoms, they together represent: - (CH ２ ) ３ -, -CH ２ -CH(OH)-CH ２ -, -(CH ２ ) ４ -, -O-(CH ２ ) ２ -, -(CH ２ ) ２ —O—, —CH ２ -CH(CH ３ ) —O—, —CH ２ -O-CH ２ -, -O-(CH ２ ) ３ -, -(CH ２ ) ３ —O—, —CH ２ -O-(CH ２ ) ２ -, -(CH ２ ) ２ -O-CH ２ --, --O-CH ２ -O-, -OC(CH ３ ) ２ -O-, -O-(CH ２ ) ２ -O-, -N(R １８ )-C(=O)-(C(R １８ ) (R １９ )) ｍ -, -N(R １８ )-C(=O)-(C(CH3)2)-, -N(R １８ )-(C(R １８ ) (R １９ )) ｍ -, -N(R １８ )-C(=O)-O- and -N(R １８ )-C(=O)-N(R １８ )-, wherein the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group are linked via a carbon atom of the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group to the phenyl, naphthyl, or 5- to 10-membered heteroaryl group to which it is attached; and wherein the 4- to 7-membered heterocycloalkyl group, the 5- to 7-membered heterocycloalkenyl group and the (4- to 7-membered heterocycloalkyl)oxy group may be substituted once, twice or three times, and each substituent may be a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; and Here, the C １ -C ６ -Alkyl and C １ -C ６ -alkoxy group is C ３ -C ４ - optionally substituted with a group selected from cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl; wherein the 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of the 4- to 7-membered heterocycloalkyl group to the C 1 -C 6 -alkyl or C 1 -C 6 -alkoxy group to which it is attached, and wherein the 4- to 7-membered heterocycloalkyl group may be substituted one, two or three times, and each substituent is a halogen atom or a C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; and wherein the phenyl group may be substituted one or two times, each substituent being a halogen atom or a C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from the group Here, C ３ -C ４ the cycloalkyl group may be substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from cyano and hydroxy; and Here, the C ３ -C ６ -cycloalkyl groups may be substituted one or two times, each substituent independently being a halogen atom or a C １ -C ４ - alkyl groups, wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be substituted one or two times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from R ３ is a hydrogen atom, a halogen atom, or C １ -C ６ -Alkyl, C ２ -C ６ -alkenyl, C ２ -C ６ -alkynyl, C ３ -C ６ -cycloalkyl, C ４ -C ６ -cycloalkenyl, C １ -C ６ -hydroxyalkyl, C １ -C ６ -haloalkyl, (C １ -C ２ -alkoxy)-(C １ -C ６ -alkyl)-, C １ -C ６ -alkoxy, (C １ -C ２ alkoxy)-(C １ -C ６ -alkoxy)-, C １ -C ４ -haloalkoxy, C ３ -C ６ -cycloalkyloxy, phenoxy, -SR １４ , -S(=O)R １４ , -S(=O) ２ R １４ , cyano, hydroxy, -N(R ９ ) (R １０ ), -C(=O)N(R ９ ) (R １０ ), -C(=O)R １１ , -N(R １２ ) C(=O)R １３ , -N(R １２ ) S(=O) ２ R １４ , -N=S(=NH)(R １４ ) ２ , -N=S(=O)(R １４ ) ２、 -P(=O)(R １４ ) ２ represents a group selected from 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl; wherein the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group are linked to the aminoquinoline core to which R 3 is attached via a carbon atom of the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group; and wherein the 4- to 7-membered heterocycloalkyl group, the 5- to 7-membered heterocycloalkenyl group and the (4- to 7-membered heterocycloalkyl)oxy group may be substituted once, twice or three times, and each substituent may be a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; and Here, the C １ -C ６ -Alkyl, C ２ -C ６ -alkenyl, C ２ -C ６ -alkynyl and C １ -C ６ -alkoxy group is C ３ -C ４ - optionally substituted with a group selected from cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl; wherein the 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of the 4- to 7-membered heterocycloalkyl group to the C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl or C 1 -C 6 -alkoxy group to which it is attached, and wherein the 4- to 7-membered heterocycloalkyl group may be substituted one, two or three times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; and wherein the phenyl group may be substituted one or two times, each substituent being a halogen atom or a C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from the group Here, C ３ -C ４ the cycloalkyl group may be substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from cyano and hydroxy; and Here, the C ２ -C ６ -Alkenyl group is C １ -C ４ -optionally substituted with haloalkyl groups, Here, the C ３ -C ６ -cycloalkyl and C ４ -C ６ The cycloalkenyl group may be substituted one or two times, each substituent being a halogen atom or a C １ -C ４ -Alkyl and C １ -C ４ -haloalkyl, and wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be substituted one or two times, each substituent being a halogen atom or a C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from R ４ is a hydrogen atom, a halogen atom, or C １ -C ６ -Alkyl, C ２ -C ６ -alkenyl, C ２ -C ６ -alkynyl, C ３ -C ６ -cycloalkyl, C ４ -C ６ -cycloalkenyl, C １ -C ６ -hydroxyalkyl, C １ -C ６ -haloalkyl, (C １ -C ２ -alkoxy)-(C １ -C ６ -alkyl)-, C １ -C ６ -alkoxy, (C １ -C ２ alkoxy)-(C １ -C ６ -alkoxy)-, C １ -C ４ -haloalkoxy, -O-(C １ -C ４ -alkyl)-C(=O)OR １５ , —O—(C １ -C ４ -alkyl)-C(=O)N(R ９ ) (R １０ ), C ３ -C ６ -cycloalkyloxy, -S(=O)R １４ , -S(=O) ２ R １４ , cyano, nitro, hydroxy, -N(R ９ ) (R １０ ), -N(R １６ ) (R １７ ), -N(R １６ ) (R ２０ ), -C(=O)N(R ９ ) (R １０ ), -C(=O)R １１ , -N(R １２ ) C(=O)R １３ , -N(R １２ ) S(=O) ２ R １４ , -N=S(=NH)(R １４ ) ２ , -N=S(=O)(R １４ ) ２ , -P(=O)(R １４ ) ２ represents a group selected from 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl; wherein the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group are linked to the aminoquinoline core to which R 4 is attached via a carbon atom of the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group; and wherein the 4- to 7-membered heterocycloalkyl group, the 5- to 7-membered heterocycloalkenyl group and the (4- to 7-membered heterocycloalkyl)oxy group may be substituted once, twice or three times, and each substituent may be a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; Here, the C １ -C ６ -Alkyl, C ２ -C ６ -alkenyl, C ２ -C ６ -alkynyl and C １ -C ６ -alkoxy group is C ３ -C ４ - optionally substituted with a group selected from cycloalkyl and 4- to 7-membered heterocycloalkyl; wherein the 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of the 4- to 7-membered heterocycloalkyl group to the C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl or C 1 -C 6 -alkoxy group to which it is attached, and wherein the 4- to 7-membered heterocycloalkyl group may be substituted one, two or three times, each substituent being a halogen atom or Here, C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; and wherein the phenyl group may be substituted one or two times, each substituent being a halogen atom or a C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from Here, C ３ -C ４ the cycloalkyl group may be substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from cyano and hydroxy; and Here, the C １ -C ６ -alkoxy groups may be substituted with oxiran-2-yl groups, and Here, the C ３ -C ６ -cycloalkyl and C ４ -C ６ -cycloalkenyl groups may be substituted one or two times, each substituent independently being a halogen atom or a C １ -C ４ - alkyl groups, and wherein the phenyl and 5- or 6-membered heteroaryl groups may be substituted one or two times, each substituent being a halogen atom or a C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from R ５ is a hydrogen atom, a halogen atom, or C １ -C ６ -Alkyl, C ２ -C ６ -alkenyl, C ２ -C ６ -alkynyl, C ３ -C ６ -cycloalkyl, C ４ -C ６ -cycloalkenyl, C １ -C ６ -hydroxyalkyl, C １ -C ６ -haloalkyl, (C １ -C ２ -alkoxy)-(C １ -C ６ -alkyl)-, C １ -C ６ -alkoxy, (C １ -C ２ alkoxy)-(C ２ -C ６ -alkoxy)-, C １ -C ４ -haloalkoxy, C ３ -C ６ -cycloalkyloxy, phenoxy, -SR １４ , -S(=O)R １４ , -S(=O) ２ R １４ , cyano, hydroxy, -N(R ９ ) (R １０ ), -C(=O)N(R ９ ) (R １０ ), -C(=O)R １１ , -N(R １２ ) C(=O)R １３ , -N(R １２ ) S(=O) ２ R １４ , -N=S(=NH)(R １４ ) ２ , -N=S(=O)(R １４ ) ２、 -P(=O)(R １４ ) ２ represents a group selected from 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl; wherein the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group are linked to the aminoquinoline core to which R 5 is attached via a carbon atom of the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group; and wherein the 4- to 7-membered heterocycloalkyl group, the 5- to 7-membered heterocycloalkenyl group and the (4- to 7-membered heterocycloalkyl)oxy group may be substituted once, twice or three times, and each substituent may be a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; and Here, the C １ -C ６ -Alkyl, C ２ -C ６ -alkenyl, C ２ -C ６ -alkynyl and C １ -C ６ -alkoxy group is C ３ -C ４ - optionally substituted with a group selected from cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl; wherein the 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of the 4- to 7-membered heterocycloalkyl group to the C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl or C 1 -C 6 -alkoxy group to which it is attached, and wherein the 4- to 7-membered heterocycloalkyl group may be substituted one, two or three times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; and wherein the phenyl group may be substituted one or two times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from the group Here, C ３ -C ４ the cycloalkyl group may be substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from cyano and hydroxy; and Here, the C ３ -C ６ -cycloalkyl and C ４ -C ６ -cycloalkenyl groups may be substituted one or two times, each substituent independently being a halogen atom or a C １ -C ４ - alkyl groups, and wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be substituted one or two times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from R ６ is a hydrogen atom, a fluorine atom, or C １ -C ４ -Alkyl, C １ -C ４ -hydroxyalkyl, C １ -C ４ represents a group selected from alkoxy, hydroxy and oxo, R ７ is a hydrogen atom, a halogen atom, or C １ -C ４ -Alkyl, C １ -C ４ represents a group selected from alkoxy, hydroxy and cyano, R ８ represents a group selected from methyl and ethyl, R ９ and R １０ is, independently in each occurrence, hydrogen or C １ -C ４ -Alkyl, C ２ -C ４ -hydroxyalkyl, N≡C—(C １ -C ４ -alkyl)-, (C １ -C ４ -alkoxy)-(C ２ -C ４ -alkyl)-, C ３ -C ４ -cycloalkyl and C ２ -C ４ -haloalkyl, or R ９ and R １０ together with the nitrogen to which they are attached represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group; wherein the nitrogen-containing 4- to 7-membered heterocycloalkyl group may be substituted one, two or three times, and each substituent is a halogen atom or a C １ -C ４ -Alkyl, C ３ -C ４ independently selected from the group selected from cycloalkyl, hydroxy and oxo; or two substituents bound to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocycloalkyl group, together with the carbon atom to which they are bound, represent a 4- to 7-membered heterocycloalkyl group; wherein the 4- to 7-membered heterocyclic alkyl group may be substituted once or twice, and each substituent is a halogen atom or a C １ -C ４ -Alkyl, C ３ -C ４ -cycloalkyl, C １ -C ４ independently selected from the group selected from haloalkyl, hydroxy and oxo; R １１ is a hydrogen atom or C １ -C ４ -Alkyl, C １ -C ４ -hydroxyalkyl, C １ -C ４ represents a group selected from haloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein the phenyl group and the 5- or 6-membered heteroaryl group may be substituted once or twice, and each substituent is a halogen atom or a C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from R １２ is a hydrogen atom or C １ -C ４ represents an alkyl group, R １３ is a hydrogen atom or C １ -C ６ represents a group selected from alkyl, phenyl and 5- or 6-membered heteroaryl, wherein the phenyl group and the 5- or 6-membered heteroaryl group may be substituted once or twice, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from R １４ is C １ -C ６ -Alkyl, C １ -C ６ -haloalkyl, C ３ -C ６ represents a group selected from cycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein the phenyl group and the 5- or 6-membered heteroaryl group may be substituted once or twice, and each substituent is a halogen atom or a C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from R １５ is a hydrogen atom or C １ -C ４ represents an alkyl group, R １６ is a hydrogen atom or C １ -C ４ -Alkyl, C ３ -C ４ -cycloalkyl and C ２ -C ４ -haloalkyl, R １７ represents a 4- to 7-membered heterocyclic alkyl group, wherein the 4- to 7-membered heterocycloalkyl group may be substituted one, two or three times, and each substituent is a halogen atom or a C １ -C ４ -Alkyl, C ３ -C ４ -cycloalkyl, C １ -C ４ independently selected from the group selected from alkoxy, hydroxy and oxo, and wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the nitrogen atom of the R 4 group to which it is attached, -N(R 16 )(R 17 ); R １８ represents a hydrogen atom or a group selected from methyl and ethyl, R １９ represents a hydrogen atom or a group selected from methyl and ethyl, R ２０ is (4- to 7-membered heterocyclic alkyl)-(C １ -C ４ -alkyl)- group, wherein the (4-7 membered heterocycloalkyl) portion of the group may be substituted one, two or three times, and each substituent may be a halogen atom or a C １ -C ４ -Alkyl, C ３ -C ４ -cycloalkyl, C １ -C ４ independently selected from groups selected from alkoxy, hydroxy and oxo; m represents an integer selected from 1, 2 and 3, and n represents an integer selected from 1, 2 and 3; However, 6-fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide is excluded.

2. R １ is cyano, -C(=O)NH ２ , -C(=O)N(H)CH ３ , -C(=O)N(H)C ２ H ５ , -C(=O)N(CH ３ ) ２ and -C(=O)OR １５ represents a group selected from R ２ represents a group selected from phenyl, naphthyl and 5- to 10-membered heteroaryl; wherein the 5- to 10-membered heteroaryl group is linked to the nitrogen-containing heterocycloalkyl group to which R 2 is attached via a carbon atom of said 5- to 10-membered heteroaryl group; and wherein the phenyl, naphthyl and 5- to 10-membered heteroaryl groups may be substituted one, two, three or four times, each substituent being a halogen atom or C １ -C ６ -Alkyl, C ３ -C ５ -cycloalkyl, C １ -C ６ -hydroxyalkyl, C １ -C ４ -haloalkyl, (C １ -C ２ -alkoxy)-(C １ -C ４ -alkyl)-, C １ -C ４ -alkoxy, (C １ -C ２ alkoxy)-(C １ -C ４ -alkoxy)-, C １ -C ４ -haloalkoxy, C ３ -C ５ -cycloalkyloxy, phenoxy, -SR １４ , -S(=O)R １４ , -S(=O) ２ R １４ , -P(=O)(R １４ ) ２ , cyano, hydroxy, -N(R ９ ) (R １０ ), -C(=O)N(R ９ ) (R １０ ), -C(=O)R １１ , -N(R １２ ) C(=O)R １３ , -N(R １２ ) S(=O) ２ R １４ , -N=S(=NH)(R １４ ) ２ , -N=S(=O)(R １４ ) ２ , 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl; Or, when two substituents of said phenyl group are attached to adjacent ring atoms, they together represent: - (CH ２ ) ３ -, -CH ２ -CH(OH)-CH ２ -, -(CH ２ ) ４ -, -O-(CH ２ ) ２ -, -(CH ２ ) ２ —O—, —CH ２ -CH(CH ３ ) —O—, —CH ２ -O-CH ２ -, -O-(CH ２ ) ３ -, -(CH ２ ) ３ —O—, —CH ２ -O-(CH ２ ) ２ -, -(CH ２ ) ２ -O-CH ２ --, --O-CH ２ -O-, -OC(CH ３ ) ２ -O-, -O-(CH ２ ) ２ -O-, -N(R １８ )-C(=O)-(C(R １８ ) (R １９ )) ｍ -, -N(R １８ )-C(=O)-(C(CH3)2)-, -N(R １８ )-(C(R １８ ) (R １９ )) ｍ -, -N(R １８ )-C(=O)-O- and -N(R １８ )-C(=O)-N(R １８ )-, wherein the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are linked through a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups to the phenyl, naphthyl, or 5- to 10-membered heteroaryl groups to which they are attached; and wherein the 4- to 7-membered heterocycloalkyl group, the 5- to 7-membered heterocycloalkenyl group, and the (4- to 7-membered heterocycloalkyl)oxy group may be substituted one, two, or three times, and each substituent is a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; Here, the C １ -C ６ -Alkyl and C １ -C ４ - the alkoxy group is C ３ -C ４ - optionally substituted with a group selected from cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl; wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the C 1 -C 6 -alkyl or C 1 -C 4 -alkoxy group to which it is attached, and wherein the 4- to 7-membered heterocycloalkyl group may be substituted one, two or three times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; wherein the phenyl group may be substituted one or two times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from Here, C ３ -C ４ the cycloalkyl group may be optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from cyano and hydroxy; and Here, the C ３ -C ５ -cycloalkyl groups may be optionally substituted one or two times, each substituent independently being a halogen atom or a C １ -C ４ - alkyl groups, and wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be substituted one or two times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from R ３ is a hydrogen atom or a halogen atom, or C １ -C ６ -Alkyl, C ２ -C ４ -alkenyl, C ２ -C ４ -alkynyl, C ３ -C ５ -cycloalkyl, C ４ -C ５ -cycloalkenyl, C １ -C ４ -hydroxyalkyl, C １ -C ４ -haloalkyl, (C １ -C ２ -alkoxy)-(C １ -C ４ -alkyl)-, C １ -C ４ -alkoxy, (C １ -C ２ alkoxy)-(C １ -C ４ -alkoxy)-, C １ -C ４ -haloalkoxy, C ３ -C ５ -cycloalkyloxy, phenoxy, -SR １４ , -S(=O)R １４ , -S(=O) ２ R １４ , cyano, hydroxy, -N(R ９ ) (R １０ ), -C(=O)N(R ９ ) (R １０ ), -C(=O)R １１ , -N(R １２ ) C(=O)R １３ , -N(R １２ ) S(=O) ２ R １４ , -N=S(=NH)(R １４ ) ２ , -N=S(=O)(R １４ ) ２、 -P(=O)(R １４ ) ２ represents a group selected from 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl; wherein the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group are linked to an aminoquinoline core to which R 3 is attached via a carbon atom of the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group; wherein the 4- to 7-membered heterocycloalkyl group, the 5- to 7-membered heterocycloalkenyl group, and the (4- to 7-membered heterocycloalkyl)oxy group may be substituted one, two, or three times, and each substituent is a halogen atom, or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; Here, the C １ -C ６ -Alkyl, C ２ -C ４ -alkenyl, C ２ -C ４ -alkynyl and C １ -C ４ - the alkoxy group is C ３ -C ４ - optionally substituted with a group selected from cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl; wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the C 1 -C 6 -alkyl, C 2 -C 4 -alkenyl, C 2 -C 4 -alkynyl or C 1 -C 4 -alkoxy group to which it is attached, wherein the 4- to 7-membered heterocycloalkyl group may be substituted one, two or three times, and each substituent is a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; wherein the phenyl group may be substituted one or two times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from Here, C ３ -C ４ - the cycloalkyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from cyano and hydroxy; Here, the C ２ -C ４ -Alkenyl group is C １ -C ４ -optionally substituted with haloalkyl groups, Here, the C ３ -C ５ -cycloalkyl and C ４ -C ５ - the cycloalkenyl group may be substituted one or two times, each substituent being a halogen atom or a C １ -C ４ -Alkyl and C １ -C ４ -haloalkyl; wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be substituted one or two times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from R ４ is a hydrogen atom or a halogen atom, or C １ -C ６ -Alkyl, C １ -C ６ -haloalkyl, C ２ -C ４ -alkenyl, C ２ -C ４ -alkynyl, C ３ -C ５ -cycloalkyl, C ４ -C ５ -cycloalkenyl, C １ -C ５ -hydroxyalkyl, (C １ -C ２ -alkoxy)-(C １ -C ４ -alkyl)-, C １ -C ４ -alkoxy, (C １ -C ２ alkoxy)-(C １ -C ４ -alkoxy)-, C １ -C ４ -haloalkoxy, -O-(C １ -C ４ -alkyl)-C(=O)OR １５ , —O—(C １ -C ４ -alkyl)-C(=O)N(R ９ ) (R １０ ), C ３ -C ５ -cycloalkyloxy, -S(=O)R １４ , -S(=O) ２ R １４ , cyano, nitro, hydroxy, -N(R ９ ) (R １０ ), -N(R １６ ) (R １７ ), -N(R １６ ) (R ２０ ), -C(=O)N(R ９ ) (R １０ ), -C(=O)R １１ , -N(R １２ ) C(=O)R １３ , -N(R １２ ) S(=O) ２ R １４ , -N=S(=NH)(R １４ ) ２ , -N=S(=O)(R １４ ) ２ , -P(=O)(R １４ ) ２ represents a group selected from 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl; wherein the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group are linked to an aminoquinoline core to which R 4 is attached via a carbon atom of the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group; wherein the 4- to 7-membered heterocycloalkyl group, the 5- to 7-membered heterocycloalkenyl group, and the (4- to 7-membered heterocycloalkyl)oxy group may be substituted one, two, or three times, and each substituent is a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; Here, the C １ -C ６ -Alkyl, C ２ -C ４ -alkenyl, C ２ -C ４ -alkynyl and C １ -C ４ - the alkoxy group is C ３ -C ４ - optionally substituted with a group selected from cycloalkyl and 4- to 7-membered heterocycloalkyl; wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the C 1 -C 6 -alkyl, C 2 -C 4 -alkenyl, C 2 -C 4 -alkynyl or C 1 -C 4 -alkoxy group to which it is attached, wherein the 4- to 7-membered heterocycloalkyl group may be substituted one, two or three times, and each substituent is a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; wherein the phenyl group may be substituted one or two times, each substituent being a halogen atom or a C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from Here, C ３ -C ４ - the cycloalkyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from cyano and hydroxy; Here, the C １ -C ４ -alkoxy groups may be substituted with oxiran-2-yl groups, Here, the C ３ -C ５ -cycloalkyl and C ４ -C ６ -cycloalkenyl groups may be optionally substituted one or two times, each substituent independently being a halogen atom or １ -C ４ - alkyl groups, wherein the phenyl and 5- or 6-membered heteroaryl groups may be substituted one or two times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from R ５ is a hydrogen atom or a halogen atom, or C １ -C ５ -Alkyl, C ２ -C ４ -alkenyl, C ２ -C ４ -alkynyl, C ３ -C ５ -cycloalkyl, C ４ -C ５ -cycloalkenyl, C １ -C ４ -hydroxyalkyl, C １ -C ４ -haloalkyl, (C １ -C ２ -alkoxy)-(C １ -C ４ -alkyl)-, C １ -C ４ -alkoxy, (C １ -C ２ alkoxy)-(C ２ -C ４ -alkoxy)-, C １ -C ４ -haloalkoxy, C ３ -C ５ -cycloalkyloxy, phenoxy, -SR １４ , -S(=O)R １４ , -S(=O) ２ R １４ , cyano, hydroxy, -N(R ９ ) (R １０ ), -C(=O)N(R ９ ) (R １０ ), -C(=O)R １１ , -N(R １２ ) C(=O)R １３ , -N(R １２ ) S(=O) ２ R １４ , -N=S(=NH)(R １４ ) ２ , -N=S(=O)(R １４ ) ２、 -P(=O)(R １４ ) ２ represents a group selected from 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, phenyl, and 5- or 6-membered heteroaryl; wherein the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group are linked to an aminoquinoline core to which R 5 is attached via a carbon atom of the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group; wherein the 4- to 7-membered heterocycloalkyl group, the 5- to 7-membered heterocycloalkenyl group, and the (4- to 7-membered heterocycloalkyl)oxy group may be substituted one, two, or three times, and each substituent is a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; Here, the C １ -C ５ -Alkyl, C ２ -C ４ -alkenyl, C ２ -C ４ -alkynyl and C １ -C ４ - the alkoxy group is C ３ -C ４ - optionally substituted with a group selected from cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl; wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the C 1 -C 5 -alkyl, C 2 -C 4 -alkenyl, C 2 -C 4 -alkynyl or C 1 -C 4 -alkoxy group to which it is attached, wherein the 4- to 7-membered heterocycloalkyl group may be substituted one, two or three times, and each substituent is a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; wherein the phenyl group may be substituted once or twice, and each substituent is a halogen atom or a C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from Here, C ３ -C ４ - the cycloalkyl group is optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from cyano and hydroxy; Here, the C ３ -C ５ -cycloalkyl and C ４ -C ５ - the cycloalkenyl group may be optionally substituted one or two times, each substituent independently being a halogen atom or a C １ -C ４ - alkyl groups, wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be substituted one or two times, each substituent being a halogen atom or a C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from R ６ is a hydrogen atom or a fluorine atom, or C １ -C ４ -Alkyl, C １ -C ４ -hydroxyalkyl, C １ -C ４ represents a group selected from alkoxy, hydroxy and oxo, R ７ is a hydrogen atom or a halogen atom, or C １ -C ４ -Alkyl, C １ -C ４ represents a group selected from alkoxy, hydroxy and cyano, R ８ represents a group selected from methyl and ethyl, R ９ and R １０ is, independently in each occurrence, hydrogen, or C １ -C ４ -Alkyl, C ２ -C ４ -hydroxyalkyl, N≡C—(C １ -C ４ -alkyl)-, (C １ -C ４ -alkoxy)-(C ２ -C ４ -alkyl)-, C ３ -C ４ -cycloalkyl and C ２ -C ４ -haloalkyl, or R ９ and R １０ together with the nitrogen to which they are attached represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group; wherein the nitrogen-containing 4- to 7-membered heterocyclic alkyl group may be substituted one, two or three times, and each substituent is a halogen atom or a C １ -C ４ -Alkyl, C ３ -C ４ independently selected from the group selected from cycloalkyl, hydroxy and oxo; or two substituents bound to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocycloalkyl group, together with the carbon atom to which they are bound, represent a 4- to 7-membered heterocycloalkyl group; The 4- to 7-membered heterocycloalkyl group may be substituted one or two times, and each substitution group may be a halogen atom or a C １ -C ４ -Alkyl, C ３ -C ４ -cycloalkyl, C １ -C ４ independently selected from the group selected from haloalkyl, hydroxy and oxo; R １１ is a hydrogen atom or C １ -C ４ -Alkyl, C １ -C ４ -hydroxyalkyl, C １ -C ４ represents a group selected from haloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein the phenyl and 5- or 6-membered heteroaryl groups may be substituted one or two times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from R １２ is a hydrogen atom or C １ -C ４ represents an alkyl group, R １３ is a hydrogen atom or C １ -C ４ represents a group selected from alkyl, phenyl and 5- or 6-membered heteroaryl, wherein the phenyl and 5- or 6-membered heteroaryl groups may be substituted one or two times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from R １４ But C １ -C ４ -Alkyl, C １ -C ４ -haloalkyl, C ３ -C ５ represents a group selected from cycloalkyl, phenyl and 5- or 6-membered heteroaryl, wherein the phenyl and 5- or 6-membered heteroaryl groups may be substituted one or two times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from R １５ is a hydrogen atom or C １ -C ４ represents an alkyl group, R １６ is a hydrogen atom, or C １ -C ４ -Alkyl, C ３ -C ４ -cycloalkyl and C ２ -C ４ -haloalkyl, R １７ represents a 4- to 7-membered heterocyclic alkyl group; wherein the 4- to 7-membered heterocycloalkyl group may be substituted one, two or three times, and each substituent is a halogen atom or C １ -C ４ -Alkyl, C ３ -C ４ -cycloalkyl, C １ -C ４ independently selected from groups selected from alkoxy, hydroxy and oxo; wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the nitrogen atom of the R 4 group to which it is attached, -N(R 16 )(R 17 ); R １８ represents a hydrogen atom or a group selected from methyl and ethyl, R １９ represents a hydrogen atom or a group selected from methyl and ethyl, R ２０ is (4- to 7-membered heterocyclic alkyl)-(C １ -C ４ -alkyl)- group, wherein the (4- to 7-membered heterocyclic alkyl) portion of the group may be substituted one, two or three times, each substituent being a halogen atom or C １ -C ４ -Alkyl, C ３ -C ４ -cycloalkyl, C １ -C ４ independently selected from groups selected from alkoxy, hydroxy and oxo; m represents an integer selected from 1, 2 and 3; and n represents an integer selected from 1, 2 and 3; 2. The compound of claim 1, or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a mixture thereof.

3. R １ is cyano, -C(=O)NH ２ , -C(=O)N(H)CH ３ , -C(=O)N(H)C ２ H ５ , -C(=O)N(CH ３ ) ２ and -C(=O)OR １５ represents a group selected from R ２ represents a group selected from phenyl, naphthyl and 5- to 10-membered heteroaryl; wherein the 5- to 10-membered heteroaryl group is linked to the nitrogen-containing heterocycloalkyl group to which R 2 is attached via a carbon atom of said 5- to 10-membered heteroaryl group; and wherein the phenyl, naphthyl and 5- to 10-membered heteroaryl groups may be substituted one, two, three or four times, each substituent being a halogen atom or C １ -C ６ -Alkyl, C ３ -C ５ -cycloalkyl, C １ -C ４ -haloalkyl, (C １ -C ２ -alkoxy)-(C １ -C ２ -alkyl)-, C １ -C ４ -alkoxy, C １ -C ４ -haloalkoxy, phenoxy, -S(=O) ２ R １４ , -P(=O)(R １４ ) ２ , cyano, hydroxy, -N(R ９ ) (R １０ ), -C(=O)N(R ９ ) (R １０ ), -C(=O)R １１ , -N(R １２ ) C(=O)R １３ , -N(R １２ ) S(=O) ２ R １４ , -N=S(=O)(R １４ ) ２ , 4- to 7-membered heterocycloalkyl, phenyl, and 5- or 6-membered heteroaryl; Or, when two substituents of said phenyl group are attached to adjacent ring atoms, they together represent: -CH ２ -CH(OH)-CH ２ -, -CH ２ -CH(CH ３ )-O-, -OC(CH ３ ) ２ -O-, -N(R １８ )-C(=O)-(C(R １８ ) (R １９ )) ｍ -, -N(R １８ )-C(=O)-(C(CH3)2)-, -N(R １８ )-(C(R １８ ) (R １９ )) ｍ -, -N(R １８ )-C(=O)-O- and -N(R １８ )-C(=O)-N(R １８ )-, wherein said 4- to 7-membered heterocycloalkyl group is linked through a carbon atom of said 4- to 7-membered heterocycloalkyl group to the phenyl, naphthyl, or 5- to 10-membered heteroaryl group to which it is attached; and Here, the C １ -C ４ the alkoxy group is optionally substituted with a group selected from phenyl and 4- to 7-membered heterocycloalkyl; wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the C 1 -C 4 -alkoxy group to which it is attached, wherein the phenyl group may be substituted one or two times, each substituent being a halogen atom or a C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from the group wherein the phenyl, phenoxy and 5- or 6-membered heteroaryl groups may be substituted one or two times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from R ３ is a hydrogen atom or a halogen atom, or C １ -C ６ -Alkyl, C ２ -C ４ -alkenyl, C ３ -C ５ -cycloalkyl, (C １ -C ２ -alkoxy)-(C １ -C ４ -alkyl)-, C １ -C ４ -alkoxy, C １ -C ４ -haloalkoxy, C ３ -C ５ -cycloalkyloxy, -S(=O) ２ R １４ , cyano, hydroxy, -N(R ９ ) (R １０ ), -C(=O)N(R ９ ) (R １０ ), -P(=O)(R １４ ) ２ represents a group selected from 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, and phenyl; wherein the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group are linked through a carbon atom of the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group to an aminoquinoline core to which R 3 is attached; and wherein the 4- to 7-membered heterocycloalkyl group, the 5- to 7-membered heterocycloalkenyl group and the (4- to 7-membered heterocycloalkyl)oxy group may be substituted one, two or three times, and each substituent is a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; and Here, the C １ -C ６ -Alkyl and C １ -C ４ - the alkoxy group is C ３ -C ４ - optionally substituted with a group selected from cycloalkyl and 4- to 7-membered heterocycloalkyl; wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the C 1 -C 6 -alkyl or C 1 -C 4 -alkoxy group to which it is attached, wherein the 4- to 7-membered heterocycloalkyl group may be substituted one, two or three times, and each substituent is a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; and Here, C ３ -C ４ the cycloalkyl group may be optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from cyano and hydroxy; and Here, the C ２ -C ４ -Alkenyl group is C １ -C ４ - optionally substituted with a haloalkyl group, and Here, the C ３ -C ５ The cycloalkyl group may be substituted one or two times, each substituent being a halogen atom or a C １ -C ４ -Alkyl and C １ -C ４ -haloalkyl; R ４ is a hydrogen atom or a halogen atom, or C １ -C ６ -Alkyl, C １ -C ６ -haloalkyl, C ３ -C ５ -cycloalkyl, (C １ -C ２ -alkoxy)-(C １ -C ４ -alkyl)-, C １ -C ４ -alkoxy, (C １ -C ２ alkoxy)-(C １ -C ４ -alkoxy)-, -O-(C １ -C ４ -alkyl)-C(=O)OR １５ , —O—(C １ -C ４ -alkyl)-C(=O)N(R ９ ) (R １０ ), C ３ -C ５ -cycloalkyloxy, -S(=O) ２ R １４ , cyano, nitro, hydroxy, -N(R ９ ) (R １０ ), -N(R １６ ) (R １７ ), -N(R １６ ) (R ２０ ), -N=S(=NH)(R １４ ) ２ , -N=S(=O)(R １４ ) ２ , -P(=O)(R １４ ) ２ represents a group selected from 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, and phenyl; wherein the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group are linked through a carbon atom of the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group to the aminoquinoline core to which R 4 is attached; and wherein the 4- to 7-membered heterocycloalkyl group, the 5- to 7-membered heterocycloalkenyl group, and the (4- to 7-membered heterocycloalkyl)oxy group may be substituted one, two, or three times, and each substituent is a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; Here, the C １ -C ６ -Alkyl and C １ -C ４ - the alkoxy group is C ３ -C ４ - optionally substituted with a group selected from cycloalkyl and 4- to 7-membered heterocycloalkyl; wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the C 1 -C 6 -alkyl or C 1 -C 4 -alkoxy group to which it is attached, and wherein the 4- to 7-membered heterocycloalkyl group may be substituted one, two or three times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; and Here, C ３ -C ４ the cycloalkyl group may be optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from cyano and hydroxy; and Here, the C １ -C ４ -alkoxy groups may be substituted with oxiran-2-yl groups, and Here, the C ３ -C ５ -cycloalkyl groups may be optionally substituted one or two times, each substituent independently being a halogen atom or a C １ -C ４ - alkyl groups, wherein the phenyl group may be substituted one or two times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from R ５ is a hydrogen atom or a halogen atom, or C １ -C ５ -Alkyl, C ３ -C ５ -cycloalkyl, C １ -C ４ -alkoxy, C ３ -C ５ -cycloalkyloxy, -S(=O) ２ R １４ , cyano, hydroxy, -N(R ９ ) (R １０ ), -C(=O)N(R ９ ) (R １０ ), -C(=O)R １１ , -N(R １２ ) C(=O)R １３ , -N(R １２ ) S(=O) ２ R １４ , -N=S(=NH)(R １４ ) ２ , -N=S(=O)(R １４ ) ２、 -P(=O)(R １４ ) ２ represents a group selected from 4- to 7-membered heterocycloalkyl and (4- to 7-membered heterocycloalkyl)oxy; wherein said 4- to 7-membered heterocycloalkyl group is linked to the aminoquinoline core to which R 5 is attached via a carbon atom of said 4- to 7-membered heterocycloalkyl group; and wherein the 4- to 7-membered heterocycloalkyl group, the 5- to 7-membered heterocycloalkenyl group, and the (4- to 7-membered heterocycloalkyl)oxy group may be substituted one, two, or three times, and each substituent is a halogen atom, or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; and Here, the C １ -C ５ -Alkyl and C １ -C ４ - the alkoxy group is C ３ -C ４ - optionally substituted with a group selected from cycloalkyl, phenyl and 4- to 7-membered heterocycloalkyl; wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the C 1 -C 5 -alkyl or C 1 -C 4 -alkoxy group to which it is attached, wherein the 4- to 7-membered heterocycloalkyl group may be substituted one, two or three times, and each substituent is a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl, -N(R ９ ) (R １０ ) and oxo; and wherein the phenyl group may be substituted one or two times, each substituent being a halogen atom or C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from the group Here, C ３ -C ４ the cycloalkyl group may be optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from cyano and hydroxy; and Here, the C ３ -C ５ -cycloalkyl groups may be optionally substituted one or two times, each substituent independently being a halogen atom or a C １ -C ４ - alkyl groups, R ６ is a hydrogen atom, or C １ -C ４ -Alkyl, C １ -C ４ -hydroxyalkyl, C １ -C ４ represents a group selected from alkoxy, hydroxy and oxo, R ７ is a hydrogen atom or a halogen atom, or C １ -C ４ -Alkyl, C １ -C ４ represents a group selected from alkoxy and hydroxy, R ８ represents a group selected from methyl and ethyl, R ９ and R １０ is, independently in each occurrence, hydrogen, or C １ -C ４ -Alkyl, C ２ -C ４ -hydroxyalkyl, N≡C—(C １ -C ４ -alkyl)-, (C １ -C ４ -alkoxy)-(C ２ -C ４ -alkyl)- and C ３ -C ４ -cycloalkyl, or R ９ and R １０ together with the nitrogen to which they are attached represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group; wherein the nitrogen-containing 4- to 7-membered heterocyclic alkyl group may be substituted one, two or three times, and each substituent is a halogen atom or a C １ -C ４ -Alkyl, C ３ -C ４ independently selected from the group selected from cycloalkyl, hydroxy and oxo; or two substituents bound to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocycloalkyl group, together with the carbon atom to which they are bound, represent a 4- to 7-membered heterocycloalkyl group; wherein the 4- to 7-membered heterocycloalkyl group may be substituted once or twice, and each substituent is a halogen atom or a C １ -C ４ -Alkyl, C ３ -C ４ -cycloalkyl, C １ -C ４ independently selected from the group selected from haloalkyl, hydroxy and oxo; R １１ is a hydrogen atom or C １ -C ４ -Alkyl and C １ -C ４ -haloalkyl, R １２ represents a hydrogen atom, R １３ represents a phenyl group, R １４ But C １ -C ４ represents a group selected from alkyl and phenyl, wherein the phenyl group may be substituted one or two times, each substituent being a halogen atom or a C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl, cyano, hydroxy, C １ -C ２ -alkoxy, C ３ -C ４ -cycloalkyl and -N(R ９ ) (R １０ ) independently selected from groups selected from R １５ is a hydrogen atom or C １ -C ４ represents an alkyl group, R １６ is a hydrogen atom or C １ -C ４ represents an alkyl group, R １７ represents a 4- to 7-membered heterocyclic alkyl group; wherein the 4- to 7-membered heterocyclic alkyl group is C １ -C ４ - optionally substituted once or twice with alkyl groups, and wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the nitrogen atom of the R 4 group to which it is attached, -N(R 16 )(R 17 ); R １８ represents a hydrogen atom or a methyl group; R １９ represents a hydrogen atom or a methyl group; R ２０ is (4- to 7-membered heterocyclic alkyl)-(C １ -C ４ -alkyl)- group, wherein the (4- to 7-membered heterocyclic alkyl) portion of the group is C １ -C ４ - optionally substituted once or twice with alkyl groups, m represents an integer selected from 1 and 2, and n represents an integer selected from 1, 2 and 3; 3. The compound according to claim 1 or 2, or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a mixture thereof.

4. R １ is cyano, -C(=O)NH ２ , -C(=O)N(H)CH ３ and -C(=O)N(CH ３ ) ２ represents a group selected from R ２ represents a group selected from phenyl, naphthyl and 5- to 10-membered heteroaryl; wherein the 5- to 10-membered heteroaryl group is linked to the nitrogen-containing heterocycloalkyl group to which R 2 is attached via a carbon atom of said 5- to 10-membered heteroaryl group; wherein the phenyl, naphthyl and 5- to 10-membered heteroaryl groups may be substituted one, two, three or four times, each substituent being a halogen atom, or C １ -C ６ -Alkyl, C ３ -C ５ -cycloalkyl, C １ -C ４ -haloalkyl, (C １ -C ２ -alkoxy)-(C １ -C ２ -alkyl)-, C １ -C ４ -alkoxy, C １ -C ４ -haloalkoxy, phenoxy, -S(=O) ２ R １４ , -P(=O)(R １４ ) ２ , cyano, hydroxy, -N(R ９ ) (R １０ ), -C(=O)N(R ９ ) (R １０ ), -C(=O)R １１ , -N(R １２ ) C(=O)R １３ , -N(R １２ ) S(=O) ２ R １４ , -N=S(=O)(R １４ ) ２ , 4- to 7-membered heterocycloalkyl, phenyl, and 5- or 6-membered heteroaryl; Or, when two substituents of said phenyl group are attached to adjacent ring atoms, they together represent: -CH ２ -CH(OH)-CH ２ -, -CH ２ -CH(CH ３ )-O-, -OC(CH ３ ) ２ -O-, -N(R １８ )-C(=O)-(C(R １８ ) (R １９ )) ｍ -, -N(R １８ )-C(=O)-(C(CH3)2)-, -N(R １８ )-(C(R １８ ) (R １９ )) ｍ -, -N(R １８ )-C(=O)-O- and -N(R １８ )-C(=O)-N(R １８ )-, wherein the 4- to 7-membered heterocycloalkyl group is linked through a carbon atom of the 4- to 7-membered heterocycloalkyl group to the phenyl, naphthyl, or 5- to 10-membered heteroaryl group to which it is attached; and Here, the C １ -C ４ the alkoxy group is optionally substituted with a group selected from 4- to 7-membered heterocycloalkyl and phenyl; wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the C 1 -C 4 -alkoxy group to which it is attached, and wherein the phenyl and 5- or 6-membered heteroaryl groups may be substituted one or two times, each substituent being a halogen atom or a C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl and C １ -C ２ -alkoxy; R ３ is a hydrogen atom or a halogen atom, or C １ -C ６ -Alkyl, C ２ -C ４ -alkenyl, C ３ -C ５ -cycloalkyl, (C １ -C ２ -alkoxy)-(C １ -C ４ -alkyl)-, C １ -C ４ -alkoxy, C １ -C ４ -haloalkoxy, C ３ -C ５ -cycloalkyloxy, -S(=O) ２ R １４ , cyano, hydroxy, -N(R ９ ) (R １０ ), -C(=O)N(R ９ ) (R １０ ), -P(=O)(R １４ ) ２ represents a group selected from 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, and phenyl; wherein the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group are linked through a carbon atom of the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group to an aminoquinoline core to which R 3 is attached; and Here, the C １ -C ６ -Alkyl and C １ -C ４ - the alkoxy group is C ３ -C ４ - optionally substituted with a group selected from cycloalkyl and 4- to 7-membered heterocycloalkyl; wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the C 1 -C 6 -alkyl or C 1 -C 4 -alkoxy group to which it is attached, and Here, C ３ -C ４ the cycloalkyl group may be substituted once or twice with a cyano group, and Here, the C ２ -C ４ -Alkenyl group is C １ -C ４ - optionally substituted with a haloalkyl group, and Here, the C ３ -C ５ -cycloalkyl groups may be optionally substituted one or two times, each substituent independently being a halogen atom or a C １ -C ４ -Alkyl and C １ -C ４ -haloalkyl, R ４ is a hydrogen atom or a halogen atom, or C １ -C ６ -Alkyl, C １ -C ６ -haloalkyl, C ３ -C ５ -cycloalkyl, (C １ -C ２ -alkoxy)-(C １ -C ４ -alkyl)-, C １ -C ４ -alkoxy, (C １ -C ２ alkoxy)-(C １ -C ４ -alkoxy)-, -O-(C １ -C ４ -alkyl)-C(=O)OR １５ , —O—(C １ -C ４ -alkyl)-C(=O)N(R ９ ) (R １０ ), C ３ -C ５ -cycloalkyloxy, -S(=O) ２ R １４ , cyano, nitro, hydroxy, -N(R ９ ) (R １０ ), -N(R １６ ) (R １７ ), -N(R １６ ) (R ２０ ), -N=S(=NH)(R １４ ) ２ , -N=S(=O)(R １４ ) ２ , -P(=O)(R １４ ) ２ represents a group selected from 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, and phenyl; the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups are linked through a carbon atom of the 4- to 7-membered heterocycloalkyl and 5- to 7-membered heterocycloalkenyl groups to the aminoquinoline core to which R 4 is attached; and Here, the C １ -C ６ -Alkyl and C １ -C ４ - the alkoxy group is C ３ -C ４ - optionally substituted with a group selected from cycloalkyl and 4- to 7-membered heterocycloalkyl; wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the C 1 -C 6 -alkyl or C 1 -C 4 -alkoxy group to which it is attached, and Here, C ３ -C ４ the cycloalkyl group may be optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from cyano and hydroxy; and Here, the C １ -C ４ -alkoxy groups may be substituted with oxiran-2-yl groups, and Here, the C ３ -C ５ -cycloalkyl may be optionally substituted one or two times, each substituent independently being a halogen atom or a C １ -C ４ - alkyl groups, R ５ is a hydrogen atom or a halogen atom, or C １ -C ５ -Alkyl, C ３ -C ５ -cycloalkyl, C １ -C ４ -alkoxy, C ３ -C ５ -cycloalkyloxy, -S(=O) ２ R １４ , cyano, hydroxy, -N(R ９ ) (R １０ ), a group selected from 4- to 7-membered heterocycloalkyl and (4- to 7-membered heterocycloalkyl)oxy; wherein said 4- to 7-membered heterocycloalkyl group is linked to an aminoquinoline core to which R 5 is attached via a carbon atom of said 4- to 7-membered heterocycloalkyl group; R ６ is a hydrogen atom, or C １ -C ４ -Alkyl and C １ -C ４ -hydroxyalkyl, R ７ is a hydrogen atom or a halogen atom, or C １ -C ４ -Alkyl, C １ -C ４ represents a group selected from alkoxy and hydroxy, R ８ represents a group selected from methyl and ethyl, R ９ and R １０ is, independently in each occurrence, a hydrogen atom or C １ -C ４ -Alkyl, C ２ -C ４ -hydroxyalkyl, N≡C—(C １ -C ４ -alkyl)-, (C １ -C ４ -alkoxy)-(C ２ -C ４ -alkyl)- and C ３ -C ４ -cycloalkyl, or R ９ and R １０ together with the nitrogen to which they are attached represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group; wherein the nitrogen-containing 4- to 7-membered heterocycloalkyl group may be substituted one, two or three times, and each substituent is a halogen atom or a C １ -C ４ - independently selected from groups selected from alkyl, hydroxy and oxo; or two substituents bound to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocycloalkyl group, together with the carbon atom to which they are bound, represent a 4- to 7-membered heterocycloalkyl group; wherein the 4- to 7-membered heterocyclic alkyl group is C １ -C ４ - optionally substituted once or twice with alkyl groups, R １１ But C １ -C ４ -Alkyl and C １ -C ４ -haloalkyl, R １２ represents a hydrogen atom, R １３ represents a phenyl group, R １４ But C １ -C ４ represents a group selected from alkyl and phenyl, R １５ is a hydrogen atom or C １ -C ４ represents an alkyl group, R １６ is a hydrogen atom or C １ -C ４ represents an alkyl group, R １７ represents a 4- to 7-membered heterocyclic alkyl group; wherein the 4- to 7-membered heterocyclic alkyl group is C １ -C ４ - optionally substituted once or twice with alkyl groups, and wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the nitrogen atom of the R 4 group to which it is attached, -N(R 16 )(R 17 ); R １８ represents a hydrogen atom or a methyl group; R １９ represents a hydrogen atom or a methyl group; R ２０ is (4- to 7-membered heterocyclic alkyl)-(C １ -C ４ -alkyl)- group, wherein the (4- to 7-membered heterocyclic alkyl) portion of the group is C １ -C ４ - optionally substituted once or twice with alkyl groups, m represents an integer selected from 1 and 2, and n represents an integer selected from 1, 2 and 3; 4. The compound according to claim 1, 2 or 3, or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a mixture thereof.

5. R １ is cyano, -C(=O)NH ２ , -C(=O)N(H)CH ３ and -C(=O)N(CH ３ ) ２ represents a group selected from R ２ represents a group selected from phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl; wherein the 5- to 10-membered heteroaryl group is selected from pyrazolyl, 1,2,4-oxadiazole, 1,3,4-oxadiazole, 1H-1,2,3-triazolyl, 2H-1,2,3-triazolyl, 1,3-thiazolyl, pyridinyl, pyrazinyl, indolyl, benzothiophenyl, benzofuranyl, 1,3-benzoxazolyl, indazolyl, benzimidazolyl, 1,3-benzothiazolyl, pyrrolo[2,3-b]pyridinyl, quinolinyl, isoquinolinyl, quinoxalinyl, and 1,3-thiazolo[5,4-b]pyridinyl; wherein the 5- to 10-membered heteroaryl group is linked to the nitrogen-containing heterocycloalkyl group to which R 2 is attached via a carbon atom of said 5- to 10-membered heteroaryl group, and wherein the phenyl, 1-naphthyl, 2-naphthyl and 5- to 10-membered heteroaryl groups may be substituted one, two, three or four times, each substituent being a halogen atom, or C １ -C ６ -Alkyl, C ３ -C ５ -cycloalkyl, C １ -C ４ -haloalkyl, (C １ -C ２ -alkoxy)-(C １ -C ２ -alkyl)-, C １ -C ４ -alkoxy, C １ -C ４ -haloalkoxy, phenoxy, -S(=O) ２ R １４ , -P(=O)(R １４ ) ２ , cyano, hydroxy, -N(R ９ ) (R １０ ), -C(=O)N(R ９ ) (R １０ ), -C(=O)R １１ , -N(R １２ ) C(=O)R １３ , -N(R １２ ) S(=O) ２ R １４ , -N=S(=O)(R １４ ) ２ , 4- to 7-membered heterocycloalkyl, phenyl, and pyridinyl; Or, when two substituents of said phenyl group are attached to adjacent ring atoms, they together represent: -CH ２ -CH(OH)-CH ２ -, -CH ２ -CH(CH ３ )-O-, -OC(CH ３ ) ２ -O-, -NH-C(=O)-CH(CH ３ ) -, -N(CH ３ )-C(=O)-C(CH ３ ) ２ -, -NH-C(=O)-(C(CH3)2)-, -NH-CH ２ -C(CH ３ ) ２ -, -N(CH ３ )-C(=O)-O- and -N(CH ３ )-C(=O)-N(CH ３ )-, wherein the 4- to 7-membered heterocycloalkyl group is linked through a carbon atom of the 4- to 7-membered heterocycloalkyl group to the phenyl, 1-naphthyl, 2-naphthyl, or 5- to 10-membered heteroaryl group to which it is attached; and Here, the C １ -C ４ the alkoxy group is optionally substituted with a group selected from 4- to 7-membered heterocycloalkyl and phenyl; wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the C 1 -C 4 -alkoxy group to which it is attached, and wherein the phenyl group may be substituted one or two times, each substituent being a halogen atom or a C １ -C ２ -Alkyl, C １ -C ２ -haloalkyl and C １ -C ２ -alkoxy; R ３ is a hydrogen atom or a halogen atom, or C １ -C ６ -Alkyl, C ２ -C ４ -alkenyl, C ３ -C ５ -cycloalkyl, (C １ -C ２ -alkoxy)-(C １ -C ４ -alkyl)-, C １ -C ４ -alkoxy, C １ -C ４ -haloalkoxy, C ３ -C ５ -cycloalkyloxy, -S(=O) ２ R １４ , cyano, hydroxy, -N(R ９ ) (R １０ ), -C(=O)N(R ９ ) (R １０ ), -P(=O)(R １４ ) ２ represents a group selected from 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, and phenyl; wherein the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group are linked through a carbon atom of the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group to an aminoquinoline core to which R 3 is attached; and Here, the C １ -C ６ -Alkyl and C １ -C ４ - the alkoxy group is C ３ -C ４ - optionally substituted with a group selected from cycloalkyl and 4- to 7-membered heterocycloalkyl; wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the C 1 -C 6 -alkyl or C 1 -C 4 -alkoxy group to which it is attached, and Here, C ３ -C ４ the cycloalkyl group may be substituted once or twice with a cyano group, and Here, the C ２ -C ４ -Alkenyl group is C １ -C ４ - optionally substituted with a haloalkyl group, and Here, the C ３ -C ５ - the cycloalkyl group is a halogen atom or １ -C ４ -Alkyl and C １ -C ４ -haloalkyl, R ４ is a hydrogen atom or a halogen atom, or C １ -C ６ -Alkyl, C １ -C ６ -haloalkyl, C ３ -C ５ -cycloalkyl, (C １ -C ２ -alkoxy)-(C １ -C ４ -alkyl)-, C １ -C ４ -alkoxy, (C １ -C ２ alkoxy)-(C １ -C ４ -alkoxy)-, -O-CH ２ -C(=O)OR １５ , —O—CH ２ -C(=O)N(R ９ ) (R １０ ), C ３ -C ５ -cycloalkyloxy, -S(=O) ２ R １４ , cyano, nitro, hydroxy, -N(R ９ ) (R １０ ), -N(R １６ ) (R １７ ), -N(R １６ ) (R ２０ ), -N=S(=NH)(R １４ ) ２ , -N=S(=O)(R １４ ) ２ , -P(=O)(R １４ ) ２ represents a group selected from 4- to 7-membered heterocycloalkyl, 5- to 7-membered heterocycloalkenyl, (4- to 7-membered heterocycloalkyl)oxy, and phenyl; wherein the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group are linked to an aminoquinoline core to which R 4 is attached via a carbon atom of the 4- to 7-membered heterocycloalkyl group and the 5- to 7-membered heterocycloalkenyl group; Here, the C １ -C ６ -Alkyl and C １ -C ４ -alkoxy groups, C ３ -C ４ - optionally substituted with a group selected from cycloalkyl and 4- to 7-membered heterocycloalkyl; wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the C 1 -C 6 -alkyl or C 1 -C 4 -alkoxy group to which it is attached, and Here, C ３ -C ４ the cycloalkyl group may be optionally substituted one or two times, each substituent being independently selected from a halogen atom or a group selected from cyano and hydroxy; and Here, the C １ -C ４ -alkoxy groups may be substituted with oxiran-2-yl groups, and Here, the C ３ -C ５ -cycloalkyl groups may be optionally substituted one or two times, each substituent independently being a halogen atom or a C １ -C ４ - alkyl groups, R ５ is a hydrogen atom or a halogen atom, or C １ -C ５ -Alkyl, C ３ -C ５ -cycloalkyl, C １ -C ４ -alkoxy, C ３ -C ５ -cycloalkyloxy, -S(=O) ２ R １４ , cyano, hydroxy, -N(R ９ ) (R １０ ), a group selected from 4- to 7-membered heterocycloalkyl and (4- to 7-membered heterocycloalkyl)oxy; wherein said 4- to 7-membered heterocycloalkyl group is linked to an aminoquinoline core to which R 5 is attached via a carbon atom of said 4- to 7-membered heterocycloalkyl group; R ６ is a hydrogen atom, or C １ -C ４ -Alkyl and C １ -C ４ -hydroxyalkyl, R ７ is a hydrogen atom or a halogen atom, or C １ -C ４ -Alkyl, C １ -C ４ represents a group selected from alkoxy and hydroxy, R ８ represents a group selected from methyl and ethyl, R ９ and R １０ is, independently in each occurrence, a hydrogen atom or C １ -C ４ -Alkyl, C ２ -C ４ -hydroxyalkyl, N≡C—(C １ -C ４ -alkyl)-, (C １ -C ４ -alkoxy)-(C ２ -C ４ -alkyl)- and C ３ -C ４ -cycloalkyl, or R ９ and R １０ together with the nitrogen to which they are attached represent a nitrogen-containing 4- to 7-membered heterocycloalkyl group; wherein the nitrogen-containing 4- to 7-membered heterocycloalkyl group may be substituted one, two or three times, and each substituent is a halogen atom or a C １ -C ４ - independently selected from groups selected from alkyl, hydroxy and oxo; or two substituents bound to the same carbon atom of the nitrogen-containing 4- to 7-membered heterocycloalkyl group, together with the carbon atom to which they are bound, represent a 4- to 7-membered heterocycloalkyl group; wherein the 4- to 7-membered heterocyclic alkyl group is C １ -C ４ - optionally substituted once or twice with alkyl groups, R １１ But C １ -C ４ -Alkyl and C １ -C ４ -haloalkyl, R １２ represents a hydrogen atom, R １３ represents a phenyl group, R １４ But C １ -C ４ represents a group selected from alkyl and phenyl, R １５ is a hydrogen atom or C １ -C ４ represents an alkyl group, R １６ is a hydrogen atom or C １ -C ４ represents an alkyl group, R １７ represents a 4- to 7-membered heterocyclic alkyl group; wherein said 4- to 7-membered heterocycloalkyl group is linked via a carbon atom of said 4- to 7-membered heterocycloalkyl group to the nitrogen atom of the R 4 group to which it is attached, -N(R 16 )(R 17 ); R ２０ is (4- to 7-membered heterocyclic alkyl)-(C １ -C ４ -alkyl)- group, and n represents an integer selected from 1, 2 and 3; 5. A compound according to claim 1, 2, 3 or 4, or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a mixture thereof.

6. R １ is cyano, -C(=O)NH ２ , -C(=O)N(H)CH ３ and -C(=O)N(CH ３ ) ２ represents a group selected from R ２ Examples of the aryl group include phenyl, 1-naphthyl, 2-naphthyl, 1H-pyrazol-3-yl, 1H-pyrazol-4-yl, 1H-pyrazol-5-yl, 1,2,4-oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 1H-1,2,3-triazol-4-yl, 2H-1,2,3-triazol-4-yl, 1,3-thiazol-2-yl, pyridin-3-yl, pyrazin-2-yl, 1H-indol-5-yl, 1-benzofuran-4-yl, 1-benzofuran-7-yl, 1H-indol-6-yl, benzothiophen-2-yl, 1,3-benzoxazol-2-yl, 1,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl, 1,3-benzobenzoxazol-6-yl, 1,3-benzobenzoxazol-2-yl, 1,3-benzobenzoxazol-5-yl, 1,3-benzobenzoxazol-6-yl, 1,3-benzobenzoxazol-2 ...6-yl, 1,3-benzobenzoxazol-2-yl, 1,3-benzobenzoxazol-5-yl, 1,3-benzobenzoxazol-6-yl, 1,3-benzobenzoxazol- represents a group selected from thiazolo[2,3-b]pyridin-3-yl, quinolin-2-yl, quinolin-4-yl, quinolin-6-yl, quinolin-7-yl, 1H-indazol-5-yl, 1H-benzimidazol-2-yl, 1H-benzimidazol-4-yl, 1,3-benzothiazol-2-yl, 1,3-benzothiazol-4-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, 1,3-benzothiazol-7-yl, 1H-pyrrolo[2,3-b]pyridin-3-yl, quinolin-2-yl, quinolin-4-yl, quinolin-6-yl, quinolin-7-yl, isoquinolin-5-yl, isoquinolin-7-yl, isoquinolin-8-yl, quinoxalin-2-yl, quinoxalin-5-yl and 1,3-thiazolo[5,4-b]pyridin-2-yl, The group may be substituted one or two times, each substituent independently being a fluorine, chlorine or bromine atom; Methyl, propyl, isopropyl, tert-butyl, cyclopropyl, difluoromethyl, trifluoromethyl, methoxy, ethoxy, propoxy, (propan-2-yl)oxy, methoxymethyl, 2-methoxyethyl, benzyloxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, phenoxy, (oxolan-2-yl)methoxy, (tetrahydrofuran-2-yl)methoxy, methanesulfonyl, dimethylphosphoryl, cyano, hydroxy, dimethylamino, oxetan-3-yl, 2-oxopyrrolidin-1-yl, 4-methyl-2-oxopiperazin-1-yl, 4-methyl-3-oxopiperazin-1-yl, morpholino-4-yl, carbamoyl, acetyl, trifluoroacetyl, benzamido, benzenesulfonamido, [dimethyl(oxide)-λ ６ -sulfanylidene]amino, phenyl, 3-chlorophenyl, 4-chlorophenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3-trifluoromethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl and pyridin-3-yl; or When two substituents of the phenyl group are attached to adjacent ring atoms, they together form: -CH ２ -CH(OH)-CH ２ -, -CH ２ -CH(CH ３ )-O-, -OC(CH ３ ) ２ -O-, -NH-C(=O)-CH(CH ３ ) -, -N(CH ３ )-C(=O)-C(CH ３ ) ２ -, -NH-C(=O)-(C(CH3)2)-, -NH-CH ２ -C(CH ３ ) ２ -, -N(CH ３ )-C(=O)-O- and -N(CH ３ )-C(=O)-N(CH ３ )—, R ３ represents a hydrogen atom, or a fluorine, chlorine or bromine atom, or a group selected from methyl, sec-butyl, (oxetan-3-yl)methyl, 3,3,3-trifluoroprop-1-en-2-yl, cyclopropyl, (trifluoromethyl)cyclopropyl, cyclobutyl, 2,2-dimethylcyclobutyl, 3,3-difluorocyclobutyl, methoxymethyl, methoxy, ethoxy, propoxy, 2,2-difluoroethoxy, 2,2-difluoropropoxy, cyclopropylmethoxy, (1-cyanocyclopropyl)methoxy, cyclopropyloxy, cyclobutyloxy, methanesulfonyl, cyano, hydroxy, 4-hydroxy-2-oxo-pyrrolidin-1-yl, carbamoyl, dimethylphosphoryl, oxetan-3-yl, 3,6-dihydro-2H-pyran-4-yl, (oxetan-3-yl)oxy and phenyl, R ４ is a hydrogen atom, or a fluorine, chlorine or bromine atom, or methyl, sec-butyl, (oxetan-3-yl)methyl, trifluoromethyl, cyclopropyl, 3,3-difluorocyclobutyl, methoxymethyl, methoxy, propoxy, 2-methoxyethoxy, (1-hydroxycyclopropyl)methoxy, (1-cyanocyclopropyl)methoxy, (oxiran-2-yl)methoxy, carboxymethoxy, 2-tert-butoxy-2-oxo-ethoxy, 2-amino-2-oxo-ethoxy, cyclopropyloxy, cyclobutyloxy, methanesulfonyl, dimethylphosphoryl, Cyano, nitro, hydroxy, (cyanomethyl)(methyl)amino, (2-hydroxyethyl)amino, (2-hydroxyethyl)(methyl)amino, (2-methoxyethyl)amino, (2-methoxyethyl)(methyl)amino, cyclopropylamino, (oxetan-3-yl)amino, methyl(oxetan-3-yl)amino, methyl(oxolan-3-yl)amino, 3-hydroxyazetidin-1-yl, 2-oxopyrrolidin-1-yl, morpholino, 1,1-dioxidethiomorpholin-4-yl, 4-hydroxy-2-oxo-pyrrolidin-1-yl, 2,2-dimethyl-2λ ６ -diazathia-1,2-dien-1-yl, [dimethyl(oxide)-λ ６ -sulfanylidene]amino, methyl(tetrahydrofuran-3-yl)amino, tetrahydrofuran-3-ylmethoxy, (tetrahydrofuran-3-ylmethyl)amino, oxetan-3-yl, 3,6-dihydro-2H-pyran-4-yl, (oxetan-3-yl)oxy, (tetrahydrofuran-3-yl)oxy, (tetrahydro-2H-pyran-3-yl)oxy, (tetrahydro-2H-pyran-4-yl)oxy and phenyl; R ５ represents a hydrogen atom, or a fluorine, chlorine or bromine atom, or a group selected from methyl, cyclopropyl, methoxy, propoxy, cyclopropyloxy, methanesulfonyl, cyano, hydroxy, oxetan-3-yl and oxetan-3-yloxy, R ６ represents a hydrogen atom or a group selected from methyl and hydroxymethyl, R ７ represents a hydrogen atom or a fluorine atom or a group selected from methyl, ethyl, methoxy and hydroxy, R ８ represents a group selected from methyl and ethyl, n represents an integer selected from 1, 2 and 3; 6. A compound according to claim 1, 2, 3, 4 or 5, or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a mixture thereof.

7. 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(7-fluoro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(6-fluoro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-fluoro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(6-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{4-[5-(propan-2-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(6-chloro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-bromo-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-chloro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-fluoro-1,3-benzothiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(6-bromo-1,3-benzothiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(7-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)-4-fluoropiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(4-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-chloro-1,3-benzothiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-chloro[1,3]thiazolo[5,4-b]pyridin-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-methyl-4-[6-(trifluoromethoxy)-1,3-benzoxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-methyl-4-[5-(propan-2-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5,6-difluoro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{4-[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-tert-butyl-1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[5-(methanesulfonyl)-1,3-benzoxazol-2-yl]-4-methylpiperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-fluoro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-7-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-1-methyl-4-{4-methyl-4-[6-(trifluoromethoxy)-1,3-benzoxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-4-[4-(5-chloro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-1-methyl-2-oxo-4-{4-[5-(propan-2-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-4-[4-(5,6-difluoro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-4-[4-(6-chloro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-7-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-1-methyl-4-{4-methyl-4-[5-(propan-2-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-7-(2-oxopyrrolidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-7-(2-oxopyrrolidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{4-[4-(2,2,2-trifluoroethoxy)phenyl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-(4-{4-[(propan-2-yl)oxy]phenyl}piperidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-ethoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-cyclopropylphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-[4-(4-propoxyphenyl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, N-{4-[1-(3-cyano-1-methyl-2-oxo-1,2-dihydroquinolin-4-yl)piperidin-4-yl]phenyl}benzenesulfonamide, 4-[4-(3-cyclopropylphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[4-(dimethylamino)phenyl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{4-[4-(propan-2-yl)phenyl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[4-(benzyloxy)phenyl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, N-{4-[1-(3-cyano-1-methyl-2-oxo-1,2-dihydroquinolin-4-yl)piperidin-4-yl]phenyl}benzamide, 1-methyl-4-[4-(1-methyl-1H-indol-5-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(3-fluoro-5-methylphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(2-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-([1,1′-biphenyl]-4-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-chlorophenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(3-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-[4-(4-phenoxyphenyl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-(4-phenylpiperidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-(4-methyl-4-phenylpiperidin-1-yl)-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{4-[4-(2-oxopyrrolidin-1-yl)phenyl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(2-fluorophenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{4-[4-(trifluoromethyl)phenyl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(3-fluorophenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[3-(morpholin-4-yl)phenyl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(3-cyano-2-methylphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[4-(methanesulfonyl)phenyl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[4-(4-methyl-2-oxopiperazin-1-yl)phenyl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-5-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, N-{3-[1-(3-cyano-1-methyl-2-oxo-1,2-dihydroquinolin-4-yl)piperidin-4-yl]phenyl}benzenesulfonamide, 4-[4-(3-{[dimethyl(oxo)-λ ６ -sulfanylidene]amino}phenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(naphthalen-1-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-4-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[1-methyl-3-(trifluoroacetyl)-1H-indol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1-benzofuran-7-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(isoquinolin-7-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-7-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, N-{3-[1-(3-cyano-1-methyl-2-oxo-1,2-dihydroquinolin-4-yl)piperidin-4-yl]phenyl}benzamide, 4-[4-(isoquinolin-8-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(isoquinolin-5-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-[4-(quinoxalin-5-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[3-(methanesulfonyl)phenyl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-fluorophenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(2-methylphenyl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(4-methylphenyl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(3,5-dichlorophenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(3-bromophenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-cyanophenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[3-(difluoromethyl)phenyl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-bromophenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-1-methyl-2-oxo-4-(4-phenylpiperidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1,7-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-7-phenyl-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3,7-dicarbonitrile, 7-cyclopropyl-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(2,2-dimethyl-2λ ６ -diazathia-1,2-dien-1-yl)-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-7-(2-oxopyrrolidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-7-(oxetan-3-yl)-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(methanesulfonyl)-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-{[dimethyl(oxo)-λ ６ -sulfanylidene]amino}-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(3,6-dihydro-2H-pyran-4-yl)-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1-benzofuran-4-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-(4-{4-[(propan-2-yl)oxy]phenyl}piperidin-1-yl)-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-methyl-4-[5-(propan-2-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-7-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-ethylpiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-2-oxo-4-{4-[4-(trifluoromethoxy)phenyl]piperidin-1-yl}-1,2-dihydroquinoline-3-carboxamide, 4-[4-(5,6-difluoro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 7-bromo-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[3-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, mixture of stereoisomers, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-2-oxo-4-(4-phenylpiperidin-1-yl)-1,2-dihydroquinoline-3-carboxamide, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-7-(oxetan-3-yl)-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-7-(2-oxopyrrolidin-1-yl)-1,2-dihydroquinoline-3-carboxamide, (rac)-1-methyl-2-oxo-4-{4-[4-(propan-2-yl)phenyl]azepan-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{(4S)-4-[4-(propan-2-yl)phenyl]azepan-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{(4R)-4-[4-(propan-2-yl)phenyl]azepan-1-yl}-1,2-dihydroquinoline-3-carbonitrile, (rac)-4-[4-(1,3-benzoxazol-2-yl)azepan-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-[4-{4-[(propan-2-yl)oxy]phenyl}azepan-1-yl]-1,2-dihydroquinoline-3-carbonitrile, (rac)-4-[4-(4-methoxyphenyl)azepan-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[(4R)-4-(4-methoxyphenyl)azepan-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[(4S)-4-(4-methoxyphenyl)azepan-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-4-[4-(1,3-benzoxazol-2-yl)azepan-1-yl]-7-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[(4R)-4-(1,3-benzoxazol-2-yl)azepan-1-yl]-7-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[(4S)-4-(1,3-benzoxazol-2-yl)azepan-1-yl]-7-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-4-[4-(4-chlorophenyl)azepan-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[(4R)-4-(4-chlorophenyl)azepan-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[(4SR)-4-(4-chlorophenyl)azepan-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-2-oxo-4-[4-phenylazepan-1-yl]-1,2-dihydroquinoline-3-carbonitrile, (rac)-7-bromo-1-methyl-2-oxo-4-[4-phenylazepan-1-yl]-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-7-(oxetan-3-yl)-2-oxo-4-[4-phenylazepan-1-yl]-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-7-(morpholin-4-yl)-2-oxo-4-[4-phenylazepan-1-yl]-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-2-oxo-7-(2-oxopyrrolidin-1-yl)-4-[4-phenylazepan-1-yl]-1,2-dihydroquinoline-3-carbonitrile, (rac)-7-(1,1-dioxo-1λ ６ -thiomorpholin-4-yl)-1-methyl-2-oxo-4-[4-phenylazepan-1-yl]-1,2-dihydroquinoline-3-carbonitrile, (rac)-7-bromo-1-methyl-2-oxo-4-[4-phenylazepan-1-yl]-1,2-dihydroquinoline-3-carboxamide, 7-bromo-1-methyl-2-oxo-4-[(4S)-4-phenylazepan-1-yl]-1,2-dihydroquinoline-3-carboxamide, 7-bromo-1-methyl-2-oxo-4-[(4S)-4-phenylazepan-1-yl]-1,2-dihydroquinoline-3-carboxamide, 4-[4-ethyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-4-[4-ethyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(6-methoxypyridin-3-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(6-methylpyridin-3-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-[4-(pyridin-3-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-N,1-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-N,N,1-trimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-(1-methyl-1H-benzimidazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-[4-(3-propyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-[4-(pyrazin-2-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-hydroxy-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 8-fluoro-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-8-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-8-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-8-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 8-bromo-4-[4-(6-chloro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 8-bromo-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 8-bromo-4-[4-(5-chloro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 8-bromo-4-[4-(5,6-difluoro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-8-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-8-chloro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3,8-dicarbonitrile, 8-(methanesulfonyl)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-6-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-6-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-1-methyl-2-oxo-4-{4-[5-(propan-2-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3,6-dicarbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3,6-dicarbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3,6-dicarbonitrile, 6-cyclopropyl-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-(methanesulfonyl)-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-6-(oxetan-3-yl)-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-(3,6-dihydro-2H-pyran-4-yl)-4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-6-phenyl-1,2-dihydroquinoline-3-carbonitrile, 6-(methanesulfonyl)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(6-chloro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-[4-(6-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-chloro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-2-oxo-4-{4-[5-(propan-2-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-[4-methyl-4-(6-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-{4-methyl-4-[5-(propan-2-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-4-[4-(6-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-4-[4-methyl-4-(6-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-chloro-1-methyl-4-[4-methyl-4-(6-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-4-[4-(6-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-4-[4-methyl-4-(6-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-4-{4-methyl-4-[5-(propan-2-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-2-oxo-4-{4-[5-(propan-2-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carboxamide, 4-[4-(5-chloro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(6-chloro-1,3-benzoxazol-2-yl)piperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-bromo-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)azepan-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)azepan-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-6-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3,6-dicarbonitrile, 6-cyano-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-(3,3-difluorocyclobutyl)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-cyclopropyl-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-(butan-2-yl)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(methoxymethyl)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-(methoxymethyl)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1,6-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-fluoro-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-6-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1,7-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1,7-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,7-dimethyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,7-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-1,7-dimethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-ethylpiperidin-1-yl]-7-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-7-bromo-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 8-bromo-1,6-dimethyl-4-[4-methyl-4-(6-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-7-chloro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-7-chloro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-chloro-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-8-chloro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 8-chloro-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 8-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 8-bromo-1-methyl-4-{4-methyl-4-[5-methyl-4-(trifluoromethyl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[(2S,4S)-2-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-7-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-7-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-fluoro-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(1-hydroxycyclopropyl)methoxy]-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-7-methoxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[(oxetan-3-yl)oxy]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-hydroxy-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-7-methoxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(cyclopropyloxy)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-8-(oxetan-3-yl)-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(cyclobutyloxy)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-methoxy-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3,7-dicarbonitrile, 7-cyclopropyl-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(1-cyanocyclopropyl)methoxy]-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(3,3-difluorocyclobutyl)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-8-[(oxetan-3-yl)oxy]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5,6-difluoro-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-methoxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,7-dimethyl-2-oxo-4-(4-phenylpiperidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 7-methoxy-1-methyl-2-oxo-4-(4-phenylpiperidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-propoxy-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(6-chloro-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-methoxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-chloro-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-methoxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 8-methoxy-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-(oxetan-3-yl)-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 8-(cyclopropyloxy)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,8-dimethyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(cyclopropyloxy)-1-methyl-2-oxo-4-(4-phenylpiperidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[4-(2-methoxyethyl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(2S)-butan-2-yl]-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-6-[(oxetan-3-yl)oxy]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-[(1-cyanocyclopropyl)methoxy]-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(4R)-4-hydroxy-2-oxopyrrolidin-1-yl]-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-7-propoxy-1,2-dihydroquinoline-3-carbonitrile, 8-hydroxy-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 8-cyclopropyl-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-8-propoxy-1,2-dihydroquinoline-3-carbonitrile, 6-(cyclopropyloxy)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3,7-dicarbonitrile, 4-[4-(1,3-benzothiazol-2-yl)piperidin-1-yl]-6-cyclopropyl-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-[(4R)-4-hydroxy-2-oxopyrrolidin-1-yl]-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-(cyclobutyloxy)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-6-propoxy-1,2-dihydroquinoline-3-carbonitrile, 6-[(4R)-4-hydroxy-2-oxopyrrolidin-1-yl]-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 7-bromo-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(dimethylphosphoryl)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[5-(2-methoxyethyl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[6-(2-methoxyethyl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[(oxetan-3-yl)methyl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-6-[(oxetan-3-yl)methyl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[5-(oxetan-3-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-(trifluoromethyl)-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-(trifluoromethyl)-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-7-(trifluoromethyl)-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1-methyl-2-oxo-7-(trifluoromethyl)-1,2-dihydroquinoline-3-carbonitrile, 7-hydroxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(6-bromo-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[5-(2-methoxyethyl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-6-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-7-chloro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-6-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-7-chloro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 7-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-7-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 7-fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-7-fluoro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1-methyl-2-oxo-7-(trifluoromethyl)-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-(trifluoromethyl)-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-7-(trifluoromethyl)-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-8-chloro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-8-chloro-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-1,7-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1,7-dimethyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1,7-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1,7-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-{4-[4-(2-methoxyethyl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-{4-[6-(2-methoxyethyl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-7-(2-oxopyrrolidin-1-yl)-1,2-dihydroquinoline-3-carboxamide, 8-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(4,5-dimethyl-1,3-thiazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-[4-(quinoxalin-2-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-[4-(1H-pyrazol-3-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(1-methyl-1H-pyrazol-4-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(3,4-dimethoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(3-chlorophenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[(2S,4S)-2-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)-1-piperidyl]-2-oxo-quinoline-3-carbonitrile, 4-[4-(3-cyanophenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 8-fluoro-1-methyl-2-oxo-4-[(4S)-4-phenylazepan-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[rac-(2R,3S)-2-methyl-3-phenylpyrrolidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[1-(3-cyano-1-methyl-2-oxo-1,2-dihydroquinolin-4-yl)piperidin-4-yl]benzamide, 4-[4-hydroxy-4-(2-methoxyphenyl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-chlorophenyl)piperidin-1-yl]-1-ethyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{4-[5-(2-oxopyrrolidin-1-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-acetylphenyl)-4-methylpiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(3-chlorophenyl)-4-methoxypiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-(dimethylphosphoryl)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-(dimethylphosphoryl)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-(methanesulfonyl)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1-benzothiophen-2-yl)-4-hydroxypiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1-benzothiophen-2-yl)-4-methoxypiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1-benzothiophen-2-yl)-4-methylpiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(6-methoxynaphthalen-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-[1-(3-cyano-1-methyl-2-oxo-1,2-dihydroquinolin-4-yl)piperidin-4-yl]-2-methylquinoline-4-carbonitrile, 1-methyl-4-[4-(2-methyl-1,3-benzoxazol-5-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(2-methyl-1,3-benzothiazol-5-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-4-[4-(3-methyl-2-oxo-2,3-dihydro-1H-indol-5-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[3-(3-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[5-(3-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[5-(3-chlorophenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[5-(3-chlorophenyl)-1,3,4-oxadiazol-2-yl]-4-methylpiperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(3,3-dimethyl-2,3-dihydro-1H-indol-5-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[(2R)-2-methyl-2,3-dihydro-1-benzofuran-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-[4-(1,3,3-trimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(2-hydroxy-2,3-dihydro-1H-inden-5-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(2,2-dimethyl-2H-1,3-benzodioxol-5-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzimidazol-5-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-methyl-4-(4-methylquinolin-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(4-fluoro-1-methyl-1H-indol-6-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[1-(3-methylphenyl)-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[1-(2-methylphenyl)-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[1-(4-chlorophenyl)-1H-pyrazol-3-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-{4-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(2-methylquinolin-6-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[4-(3-methoxyphenyl)-1,3-thiazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[4-(2-methoxyphenyl)-1,3-thiazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[4-(4-methylphenyl)-1,3-thiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-dimethyl-1H-indazol-5-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(2-methyl-1,3-benzoxazol-6-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(2-methyl-1,3-benzothiazol-6-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[3-(difluoromethyl)quinolin-7-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carbonitrile 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carbonitrile 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[(oxan-4-yl)oxy]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(2-methoxyethoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-{[oxiran-2-yl]methoxy}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[(oxetan-3-yl)oxy]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-methoxy-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-2-oxo-4-(4-{5-[(oxolan-2-yl)methoxy]-1,3-benzoxazol-2-yl}piperidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-{4-[6-(oxetan-3-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-fluoropiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)-4-methoxypiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[5-(methoxymethyl)-1,3-benzoxazol-2-yl]-4-methylpiperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-{4-[6-(methoxymethyl)-1,3-benzoxazol-2-yl]-4-methylpiperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-fluoro-4-(5-methoxy-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(5-cyclopropyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(6-cyclopropyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 8-bromo-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[methyl(oxetan-3-yl)amino]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(2-hydroxyethyl)(methyl)amino]-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[methyl(oxolan-3-yl)amino]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(cyanomethyl)(methyl)amino]-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3,6-dicarbonitrile, 3-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-6-carboxamide, 6-ethoxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-(2,2-difluoropropoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-(2,2-difluoroethoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-(cyclopropylmethoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-cyclobutyl-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-[2,2-dimethylcyclobutyl]-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-6-(3,3,3-trifluoroprop-1-en-2-yl)-1,2-dihydroquinoline-3-carbonitrile, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-6-[1-(trifluoromethyl)cyclopropyl]-1,2-dihydroquinoline-3-carbonitrile, 2-({3-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinolin-7-yl}oxy)acetamide, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-{[oxan-3-yl]oxy}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-tert-butyl({3-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinolin-7-yl}oxy)acetate, ({3-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinolin-7-yl}oxy)acetic acid, (rac)-4-[4-fluoro-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-7-(tetrahydrofuran-3-yloxy)-1,2-dihydroquinoline-3-carbonitrile, 7-(cyclopropylamino)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-methoxy-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-4-[4-fluoro-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-methoxy-1-methyl-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-nitro-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-7-hydroxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-7-hydroxy-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-bromo-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[tetrahydrofuran-3-yloxy]-1,2-dihydroquinoline-3,6-dicarbonitrile, 7-hydroxy-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3,6-dicarbonitrile, (rac)-6-ethoxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[tetrahydrofuran-3-yloxy]-1,2-dihydroquinoline-3-carbonitrile, 7-hydroxy-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[tetrahydrofuran-3-yloxy]-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-(2,2-difluoroethoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[tetrahydrofuran-3-yloxy]-1,2-dihydroquinoline-3-carbonitrile, (rac)-4-[4-fluoro-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-6-methoxy-1-methyl-2-oxo-7-[tetrahydrofuran-3-yloxy]-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3,6-dicarbonitrile, (rac)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-6-(3,3,3-trifluoroprop-1-en-2-yl)-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-6-[1-(trifluoromethyl)cyclopropyl]-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-1-methyl-2-oxo-4-(4-{5-[3-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl}piperidin-1-yl)-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-4-{4-[3-(3-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-2-oxo-4-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-2-oxo-4-[4-(5-phenyl-1,3,4-oxadiazol-2-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-1-methyl-2-oxo-4-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-1-methyl-2-oxo-4-[4-(5-phenyl-1,3,4-oxadiazol-2-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-1-methyl-4-{4-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-1-methyl-4-{4-[5-(3-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-hydroxy-1-methyl-4-{4-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-7-hydroxy-1-methyl-4-{4-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-1-methyl-4-{4-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-7-{[oxan-3-yl]oxy}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 4-[4-(1,3-benzoxazol-2-yl)piperidin-1-yl]-N,1-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, N,1-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methylpiperidin-1-yl]-N,1-dimethyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-2-oxo-4-{4-[5-(2-oxopyrrolidin-1-yl)-1,3-benzoxazol-2-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carboxamide, 4-[4-(3-chlorophenyl)-4-methoxypiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-(dimethylphosphoryl)-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-(dimethylphosphoryl)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-(methanesulfonyl)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1-benzothiophen-2-yl)-4-methoxypiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1-benzothiophen-2-yl)-4-hydroxypiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(6-methoxynaphthalen-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-{4-[3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-[3-(3-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-[5-(3-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-{4-[5-(3-chlorophenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-{4-[5-(3-chlorophenyl)-1,3,4-oxadiazol-2-yl]-4-methylpiperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-[2-methyl-2,3-dihydro-1-benzofuran-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(2-hydroxy-2,3-dihydro-1H-inden-5-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(2,2-dimethyl-2H-1,3-benzodioxol-5-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-methyl-4-(4-methylquinolin-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(4-fluoro-1-methyl-1H-indol-6-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-[1-(3-methylphenyl)-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-[1-(2-methylphenyl)-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-{4-[1-(3-chlorophenyl)-1H-pyrazol-3-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-2-oxo-4-{4-[3-(pyridin-3-yl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carboxamide, 4-{4-[4-(3-methoxyphenyl)-1,3-thiazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-{4-[4-(2-methoxyphenyl)-1,3-thiazol-2-yl]piperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-[4-(4-methylphenyl)-1,3-thiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[(oxan-4-yl)oxy]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 7-(2-methoxyethoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-{[oxiran-2-yl]methoxy}-2-oxo-1,2-dihydroquinoline-3-carboxamide, (rac)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, (-)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, (+)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[(oxetan-3-yl)oxy]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(5-methoxy-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-2-oxo-4-(4-{5-[(oxolan-2-yl)methoxy]-1,3-benzoxazol-2-yl}piperidin-1-yl)-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-fluoropiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-(1,3-benzoxazol-2-yl)-4-methoxypiperidin-1-yl]-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-{4-[5-(methoxymethyl)-1,3-benzoxazol-2-yl]-4-methylpiperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-{4-[6-(methoxymethyl)-1,3-benzoxazol-2-yl]-4-methylpiperidin-1-yl}-1-methyl-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-bromo-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 8-bromo-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[methyl(oxetan-3-yl)amino]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 7-[(2-hydroxyethyl)(methyl)amino]-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-{methyl[(3R)-oxolan-3-yl]amino}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-{methyl[(3S)-oxolan-3-yl]amino}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3,6-dicarboxamide, 7-[(cyanomethyl)(methyl)amino]-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-methoxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-ethoxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-(2,2-difluoropropoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-(2,2-difluoroethoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-(cyclopropylmethoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-cyclobutyl-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-6-[1-(trifluoromethyl)cyclopropyl]-1,2-dihydroquinoline-3-carboxamide, 7-(2-amino-2-oxoethoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 4-[4-fluoro-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-1-methyl-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-nitro-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-bromo-7-hydroxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-bromo-7-hydroxy-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, (rac)-6-bromo-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, (rac)-6-cyano-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-[4-methyl-4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, (rac)-6-(2,2-difluoroethoxy)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, (rac)-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-6-[1-(trifluoromethyl)cyclopropyl]-1,2-dihydroquinoline-3-carboxamide, 6-bromo-1-methyl-2-oxo-4-(4-{5-[3-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2-yl}piperidin-1-yl)-1,2-dihydroquinoline-3-carboxamide, 6-methoxy-1-methyl-4-{4-[3-(3-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-methoxy-1-methyl-2-oxo-4-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carboxamide, 6-methoxy-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-bromo-1-methyl-2-oxo-4-[4-(3-phenyl-1,2,4-oxadiazol-5-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carboxamide, 6-bromo-1-methyl-2-oxo-4-[4-(5-phenyl-1,3,4-oxadiazol-2-yl)piperidin-1-yl]-1,2-dihydroquinoline-3-carboxamide, 6-bromo-1-methyl-4-{4-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-bromo-1-methyl-4-{4-[5-(3-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-7-{[(3R)-oxan-3-yl]oxy}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 1-methyl-4-{4-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-7-{[(3S)-oxan-3-yl]oxy}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-bromo-7-hydroxy-1-methyl-4-{4-[5-(2-methylphenyl)-1,3,4-oxadiazol-2-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-bromo-7-methoxy-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-7-hydroxy-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-bromo-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-bromo-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, (rac)-6-cyano-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, (-)-6-bromo-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 6-methoxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carbonitrile, 6-methoxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, (rac)-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 7-[(2-methoxyethyl)amino]-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-(3-hydroxyazetidin-1-yl)-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-7-[(oxetan-3-yl)amino]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(2-hydroxyethyl)amino]-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(2-hydroxyethyl)(methyl)amino]-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(2-methoxyethyl)amino]-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 7-(3-hydroxyazetidin-1-yl)-1,6-dimethyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, (rac)-1,6-dimethyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carbonitrile, 1,6-dimethyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 1,6-dimethyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 7-[(2-hydroxyethyl)amino]-1,6-dimethyl-4-{4-[3-(2-methylphenyl)-1,2,4-oxadiazol-5-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-1,6-dimethyl-4-{4-[1-(2-methylphenyl)-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 7-[(2-hydroxyethyl)amino]-1,6-dimethyl-4-{4-[1-(2-methylphenyl)-1H-pyrazol-3-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-bromo-7-fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, 6-cyano-7-fluoro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carboxamide, (rac)-6-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(oxolan-3-yl)methyl]amino}-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-({[(3R)-oxolan-3-yl]methyl}amino)-1,2-dihydroquinoline-3-carboxamide, 6-cyano-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-({[(3S)-oxolan-3-yl]methyl}amino)-1,2-dihydroquinoline-3-carboxamide, 6-chloro-7-methoxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, 6-chloro-7-hydroxy-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carboxamide, 6-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, 6-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3S)-oxolan-3-yl]oxy}-1,2-dihydroquinoline-3-carboxamide, (rac)-6-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)methoxy]-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-[(oxolan-3-yl)methoxy]-1,2-dihydroquinoline-3-carboxamide, 6-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3R)-oxolan-3-yl]methoxy}-1,2-dihydroquinoline-3-carboxamide, 6-chloro-1-methyl-4-[4-(5-methyl-1,3-benzoxazol-2-yl)piperidin-1-yl]-2-oxo-7-{[(3S)-oxolan-3-yl]methoxy}-1,2-dihydroquinoline-3-carboxamide, (rac)-6-bromo-1-methyl-2-oxo-7-[(oxolan-3-yl)oxy]-4-{4-[2-(pyridin-3-yl)-2H-1,2,3-triazol-4-yl]piperidin-1-yl}-1,2-dihydroquinoline-3-carbonitrile, (rac)-6-bromo-1-methyl-4-{4-[1-(2-methylphenyl)-1H-1,2,3-triazol-4-yl]piperidin-1-yl}-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carbonitrile, (rac)-1,6-dimethyl-4-{4-[1-(2-methylphenyl)-1H-1,2,3-triazol-4-yl]piperidin-1-yl}-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carbonitrile, 7-bromo-1,6-dimethyl-4-{4-[1-(2-methylphenyl)-1H-pyrazol-4-yl]piperidin-1-yl}-2-oxo-1,2-dihydroquinoline-3-carbonitrile, and (rac)-1,6-dimethyl-4-{4-[1-(2-methylphenyl)-1H-pyrazol-4-yl]piperidin-1-yl}-2-oxo-7-[(oxolan-3-yl)oxy]-1,2-dihydroquinoline-3-carbonitrile 7. The compound according to claim 1, 2, 3, 4, 5 or 6, or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a mixture thereof, selected from the group consisting of:

8. R １ is -C(=O)NH ２ , -C(=O)N(H)CH ３ and -C(=O)N(CH ３ ) ２ or a stereoisomer, tautomer, N-oxide, hydrate, solvate or salt thereof, or a mixture thereof, of the compound according to claim 1, 2, 3, 4, 5, 6 or 7, wherein

9. A method for producing a compound of general formula (I) according to any one of claims 1 to 8, comprising the steps of: The method comprises the step of reacting an intermediate compound of the following general formula (II): 【Chemistry 2】 [In the formula, R １ , R ３ , R ４ , R ５ and R ８ is as defined for the compounds of general formula (I) according to any one of claims 1 to 8, and X has the meaning of chloro or bromo, A compound of the following general formula (III): 【Transformation 3】 [In the formula, R ２ , R ６ , R ７ and n are as defined for the compounds of general formula (I) according to any one of claims 1 to 8, Thereby, compounds of general formula (I): 【Chemistry 4】 [In the formula, R １ , R ２ , R ３ , R ４ , R ５ , R ６ , R ７ , R ８ and n is as defined for compounds of general formula (I) according to any one of claims 1 to 8.

10. A compound of general formula (I) according to any one of claims 1 to 8 for use in the treatment or prevention of diseases.

11. A pharmaceutical composition comprising a compound of general formula (I) according to any one of claims 1 to 8 and one or more pharmaceutically acceptable excipients.

12. - one or more first active ingredients, the compound of general formula (I) according to any one of claims 1 to 8, and one or more further active ingredients 10. A pharmaceutical combination comprising:

13. 13. The pharmaceutical combination of claim 12, wherein the further active ingredient is an immune checkpoint inhibitor.

14. The pharmaceutical combination of claim 13, wherein the immune checkpoint inhibitor is an aPD-1 / -L1 axis antagonist.

15. The pharmaceutical combination of claim 13, wherein the immune checkpoint inhibitor is an inhibitor of DGKζ.

16. 12. The pharmaceutical composition according to claim 11 for the treatment or prevention of a disease.

17. Use of a compound of general formula (I) according to any one of claims 1 to 8 for the manufacture of a medicament for the treatment or prevention of a disease.

18. 17. The pharmaceutical composition of claim 16, wherein the disease is cancer or a condition involving dysregulation of the immune response or a disorder associated with abnormal DGKα signaling, such as liquid tumors and solid tumors.

19. A compound of the following general formula (II): 【Transformation 5】 [In the formula, R １ is -C(=O)NH ２ , -C(=O)N(H)CH ３ and -C(=O)N(CH ３ ) ２ represents a group selected from R ３ , R ４ , R ５ and R ８ is as defined for the compounds of general formula (I) according to any one of claims 1 to 8, and X has the meaning of chloro or bromo.

20. Use of a compound of the following general formula (II) for the production of a compound of general formula (I) according to any one of claims 1 to 8: 【Transformation 6】 [In the formula, R １ is -C(=O)NH ２ , -C(=O)N(H)CH ３ and -C(=O)N(CH ３ ) ２ represents a group selected from R ３ , R ４ , R ５ and R ８ is as defined for the compounds of general formula (I) according to any one of claims 1 to 8, and X has the meaning of chloro or bromo.

Images